Indicate by check mark whether the registrant
has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial
reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or
issued its audit report. ☐
PART
I
ITEM
1. IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
A. |
Directors
and Senior Management |
Not
required.
Not
required.
Not
required.
ITEM
2. OFFER STATISTICS AND EXPECTED TIMETABLE
Not
required.
ITEM
3. KEY INFORMATION
A. |
Selected
financial data |
[RESERVED]
B. |
Capitalization
and Indebtedness |
Not
required.
C. |
Reasons
for the Offer and Use of Proceeds |
Not
required.
In
conducting our business, we face many risks that may interfere with our business objectives. Some of these risks could materially and
adversely affect our business, financial condition and results of operations. In particular, we are subject to various risks resulting
from changing economic, political, industry, business and financial conditions. The risks and uncertainties described below are not the
only ones we face. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially
adversely affect our business, financial condition and results of operations.
You
should carefully consider the following factors and other information in this Annual Report before you decide to invest in our ordinary
shares. If any of the risks referred to below occur, our business, financial condition and results of operations could suffer. In any
such case, the trading price of our ordinary shares could decline, and you may lose all or part of your investment.
Risks
Factors Relating to the Company’s Business and Operations
The
COVID-19 pandemic has had an adverse effect on our business, and public health epidemics such as COVID-19 could adversely impact our
future operating results.
The
COVID-19 pandemic has negatively impacted the global economy, disrupted business operations of various industries, and created significant
volatility and disruption of financial markets. In compliance with the government mandates, our Hangzhou, Shangyu, Guangzhou and Urumqi offices closed and
our operations temporarily halted in the spring of 2020. During the closure, employees had only limited access to our facilities and
delayed our project timeline, which affected our operating results and financial condition. In December 2021, Shangyu District, Shaoxing
City, Zhejiang Province, where the subsidiary company Zhejiang Jingyuxin Financing Guarantee Co., Ltd. is located, was closed and suspended
due to the epidemic, resulting in delays in our services to some customers. After the lockdown was lifted on December 31, 2021, operations
could resume. COVID-19, including any variants thereof such as the omicron variant, could continue to adversely affect our business and
financial results in 2022, including if any virus resurgences cause significant disruptions to our operations or the business of our
customers, or our logistics and service providers, or result in any negative impact to the pricing of our products. We cannot predict
the severity and duration of the impact from such resurgence, if any.
COVID-19,
any variants thereof, or any new pandemics could continue to have an adverse effect on our future business and financial performance.
If any new outbreak of COVID-19 is not effectively and timely controlled, or if government responses to outbreaks or potential outbreaks
are severe or long-lasting, our business operations and financial condition may be materially and adversely affected as a result of the
deteriorating market outlook, the slowdown in regional and national economic growth, weakened liquidity and financial condition of our
customers or other factors that we cannot foresee. Any of these factors and other factors beyond our control could have an adverse effect
on the overall business environment, cause uncertainties in the regions where we conduct business, and could materially and adversely
impact our business, financial condition and results of operations.
We do not have a history of profitability
from continuing operations. We may revert back to a loss mode.
We do not have a history of profitability from
our continuing operations. While we earned a profit from continuing operations during 2021 of $757,301, we had losses from continuing
operations of $854,606 in 2020 and $2,557,110 in 2019. As we continue to change our focus from microfinancing to industrial operations
services, we may revert back to a loss mode, which could lead to a depletion of our cash reserves.
We
have had substantial changes in its business models and we cannot guarantee our future results of operations
Since 2019, we have had substantial changes with
our organizational structure and business models, including the completion of the Lixin Acquisition in December 2019 as discussed elsewhere
in this report and disposition of Feng Hui Ding Xin (Beijing) Financial Consulting Co., Ltd. (“Ding Xin”) and its direct loan
business in September 2020 and disposition of China Roan Industrial-Financial Holdings Group Co., Ltd. in September 2021. The Company
has transformed its business from a direct loan business, to a financial, insurance, healthcare and industrial operation service related
solution provider serving middle-sized and micro enterprises (“MSMEs:”) in China.
In addition, we have substantially expanded our health management
and other health related services and industrial operation services. As we have limited operating history in the business lines in which
we are currently operating, it is difficult to evaluate our prospects, and we may not have sufficient experience in managing the changes
and addressing the risks to which companies operating in new and rapidly evolving markets such as the financial guarantee, insurance,
and health industries may be exposed. The Company will continue to encounter risks and difficulties that companies at a similar stage
of development frequently experience, including the potential failure to:
| ● | obtain
sufficient working capital and increase its registered capital to support expansion of its
financial guarantee business, asset management, supply chain financing and business factoring; |
| ● | comply
with any changes in the laws and regulations of the PRC or local province that may affect
its operations; |
| ● | expand
its customer base; |
| ● | maintain
adequate control of default risks and expenses allowing it to realize anticipated revenue
growth; |
| ● | implement
its customer development, risk management of national growth and acquisition strategies and
plans and adapt and modify them as needed; |
| ● | integrate
any future acquisitions; and |
| ● | anticipate
and adapt to changing conditions in the Chinese financing industry resulting from changes
in government regulations, mergers and acquisitions involving its competitors, and other
significant competitive and market dynamics. |
If
the Company is unable to address any or all of the foregoing risks, its business may be materially and adversely affected.
Our
limited operating history makes it difficult to evaluate our business and prospects.
In general we have a limited operating history as many of our operating
subsidiaries were formed in 2017 or later.
Hangzhou Zeshi Investment Partnership
(Limited Partnership) (“Hangzhou Zeshi”) was formed in November 2018 and commenced financial services. Yifu Health
Industry (Ningbo) Co., Ltd. (“Yi Fu”), formerly Ningbo Ding Tai Financial Leasing Co., Ltd., was formed in December 2016
but only commenced its health industry operations in 2020. Zeshi (Hangzhou) Health Management Co., Ltd. (“Zeshi Health”)
and Ningbo Zeshi Insurance Technology Co., Ltd. (“Zeshi Insurance”) began their operations in 2020.
The operating subsidiaries under Lixin Cayman
also have a limited operating history. While Zhejiang Jing Yu Xin Financing Guarantee Co., Ltd. (“Zhejiang Jingyuxin”) was
incorporated in 2013 and Zhejiang Lixin Enterprise Management Holding Group Co., Ltd.(“Zhejiang Lixin”) was incorporated
in 2015, Lixin (Hangzhou) Asset Management Co., Ltd. (“LAM”) and Lixin Supply Chain Management (Tianjin) Co., Ltd. (“Lixin
Supply Chain”) were incorporated in 2017.
As a result, the results of our operations
in prior years may not be indicative of future performance.
We have a customer concentration risk as two
of our customers represent almost half of our revenue. The loss of any one of these customers would have a material adverse effect on
our revenue and profitability.
Two of our customers represent almost 50% of our
revenue. These two customers are able to reduce the amount of their business with us at will or to cease doing business with us entirely
at any time. Therefore, our continued revenue from these customers depends on their having continued needs that we are able to service
in a manner they find more attractive than utilizing third parties. The loss or material reduction in revenue from either of these customers
would have a material adverse affect on our revenue and profitability.
The
Company’s current operations in China are geographically limited to certain areas.
Our
business focuses on Yangtze River Delta region and Pearl River Delta region. The Company’s future growth opportunities will depend
on the growth and stability of the economy in these areas. A downturn in the economy of these areas or the implementation of provincial
or local policies unfavorable to MSMEs may cause a decrease in the demand for the Company’s loan guaranty services and other services
provided to MSMEs and may negatively affect borrowers’ ability to repay their loans on a timely basis, both of which could have
a negative impact on the Company’s profitability and business. Although it is open to and are trying to develop business in more
areas, the Company still needs more time to expand its business geographically.
Regarding
its financial guarantee services to MSMEs, the Company is subject to greater credit risks than larger guarantee providers, which could
adversely affect its results of operations.
There
are inherent risks associated with our financial guarantee activities, including credit risk, which is the risk that our customers may
not repay us after we make payments for them according to our contracts. We provide financial guarantee services to MSMEs. These customers
generally have fewer financial resources in terms of capital or borrowing capacity than larger entities and may have fewer financial
resources to weather a downturn in the economy. Such customers may expose the Company to greater credit risks than guaranty providers
guaranteeing for larger, better-capitalized state-owned businesses with longer operating histories. Conditions such as inflation, economic
downturn, local policy change, adjustment of industrial structure and other factors beyond our control may increase our credit risk more
than such events would affect larger guaranty providers. In addition, since we are still focusing on Yangtze River Delta region and Pearl
River Delta region, our ability to geographically diversify the economic risks is currently limited by the local markets and economies.
Also, decreases in local real estate value could adversely affect the values of the real property used as collateral in the financial
guarantee business. Such adverse changes in the local economies may have a negative impact on the ability of customers to repay their
loans and the value of their collateral and in turn our results of operations and financial condition may be adversely affected.
Competition
in the financial industry is growing and could cause the Company to lose market share and revenues in the future.
We
believe that the financial industry is an emerging market in China. We may face growing competition in the financial industry, and the
Company believes that the financial industry is becoming more competitive as this industry matures and begins to consolidate. The Company
will compete with other financial companies and some cash-rich state-owned companies or individuals that provide financial services to
MSMEs. Some of these competitors have larger and more established customer bases and substantially greater financial, marketing and other
resources than we have. As a result, the Company could lose market share and its revenues could decline, thereby adversely affecting
our earnings and potential for growth.
The
Company’s businesses will require highly qualified personnel, and if it is unable to hire or retain qualified personnel, then it
may not be able to grow effectively.
The
Company’s future success depends upon its ability to attract and retain highly qualified personnel. Establishment of Zeshi Insurance
and Zeshi Health in the first quarter of 2020 with healthcare business and expansion of the businesses of each operating company will
require additional managers and employees with relevant industry experience, and its success will be highly dependent on its ability
to attract and retain skilled management personnel and other employees. These operating companies may not be able to attract or retain
highly qualified personnel. In addition, competition for skilled personnel is significant in China. This competition may make it more
difficult and expensive to attract, hire and retain qualified managers and employees. The Company may incur additional expenses to recruit
and retain qualified replacements and its businesses may be disrupted and its financial condition and results of operations may be materially
and adversely affected. In addition, key managers may join a competitor or form a competing company. An operating company may not be
able to successfully enforce any contractual rights with its management team, in particular in China, where all of these individuals
reside or will reside.
The
Company’s business continuity plans could prove to be inadequate, resulting in a material interruption in or disruption to, its
business and a negative impact on the Company’s results of operations.
The
Company relies on communications and information systems to conduct its business to some extent, and in general its ability to protect
its systems against damage from fire, power loss, telecommunication failure, severe weather, natural disasters, terrorism or other factors
is important to its operations. The computer systems and network infrastructure the Company uses could be vulnerable to unforeseen problems.
While the Company has a business continuity plan and other policies and procedures designed to prevent or limit the effect of a failure
or interruption of our information systems, there can be no assurance that any such failures or interruptions will not occur or, if they
do occur, that they will be adequately addressed. The occurrence of any failures or interruptions of our information systems could, among
other things, damage the Company’s reputation or result in a loss of clients, which could have a material adverse effect on the
Company’s results of operations.
The
Company has no material insurance coverage, which could expose it to significant costs and business disruption.
Risks
associated with the Company’s business and operations include, but are not limited to, clients’ failure to repay the outstanding
principal and interest after we make the payments for them and loss reserves are not sufficient to cover such failure, losses of key
personnel, business interruption due to power loss or network failure, and risks posed by natural disasters including storms, floods
and earthquakes, any of which may result in significant costs or business disruption. The Company does not maintain any credit insurance,
business interruption insurance, general third-party liability insurance, nor does it maintain key-man life insurance or any other insurance
coverage except the mandatory social insurance for employees. If the Company incurs any loss that is not covered by reserves, its business,
financial condition and results of operations could be materially and adversely affected.
The
Company maintains cash deposits with various banks. These cash accounts are not sufficiently insured or otherwise protected. Should any
bank holding these cash deposits become insolvent, or if the Company is otherwise unable to withdraw funds, it could lose the cash on
deposit with that particular bank or trust company.
The
Company uses credit reports issued by the Credit Reference Center of the People’s Bank of China for credit records, which may not
cover all accurate credit activities of guarantee customers.
The
Company generally uses credit reports issued by the Credit Reference Center of the People’s Bank of China (“CCRC”)
for guarantee customers’ credit records. According to the information from CCRC’s official website (http://www.pbccrc.org.cn/crc/),
CCRC is a professional credit information service institution directly under the People’s Bank of China (“PBOC”) which
collects comprehensive credit information about both enterprises and individuals throughout China. The 2,100 credit reports query points
of the PBOC’s branches have covered almost all rural areas in China, and CCRC has 300,000 information query ports in financial
institutions and networks around the country, and the credit information service network is used throughout China. As of the end of April
2015, CCRC’s database had collected credit information of over 860 million individuals and over 20 million enterprises and institutions,
mainly from commercial banks as well as other financial institutions. However, the CCRC’s credit reports do not cover all credit
and financing activities with all trust companies, leasing companies, asset management companies, direct lending companies, insurance
companies, and other financial companies. Moreover, the PBOC had not established a credit reporting system until 1997 when it established
the Bank Credit Registration System which upgraded to the CCRC in 2006. Therefore, CCRC’s credit reports may not be able to cover
credit and financing activities that occurred before 1997. In addition, the accuracy of credit reports provided by CCRC may be mainly
adversely affected by the followings: (1) reliability of information source; (2) victimized by criminals forging identity of the customers;
(3) mistakes made by data entry operators; and (4) technical stability of CCRC’s computer system. Furthermore, despite using credit
reports issued by the CCRC, privately-owned guarantors may be more susceptible to default than state-owned or public guarantors due to
financial difficulties or fraud and therefore, the Company may have more difficulty enforcing guarantees from privately-owned guarantors
than from state-owned or public guarantors. Finally, having clean credit history in the past does not preclude a guarantee customer from
defaulting in the future.
The business overlap of our subsidiaries
could result in inefficiencies to the Company’s business.
We completed the Lixin Acquisition in December 2019. Most of our subsidiaries
are in the financial industry and may conduct the same business. On one hand they may share resources and expand their own businesses.
On the other hand, they may target the same clients and compete with each other. This could reduce the efficiency of the Company
as a whole. For example, Hangzhou Zeshi has commenced operations of asset management from 2019. Lixin (Hangzhou) Asset Management Co.,
Ltd. (“LAM”) started its asset management business in 2017. They both focus on Zhejiang province. Hangzhou Zeshi is staffed
entirely by new hires and in some measure may compete with LAM for customers. As a result, Hangzhou Zeshi may initially struggle to establish
its business after the Lixin Acquisition and some of its success it has may come at the expense of LAM. Furthermore, because
of PRC limitations, even though the economic benefit of Hangzhou Zeshi and LAM will inure to us, each will need to have its own segregated
capital and client base. As a result, Hangzhou Zeshi and LAM will not be able to cross-collateralize or combine operations at the working
level. Although the Company plans to allocate the resources from a strategic level, this structure may not allow the Company to allocate
resources to their most efficient use and may require redundant or additional expenses.
Risks
Related to Doing Business in China
The failure
to comply with PRC regulations relating to mergers and acquisitions of domestic enterprises by offshore special purpose vehicles may subject
the Company to severe fines or penalties and create other regulatory uncertainties regarding the Company’s corporate structure.
On August 8, 2006, the Ministry of Commerce (“MOFCOM”),
joined by the China Securities Regulatory Commission (“CSRC”), the State-owned Assets Supervision and Administration Commission
of the State Council, the State Administration of Taxation (“SAT”), the State Administration for Industry and Commerce (the
“SAIC”), and the State Administration of Foreign Exchange (“SAFE”), jointly promulgated regulations entitled the
Provisions Regarding Mergers and Acquisitions of Domestic Enterprises by Foreign Investors (the “M&A Rules”), which took
effect as of September 8, 2006, and as amended on June 22, 2009. This regulation, among other things, has certain provisions that require
offshore companies formed for the purpose of acquiring PRC domestic companies and controlled directly or indirectly by PRC individuals
and companies which are the related parties with the PRC domestic companies, to obtain the approval of MOFCOM prior to engaging in such
acquisitions and to obtain the approval of the CSRC prior to publicly listing special purpose vehicles’ securities on an overseas
stock market. On September 21, 2006, the CSRC published on its official website a notice specifying the documents and materials that are
required to be submitted for obtaining CSRC approval.
The application of the M&A Rules with respect
to the Company’s corporate structure remains unclear, with no current consensus existing among leading PRC law firms regarding the
scope and applicability of the M&A Rules. We believe that the MOFCOM and CSRC approvals under the M&A Rules were not required
in the context of the Business Combination and the Lixin Acquisition because we did not acquire Feng Hui’s equity or assets and
Xinjiang Fenghui Jing Kai Direct Lending Co., Ltd. (“Jing Kai”) and Ding Xin and Lixin Group were already foreign owned. However,
we cannot be certain that the relevant PRC government agencies, including the CSRC and MOFCOM, would reach the same conclusion, and we
cannot be certain that MOFCOM or the CSRC will not deem that the Business Combination or the Lixin Acquisition circumvented the M&A
Rules, and other rules and notices, or that prior MOFCOM or CSRC approval was required for overseas financing.
If prior CSRC approval for overseas financings
is required and not obtained, the Company may face severe regulatory actions or other sanctions from MOFCOM, the CSRC or other PRC regulatory
agencies. In such event, these regulatory agencies may impose fines or other penalties on the Company’s operations in the PRC, limit
the Company’s operating privileges in the PRC, delay or restrict the repatriation of the proceeds from overseas financings into
the PRC, restrict or prohibit payment or remittance of dividends to us or take other actions that could have a material adverse effect
on our business, financial condition, results of operations, reputation and prospects, as well as the trading price of our ordinary shares.
The CSRC or other PRC regulatory agencies may also take actions requiring us, or making it advisable for us, to delay or cancel overseas
financings, to restructure the Company’s corporate structure, or to seek regulatory approvals that may be difficult or costly to
obtain.
The M&A Rules, along with certain foreign
exchange regulations discussed below, will be interpreted or implemented by the relevant government authorities in connection with our
future offshore financings or acquisitions, and we cannot predict how they will affect our acquisition strategy.
PRC regulations relating to investments
in offshore companies by PRC residents may subject our PRC-resident beneficial owners or our PRC subsidiaries to liability or penalties,
limit our ability to inject capital into our PRC subsidiaries or limit our PRC subsidiaries’ ability to increase their registered
capital or distribute profits.
SAFE promulgated the Circular on Relevant Issues
Concerning Foreign Exchange Control on Domestic Residents’ Offshore Investment and Financing and Roundtrip Investment through Special
Purpose Vehicles, or SAFE Circular 37, on July 4, 2014, which replaced the former circular commonly known as “SAFE Circular
75” promulgated by SAFE on October 21, 2005. SAFE Circular 37 requires PRC residents to register with local branches of SAFE in
connection with their direct establishment or indirect control of an offshore entity, for the purpose of overseas investment and financing,
with such PRC residents’ legally owned assets or equity interests in domestic enterprises or offshore assets or interests, referred
to in SAFE Circular 37 as a “special purpose vehicle.” SAFE Circular 37 further requires amendment to the registration in
the event of any significant changes with respect to the special purpose vehicle, such as increase or decrease of capital contributed
by PRC individuals, share transfer or exchange, merger, division or other material event. In the event that a PRC resident holding interests
in a special purpose vehicle fails to fulfill the required SAFE registration, the PRC subsidiaries of that special purpose vehicle may
be prohibited from making profit distributions to the offshore parent and from carrying out subsequent cross-border foreign exchange activities,
and the special purpose vehicle may be restricted in its ability to contribute additional capital into its PRC subsidiary. Moreover, failure
to comply with the various SAFE registration requirements described above could result in liability under PRC law for evasion of foreign
exchange controls.
SAFE promulgated the Notice of SAFE on Further
Simplifying and Improving Policies for the Foreign Exchange Administration of Direct Investment, or SAFE Circular 13, on February 13,
2015, which was effective on June 1, 2015. SAFE Circular 13 cancels two administrative approval items which are foreign exchange registration
under domestic direct investment and foreign exchange registration under overseas direct investment. Instead, banks shall directly examine
and handle foreign exchange registration under domestic direct investment and foreign exchange registration under overseas direct investment,
and SAFE and its branch shall indirectly regulate the foreign exchange registration of direct investment through banks.
We have notified substantial beneficial owners
of ordinary shares who we know are PRC residents of their filing obligations in accordance with SAFE Circular 37 and SAFE Circular 13.
However, we may not be aware of the identities of all of our beneficial owners who are PRC residents. We do not have control over our
beneficial owners and cannot assure you that all of our PRC-resident beneficial owners will comply with SAFE Circular 37, SAFE Circular
13 and subsequent implementation rules. The failure of our beneficial owners who are PRC residents to register or amend their SAFE registrations
in a timely manner pursuant to SAFE Circular 37, SAFE Circular 13 and subsequent implementation rules, or the failure of future beneficial
owners of our company who are PRC residents to comply with the registration procedures set forth in SAFE Circular 37, SAFE Circular 13
and subsequent implementation rules, may subject such beneficial owners or our PRC subsidiaries to fines and legal sanctions. Furthermore,
since SAFE Circular 37 and SAFE Circular 13 was recently promulgated and it is unclear how this regulation, and any future regulation
concerning offshore or cross-border transactions, will be interpreted, amended and implemented by the relevant PRC government authorities,
we cannot predict how these regulations will affect our business operations or future strategy. Failure to register or comply with relevant
requirements may also limit our ability to contribute additional capital to our PRC subsidiaries and limit our PRC subsidiaries’
ability to distribute dividends to our company. These risks may have a material adverse effect on our business, financial condition and
results of operations.
If any of our subsidiaries fails to maintain
the requisite registered capital, licenses and approvals required under PRC law, our business, financial condition and results of operations
may be materially and adversely affected.
Numerous regulatory authorities of the central
PRC government, provincial and local authorities are empowered to issue and implement regulations governing various aspects of the financial
industry. Each of our subsidiaries may be required to obtain and maintain certain assets relevant to its business as well as applicable
licenses or approvals from different regulatory authorities in order to provide its current services. These registered capitals, licenses
and approvals will be essential to the operation of the Company’s business. If any of our subsidiaries fails to obtain or maintain
any of the required registered capital, licenses or approvals for its business, it may be subject to various penalties, such as confiscation
of illegal net revenue, fines and the discontinuation or restriction of its operations. Any such disruption in its business operations
could materially and adversely affect our business, financial condition and results of operations.
PRC
regulation of loans to, and direct investments in, PRC entities by offshore holding companies may delay or prevent us from making loans
or additional capital contributions to our PRC operating subsidiaries and thereby prevent us from funding our business.
As
an offshore holding company with PRC subsidiaries, we may transfer funds to our PRC subsidiaries by means of loans or capital contributions.
Any loans to these PRC subsidiaries, which are foreign-invested enterprises, cannot exceed statutory limits based on the difference between
the amount of our investments and registered capital in such subsidiaries, and shall be registered with SAFE, or its local counterparts.
Furthermore, any capital increase contributions we make to our PRC subsidiaries, which are foreign-invested enterprises, shall be approved
by MOFCOM, or its local counterparts. We may not be able to obtain these government registrations or approvals on a timely basis, if
at all. If we fail to receive such registrations or approvals, our ability to provide loans or capital to increase contributions to our
PRC subsidiaries may be negatively affected, which could adversely affect their liquidity and our ability to fund and expand their business.
A
slowdown of the Chinese economy or adverse changes in economic and political policies of the PRC government could negatively impact China’s
overall economic growth, which could materially adversely affect our business.
All
of the Company’s operations are entirely conducted in the PRC. Although the PRC economy has grown in recent years, the pace of
growth has slowed, and even that rate of growth may not continue. The annual rate of growth in the PRC declined from 7.3% in 2014 to
6.9% in 2015 to 6.7% in 2016, to 6.9% in 2017, to 6.6% in 2018, to 6.1% in 2019. Due to the COVID-19 pandemic, China’s economic
growth rate in 2020 has slowed to 2.3%, its lowest since 1990. In the first quarter of fiscal year 2021, we witnessed a recovery in China’s
overall economy, benefiting from the COVID-19 pandemic control measures and the resumption of production and business. However, the recent
outbreak of the pandemic in many areas of China has caused, and may continue to cause, the authorities to implement numerous measures
to try to contain the disease and slow its spread. These include travel bans and restrictions, quarantines, shelter-in-place orders and
shutdowns. These measures have created significant uncertainty and economic disruption, both short-term and potentially long-term. Furthermore,
the global spread of COVID-19 pandemic in a significant number of countries around the world has resulted in, and may intensify, global
economic distress. A slowdown in overall economic growth, an economic downturn or recession or other adverse economic developments in
the PRC may materially reduce the demand for the Company’s services and may have a materially adverse effect on its business.
China’s
economy differs from the economies of most other countries in many respects, including the amount of government involvement in the economy,
the general level of economic development, growth rates and government control of foreign exchange and the allocation of resources. While
the PRC economy has grown significantly over the past few decades, this growth has remained uneven across different periods, regions
and economic sectors.
The
PRC government also exercises significant control over China’s economic growth by allocating resources, controlling the payment
of foreign currency-denominated obligations, setting monetary policy and providing preferential treatment to particular industries or
companies. Any actions and policies adopted by the PRC government could negatively impact the Chinese economy or the economy of the region
the Company serves, which could materially adversely affect the Company’s business.
Substantial
uncertainties and restrictions with respect to the political and economic policies of the PRC government and PRC laws and regulations
could have a significant impact upon the business the Company may be able to conduct in the PRC and accordingly on the results of its
operations and financial condition.
The
Company’s business operations may be adversely affected by the current and future political environment in the PRC. The Chinese
government exerts substantial influence and control over the manner in which the Company must conduct its business activities. The Company’s
ability to operate in China may be adversely affected by changes in Chinese laws and regulations. Under the current government leadership,
the government of the PRC has been pursuing economic reform policies that encourage private economic activities and greater economic
decentralization. However, the government of the PRC may not continue to pursue these policies, or may significantly alter these policies
from time to time without notice.
There
are certain uncertainties regarding the interpretation and application of PRC laws and regulations, including, but not limited to, the
laws and regulations governing the Company’s business, or the enforcement and performance of the Company’s arrangements with
clients. Only after 1979 did the Chinese government begin to promulgate a comprehensive system of laws that regulate economic affairs
in general, deal with economic matters such as foreign investment, corporate organization and governance, commerce, taxation and trade,
as well as encourage foreign investment in China. Although the influence of the law has been increasing, China has not developed a fully
integrated legal system and recently enacted laws and regulations may not sufficiently cover all aspects of economic activities in China.
Also, because these laws and regulations are relatively new, and because of the limited volume of published cases and their lack of force
as precedents, interpretation and enforcement of these laws and regulations involve significant uncertainties. New laws and regulations
that affect existing and proposed future businesses may also be applied retroactively. In addition, there have been constant changes
and amendments of laws and regulations over the past 30 years in order to keep up with the rapidly changing society and economy in China.
Because government agencies and courts provide interpretations of laws and regulations and decide contractual disputes and issues, their
inexperience in adjudicating new business and new polices or regulations in certain less developed areas causes uncertainty and may affect
the Company’s business. Consequently, we cannot predict the future direction of Chinese legislative activities with respect to
either businesses with foreign investment or the effectiveness on enforcement of laws and regulations in China. The uncertainties, including
new laws and regulations and changes of existing laws, as well as judicial interpretation by inexperienced officials in the agencies
and courts in certain areas, may cause possible problems to foreign investors.
The
Company’s business is subject to extensive regulation and supervision by state, provincial and local government authorities, which
may interfere with the way the Company conducts its business and may negatively impact its financial results.
The
Company conducts its business in the financial industry which is highly regulated. It is subject to extensive and complex state, provincial
and local laws, rules and regulations with regard to its financing guaranties, capital structure, and asset management, among other things.
These laws, rules and regulations are issued by different central government ministries and departments, provincial and local governments
and are enforced by different local authorities. Therefore, the interpretation and implementation of such laws, rules and regulations
may not be clear and occasionally the Company has to depend on oral inquiries with local government authorities. As a result of the complexity,
uncertainties and constant changes in these laws, rules and regulation, including changes in interpretation and implementation of such,
the Company’s business activities and growth may be adversely affected if they do not respond to the changes in a timely manner
or are found to be in violation of the applicable laws, regulations and policies as a result of a different position from theirs taken
by the competent authority in the interpretation of such applicable laws, regulations and policies. If the Company is found to be not
in compliance with these laws and regulations, they may be subject to sanctions by regulatory authorities, monetary penalties and/or
reputation damage, which could have a material adverse effect on the Company’s business operations and profitability.
You
may experience difficulties in effecting service of legal process, enforcing foreign judgments or bringing original actions against us
or our management, in China, based upon United States laws, including the U.S. federal securities laws, or other foreign laws.
We are a company organized under the laws of the British Virgin Islands.
Substantially all of our operations are conducted in China, and substantially all of our assets are located in China. None of our subsidiaries
is organized under the laws of the United States. All of our directors and officers reside in China, and substantially all of the assets
of those persons are located outside of the United States. As a result, it may be difficult for a shareholder to effect service of process
within the United States upon these persons, or to enforce judgments against us which are obtained in United States courts, including
judgments predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States.
Furthermore,
the recognition and enforcement of foreign judgments are provided for under the PRC Civil Procedures Law. PRC courts may recognize and
enforce foreign judgments in accordance with the requirements of the PRC Civil Procedures Law based either on treaties between China
and the country where the judgment is made or on principles of reciprocity between jurisdictions. China does not have any treaties or
other form of reciprocity with the United States providing for the reciprocal recognition and enforcement of foreign judgments. In addition,
according to the PRC Civil Procedures Law, courts in the PRC will not enforce a foreign judgment against us or our directors or officers
if they decide that the judgment violates the basic principles of PRC laws, national sovereignty, security or public interest. As a result,
it is uncertain whether and on what basis a PRC court would enforce a judgment rendered by a court in the United States.
Lastly,
in the event shareholders originate an action against a company without domicile in China for disputes related to contracts or other
property interests, the PRC courts may accept a cause of action if (a) the disputed contract is concluded or performed in the PRC or
the disputed subject matter is located in the PRC, (b) the company (as defendant) has properties that can be seized within the PRC, (c)
the company has a representative organization within the PRC, or (d) the parties chose to submit to the jurisdiction of the PRC courts
in the contract on the condition that such submission does not violate the requirements of jurisdiction under the PRC Civil Procedures
Law. The action may be initiated by the shareholder by filing a complaint with the PRC courts. The PRC courts would determine whether
to accept the complaint in accordance with the PRC Civil Procedures Law. The shareholder may participate in the action by itself or entrust
any other person or PRC legal counsel to participate on behalf of such shareholder. Foreign citizens and companies will have the same
rights as PRC citizens and companies in such an action unless such foreign country restricts the rights of PRC citizens and companies.
Our
Chinese subsidiaries’ ability to pay dividends to us may be restricted due to foreign exchange control and other regulations of
China.
As
an offshore holding company, we will rely principally on dividends from our subsidiaries in China, for our cash requirements. Under the
applicable PRC laws and regulations, foreign-invested enterprises in China may pay dividends only out of their accumulated profits, if
any, determined in accordance with PRC accounting standards and regulations. In addition, a foreign-invested enterprise in China is required
to set aside a portion of its after-tax profit to fund specific reserve funds prior to payment of dividends. In particular, at least
10% of its after-tax profits based on PRC accounting standards each year is required to be set aside towards its general reserves until
the accumulative amount of such reserves reach 50% of its registered capital. These reserves are not distributable as cash dividends.
Furthermore,
our Chinese subsidiaries’ ability to pay dividends may be restricted due to foreign exchange control policies and the availability
of its cash balance. Substantially all of the Company’s operations are conducted in China and all of the revenue we recognize will
be denominated in RMB. RMB is subject to exchange control regulation in China, and, as a result, our Chinese subsidiaries may be unable
to distribute any dividends outside of China due to PRC exchange control regulations that restrict our ability to convert RMB into U.S.
dollars.
The
lack of dividends or other payments from our Chinese subsidiaries may limit our ability to make investments or acquisitions that could
be beneficial to our business, pay dividends or otherwise fund, and conduct our business. Our funds may not be readily available to us
to satisfy obligations which have been incurred outside the PRC, which could adversely affect our business and prospects or our ability
to meet our cash obligations. Accordingly, if we do not receive dividends from our Chinese subsidiaries, our liquidity and financial
condition will be materially and adversely affected.
Dividends
payable to our foreign investors and gains on the sale of our ordinary shares by our foreign investors may become subject to tax by the
PRC.
Under
the Enterprise Income Tax Law and its implementation regulations issued by the State Council of the PRC, a 10% PRC withholding tax is
applicable to dividends payable to investors that are non-resident enterprises, which do not have an establishment or place of business
in the PRC or which have such establishment or place of business but the dividends are not effectively connected with such establishment
or place of business, to the extent such dividends are derived from sources within the PRC. Similarly, any gain realized on the transfer
of shares by such investors is also subject to PRC tax at a current rate of 10%, subject to any reduction or exemption set forth in relevant
tax treaties, if such gain is regarded as income derived from sources within the PRC. If we are deemed a PRC resident enterprise, dividends
paid on our shares, and any gain realized from the transfer of our shares, would be treated as income derived from sources within the
PRC and would as a result be subject to PRC taxation. Furthermore, if we are deemed a PRC resident enterprise, dividends payable to individual
investors who are non-PRC residents and any gain realized on the transfer shares by such investors may be subject to PRC tax at a current
rate of 20%, subject to any reduction or exemption set forth in applicable tax treaties. It is unclear whether we or any of our subsidiaries
established outside of China are considered a PRC resident enterprise, holders of shares would be able to claim the benefit of income
tax treaties or agreements entered into between China and other countries or areas. If dividends payable to our non-PRC investors or
gains from the transfer of our shares by such investors are subject to PRC tax, the value of your investment in our shares may decline
significantly.
Our
global income may be subject to PRC taxes under the PRC Enterprise Income Tax Law, which could have a material adverse effect on our
results of operations.
Under
the PRC Enterprise Income Tax Law, or the New EIT Law, and its implementation rules, which became effective in January 2008, an enterprise
established outside of the PRC with a “de facto management body” located within the PRC is considered a PRC resident enterprise
and will be subject to the enterprise income tax at the rate of 25% on its global income. The implementation rules define the term “de
facto management bodies” as “establishments that carry out substantial and overall management and control over the manufacturing
and business operations, personnel and human resources, finance and treasury, and acquisition and disposition of properties and other
assets of an enterprise.” On April 22, 2009, the State Administration of Taxation (the “SAT”), issued a circular, or
SAT Circular 82 (partly modified by SAT Announcement [2014]No. 9), which provides certain specific criteria for determining whether the
“de facto management body” of a PRC-controlled enterprise that is incorporated offshore is located in China. Although the
SAT Circular 82 only applies to offshore enterprises controlled by PRC enterprises or PRC enterprise groups, not those controlled
by PRC individuals or foreigners, the determining criteria set forth in the SAT Circular 82 may reflect the SAT’s general position
on how the “de facto management body” test should be applied in determining the resident status of all offshore enterprises
for the purpose of PRC tax, regardless of whether they are controlled by PRC enterprises or individuals. Although we do not believe that
our legal entities organized outside of the PRC constitute PRC resident enterprises, it is possible that the PRC tax authorities could
reach a different conclusion. In such case, we may be considered a PRC resident enterprise and may therefore be subject to the 25% enterprise
income tax on our global income, which could significantly increase our tax burden and materially and adversely affect our cash flow
and profitability. In addition to the uncertainty regarding how the new PRC resident enterprise classification for tax purposes may apply,
it is also possible that the rules may change in the future, possibly with retroactive effect.
We
and our shareholders face uncertainties with respect to indirect transfers of equity interests in PRC resident enterprises by their non-PRC
holding companies.
On
February 3, 2015, the State Administration of Taxation issued an Announcement on Several Issues Concerning Enterprise Income Tax on Income
Arising from Indirect Transfers of Property by Non-PRC Resident Enterprises, or Announcement 7, with the same effective date. Under Announcement
7, an “indirect transfer” refers to a transaction where a non-resident enterprise transfers its equity interest and other
similar interest in an offshore holding company, which directly or indirectly holds Chinese taxable assets (the assets of an “establishment
or place” situated in China; real property situated in China and equity interest in Chinese resident enterprises) and any indirect
transfer without reasonable commercial purposes are subject to the PRC taxation. In addition, Announcement 7 specifies the conditions
under which an indirect transfer is deemed to lack a reasonable commercial purpose which include: (1) 75% or more of the value of the
offshore holding company’s equity is derived from Chinese taxable assets, (2) anytime in the year prior to the occurrence
of the indirect transfer of Chinese taxable assets, 90% or more of the total assets (excluding cash) of the offshore holding company
are direct or indirect investment in China, or 90% or more of the revenue of the offshore holding company was sourced from China; (3)
the functions performed and risks assumed by the offshore holding company(ies), although incorporated in an offshore jurisdiction to
conform to the corporate law requirements there, are insufficient to substantiate their corporate existence and (4) the foreign income
tax payable in respect of the indirect transfer is lower than the Chinese tax which would otherwise be payable in respect of the direct
transfer if such transfer were treated as a direct transfer. As a result, gains derived from such indirect transfer will be subject to
PRC enterprise income tax, currently at a rate of 10%.
Announcement
7 grants a safe harbor under certain qualifying circumstances, including transfers in the public securities market and certain intragroup
restricting transactions, however, there is uncertainty as to the implementation of Announcement 7. For example, Announcement 7 requires
the buyer to withhold the applicable taxes without specifying how to obtain the information necessary to calculate taxes and when the
applicable tax shall be submitted. Announcement 7 may be determined by the tax authorities to be applicable to our offshore restructuring
transactions or sale of the shares of our offshore subsidiaries where non-resident enterprises, being the transferors, were involved.
Though Announcement 7 does not impose a mandatory obligation of filing the report of taxable events, the transferring party shall be
subject to PRC withholding tax if the certain tax filing conditions are met. Non-filing may result in an administrative penalty varying
from 50% to 300% of unpaid taxes. As a result, we and our non-resident enterprises in such transactions may become at risk of being subject
to taxation under Announcement 7, and may be required to expend valuable resources to comply with Announcement 7 or to establish that
we and our non-resident enterprises should not be taxed under Announcement 7, for any restructuring or disposal of shares of our offshore
subsidiaries, which may have a material adverse effect on our financial condition and results of operations.
Restrictions
on currency exchange may limit our ability to utilize our revenue effectively.
Substantially
all of our revenue is denominated in Renminbi. The Renminbi is currently convertible under the “current account,” which includes
dividends, trade and service-related foreign exchange transactions, but not under the “capital account,” which includes foreign
direct investment and loans. Currently, our PRC subsidiaries, which are wholly- owned foreign enterprises, may purchase foreign currency
for settlement of “current account transactions,” including payment of dividends to us, without the approval of SAFE by complying
with certain procedural requirements. However, the relevant PRC governmental authorities may limit or eliminate our ability to purchase
foreign currencies in the future for current account transactions. Since a significant amount of our future revenue will be denominated
in Renminbi, any existing and future restrictions on currency exchange may limit our ability to utilize revenue generated in Renminbi
to fund our business activities outside of the PRC or pay dividends in foreign currencies to our shareholders. Foreign exchange transactions
under the capital account remain subject to limitations and require approvals from, or registration with, SAFE or banks and other relevant
PRC governmental authorities. This could affect our ability to obtain foreign currency through debt or equity financing for our subsidiaries.
Fluctuations
in the foreign currency exchange rate between U.S. Dollars and Renminbi could adversely affect our financial condition.
The
value of the RMB against the U.S. dollar and other currencies may fluctuate. Exchange rates are affected by, among other things, changes
in political and economic conditions and the foreign exchange policy adopted by the PRC government. On July 21, 2005, the PRC government
changed its policy of pegging the value of the RMB to the U.S. dollar. Under this policy, the RMB is permitted to fluctuate within a
narrow and managed band against a basket of foreign currencies. Following the removal of the U.S. dollar peg, the RMB appreciated more
than 20% against the U.S. dollar over three years. From July 2008 until June 2010, however, the RMB traded stably within a narrow range
against the U.S. dollar. On June 20, 2010, the PBOC announced that the PRC government would reform the RMB exchange rate regime and increase
the flexibility of the exchange rate. Since June 2010, the RMB has appreciated more than 10% against the U.S. dollar. In April 2012,
the PRC government announced it would allow greater RMB exchange rate fluctuation. On August 11, 12 and 13, 2015, the PRC government
successively set the central parity rate for the RMB more than 3% lower in the aggregate than that of August 10, 2015 and announced that
it will begin taking into account previous day’s trading in setting the central parity rate. In 2015, the yuan experienced a 4.88%
drop in value, and on January 4, 2016 the PRC government set the U.S. dollar-Chinese yuan currency pair to a reference rate of 6.5%,
the lowest rate in 4.5 years. In 2019, the exchange rate of RMB against the US dollar depreciated by 4.1%. (Source: website of National
Bureau of Statistics Annual Statistic Report, dated February 28, 2020). However, it is difficult to predict how market forces or PRC
or U.S. government policy may impact the exchange rate between the RMB and the U.S. dollar in the future. As significant international
pressure remains on the PRC government to adopt a more flexible currency policy, greater fluctuation of the RMB against the U.S. dollar
could result.
Our
revenues and costs are mostly denominated in RMB, and a significant portion of our financial assets are also denominated in RMB. Any
significant fluctuations in the exchange rate between the RMB and the U.S. dollar may materially adversely affect our cash flows, revenues,
earnings and financial position, and the amount of and any dividends we may pay on our shares in U.S. dollars. Fluctuations in the exchange
rate between the RMB and the U.S. dollar could also result in foreign currency translation losses for financial reporting purposes.
If
any dividend is declared in the future and paid in a foreign currency, you may be taxed on a larger amount in U.S. dollars than the U.S.
dollar amount that you will actually ultimately receive.
If
you are a U.S. holder of our ordinary shares, you will be taxed on the U.S. dollar value of your dividends, if any, at the time you receive
them, even if you actually receive a smaller amount of U.S. dollars when the payment is in fact converted into U.S. dollars. Specifically,
if a dividend is declared and paid in a foreign currency such as the RMB, the amount of the dividend distribution that you must include
in your income as a U.S. holder will be the U.S. dollar value of the payments made in the foreign currency, determined at the spot
rate of the foreign currency to the U.S. dollar on the date the dividend distribution is includible in your income, regardless of
whether the payment is in fact converted into U.S. dollars. Thus, if the value of the foreign currency decreases before you actually
convert the currency into U.S. dollars, you will be taxed on a larger amount in U.S. dollars than the U.S. dollar amount that you will
actually ultimately receive.
Future
inflation in China may inhibit economic activity and adversely affect the Company’s operations.
The
Chinese economy has experienced periods of rapid expansion in recent years which can lead to high rates of inflation or deflation. This
has caused the PRC government to, from time to time, enact various corrective measures designed to restrict the availability of credit
or regulate growth and contain inflation. High inflation may in the future cause the PRC government to once again impose controls on
credit and/or prices, or to take other action, which could inhibit economic activity in China. Any action on the part of the PRC government
that seeks to control credit and/or prices may adversely affect the Company’s business operations.
PRC
laws and regulations have established more complex procedures for certain acquisitions of Chinese companies by foreign investors, which
could make it more difficult for the Company to pursue growth through acquisitions in China.
Further
to the Regulations on Mergers and Acquisitions of Domestic Enterprises by Foreign Investors, or the New M&A Rules, the Anti-monopoly
Law of the PRC, the Rules of Ministry of Commerce on Implementation of Security Review System of Mergers and Acquisitions of Domestic
Enterprises by Foreign Investors promulgated by MOFCOM or the MOFCOM Security Review Rules, was issued in August 2011, which established
additional procedures and requirements that are expected to make merger and acquisition activities in China by foreign investors more
time-consuming and complex, including requirements in some instances that MOFCOM be notified in advance of any change of control transaction
in which a foreign investor takes control of a PRC enterprise, or that the approval from MOFCOM be obtained in circumstances where overseas
companies established or controlled by PRC enterprises or residents acquire affiliated domestic companies. PRC laws and regulations also
require certain merger and acquisition transactions to be subject to merger control review and or security review.
The
MOFCOM Security Review Rules, effective from September 1, 2011, which implement the Notice of the General Office of the State Council
on Establishing the Security Review System for Mergers and Acquisitions of Domestic Enterprises by Foreign Investors promulgated on February
3, 2011, further provide that, when deciding whether a specific merger or acquisition of a domestic enterprise by foreign investors is
subject to the security review by MOFCOM, the principle of substance over form should be applied and foreign investors are prohibited
from bypassing the security review requirement by structuring transactions through proxies, trusts, indirect investments, leases, loans,
control through agreements control or offshore transactions.
Further,
if the business of any target company that the Company seeks to acquire falls into the scope of security review, the Company may not
be able to successfully acquire such company either by equity or asset acquisition, capital contribution or through any VIE Agreement.
The Company may grow its business in part by acquiring other companies operating in its industry. Complying with the requirements of
the relevant regulations to complete such transactions could be time consuming, and any required approval processes, including approval
from MOFCOM, may delay or inhibit its ability to complete such transactions, which could affect its ability to maintain or expand its
market share.
In
addition, SAFE promulgated the Circular on the Settlement of Foreign Currency Capital of Foreign-invested Enterprises, or Circular 19,
on June 1, 2015. Under Circular 19 (partly modified by Huifa No.39 [2019]), registered capital of a foreign-invested company settled
in RMB converted from foreign currencies may only be used within the business scope approved by the applicable governmental authority
and the equity investments in the PRC made by the foreign-invested company shall be subject to the relevant laws and regulations about
the foreign-invested company’s reinvestment in the PRC. In addition, foreign-invested companies cannot use such capital to make
the investments on securities, and cannot use such capital to issue the entrusted RMB loans (except approved in its business scope),
repay the RMB loans between the enterprises and the ones which have been transferred to the third party. Circular 19 may significantly
limit our ability to effectively use the proceeds from future financing activities as the Chinese subsidiaries may not convert the funds
received from us in foreign currencies into RMB, which may adversely affect their liquidity and our ability to fund and expand our business
in the PRC.
Failure
to comply with the United States Foreign Corrupt Practices Act and Chinese anti-corruption laws could subject us to penalties and other
adverse consequences.
As
our shares are quoted on OTC, we are subject to the United States Foreign Corrupt Practices Act, which generally prohibits United
States companies from engaging in bribery or other prohibited payments to foreign officials for the purpose of obtaining or
retaining business. Non-U.S. companies, including some that may compete with us, may not be subject to these prohibitions.
Corruption, extortion, bribery, pay-offs, theft and other fraudulent practices may occur from time-to-time in the PRC. Our employees
or other agents may engage in such conduct for which we might be held responsible. If our employees or other agents are found to
have engaged in such practices, we could suffer severe penalties and other consequences that may have a material adverse effect on
our business, financial condition and results of operations.
Our
management may have to expend time and resources becoming familiar with United States securities laws, which could lead to various regulatory
issues.
Management
of the Company has limited familiarity with United States securities laws. They may have to expend time and resources becoming more familiar
with such laws. This could be expensive and time-consuming and could lead to various regulatory issues, which may adversely affect our
operations.
If
we become directly subject to the recent scrutiny, criticism and negative publicity involving U.S.-listed Chinese companies, we may have
to expend significant resources to investigate and resolve the matter which could harm our business operations and our reputation and
could result in a loss of your investment in our shares, especially if such matter cannot be addressed and resolved favorably.
U.S.
public companies that have substantially all of their operations in China have been the subject of intense scrutiny, criticism and negative
publicity by investors, financial commentators and regulatory agencies, such as the SEC. Much of the scrutiny, criticism and negative
publicity has centered around financial and accounting irregularities, a lack of effective internal controls over financial accounting,
inadequate corporate governance policies or a lack of adherence thereto and, in many cases, allegations of fraud. As a result of the
scrutiny, criticism and negative publicity, the publicly traded stock of many U.S. listed Chinese companies has sharply decreased in
value and, in some cases, has become virtually worthless. Many of these companies are now subject to shareholder lawsuits and SEC enforcement
actions and are conducting internal and external investigations into the allegations. It is not clear what effect this sector-wide scrutiny,
criticism and negative publicity will have on our company and our business. If we become the subject of any unfavorable allegations,
whether such allegations are proven to be true or untrue, we will have to expend significant resources to investigate such allegations
and/or defend the Company. This situation may be a major distraction to our management. If such allegations are not proven to be groundless,
our Company and business operations will be severely hampered and your investment in our stock could be rendered worthless.
The
disclosures in our reports and other filings with the SEC and our other public pronouncements are not subject to the scrutiny of any
regulatory bodies in the PRC.
Our
reports and other filings with the SEC are subject to SEC review in accordance with the rules and regulations promulgated by the SEC
under the Securities Act and the Exchange Act. Our SEC filings and other disclosure and public pronouncements are not subject to the
review or scrutiny of any PRC regulatory authority. For example, the disclosure in our SEC reports and other filings are not subject
to the review by CSRC, a PRC regulator that is tasked with oversight of the capital markets in China. Accordingly, you should review
our SEC reports, filings and our other public pronouncements with the understanding that no local regulator has done any review of our
Company, our SEC reports, other filings or any of our other public pronouncements.
There
are uncertainties under the PRC laws relating to the procedures for U.S. regulators to investigate and collect evidence from companies
located in the PRC.
Shareholder
claims that are common in the U.S., including securities law class actions and fraud claims, among other matters, generally are difficult
to pursue as a matter of law or practicality in China. For example, in China, there are significant legal and other obstacles to obtaining
information needed for shareholder investigations or litigation outside China or otherwise with respect to foreign entities. Although
the local authorities in China may establish a regulatory cooperation mechanism with the securities regulatory authorities of another
country or region to implement cross-border supervision and administration, such regulatory cooperation with the securities regulatory
authorities in the Unities States have not been efficient in the absence of mutual and practical cooperation mechanism. According to
Article 177 of the PRC Securities Law, which became effective in March 2020, or Article 177, the securities regulatory authority of the
State Council may collaborate with securities regulatory authorities of other countries or regions in order to monitor and oversee cross
border securities activities. Article 177 further provides that overseas securities regulatory authorities are not permitted to carry
out investigation and evidence collection directly within the territory of the PRC, and that any Chinese entities and individuals are
not allowed to provide documents or materials related to securities business activities to overseas agencies without prior consent of
the securities regulatory authority of the State Council and the competent departments of the State Council.
Our
principal business operations are conducted in the PRC. In the event that any U.S. regulators carry out investigations with respect to
our business and need to conduct investigation or collect evidence within the territory of the PRC, the U.S. regulators may not be able
to carry out such investigation or evidence collection directly in the PRC under the PRC laws. U.S. regulators may consider cross-border
cooperation with securities regulatory authority of the PRC by way of judicial assistance, diplomatic channels or regulatory cooperation
mechanism established with the securities regulatory authority of the PRC. However, there can be no assurance that the U.S. regulators
could succeed in establishing such cross-border cooperation in a specific case or could establish the cooperation in a timely manner.
If U.S. regulators are unable to conduct such investigations, they may determine to suspend the quotation of our securities on the OTC
markets or choose to suspend or de-register our SEC registration.
Newly
enacted Holding Foreign Companies Accountable Act, recent regulatory actions taken by the SEC and the Public Company Accounting Oversight
Board, or the PCAOB, and proposed rule changes submitted by U.S. stock exchanges calling for additional and more stringent criteria to
be applied to China-based public companies could add uncertainties to our capital raising activities and compliance costs.
In
April 2020, the SEC then-Chairman, Jay Clayton, and PCAOB Chairman, William D. Duhnke III, along with other senior SEC staff, released
a joint statement highlighting the risks associated with investing in companies based in or have substantial operations in emerging markets
including China. The joint statement emphasized the risks associated with lack of access for the PCAOB to inspect auditors and audit
work papers in China and higher risks of fraud in emerging markets.
In
May 2020, the U.S. Senate passed the Holding Foreign Companies Accountable Act (“HFCAA” or the “Act”) requiring
a foreign company to certify it is not owned or controlled by a foreign government if the PCAOB is unable to audit specified reports
because the company uses a foreign auditor not subject to PCAOB inspection. If the PCAOB is unable to inspect the company’s auditors
for three consecutive years, the issuer’s securities are prohibited to trade on a national exchange.
In
August 2020, the President’s Working Group on Financial Markets (“PWG”) issued a Report on Protecting United States
Investors from Significant Risks from Chinese Companies. The Report made five recommendations designed to address risks to investors
in U.S. financial markets posed by the Chinese government’s failure to allow audit firms that are registered with the PCAOB to
comply with U.S. securities laws and investor protection requirements. Among the recommendations was advice to enhance the listing standards
of U.S. exchanges to require, as a condition of initial and continued exchange listing, PCAOB access to main auditor work papers either
directly or through co-audits.
On
December 2, 2020, the U.S. House of Representatives passed the HFCAA. On December 18, the HFCAA was signed into law. Among other things,
the HFCAA amends the Sarbanes-Oxley Act of 2002 to require the SEC to prohibit the securities of foreign companies from being traded
on U.S. securities markets, if the company retains a foreign accounting firm that cannot be inspected or investigated completely by the
PCAOB for three consecutive years, beginning in 2021. The Act also requires foreign companies to make certain disclosures about their
ownership by governmental entities.
On
March 24, 2021, the SEC adopted interim final amendments and on December 2, 2021, the SEC adopted final amendments to implement congressionally
mandated submission and disclosure requirements of the HFCAA. The interim final amendments will apply to registrants that the SEC
identifies as having filed an annual report on Form 20-F and other forms with an audit report issued by a registered public accounting
firm that is located in a foreign jurisdiction and that the PCAOB has determined it is unable to inspect or investigate completely because
of a position taken by an authority in that jurisdiction. The SEC will implement a process for identifying such a registrant and any
such identified registrant will be required to submit documentation to the SEC establishing that it is not owned or controlled by a governmental
entity in that foreign jurisdiction, and will also require disclosure in a company’s annual report regarding the audit arrangements
of, and governmental influence on, such a registrant.
The
lack of access to the audit work paper or other inspections prevents the PCAOB from fully evaluating audits and quality control procedures
of the auditors based in China. As a result, investors may be deprived of the benefits of such PCAOB inspections. The inability of the
PCAOB to conduct inspections of auditors in China makes it more difficult to evaluate the effectiveness of those accounting firms’
audit procedures or quality control procedures as compared to auditors outside of China that are subject to the PCAOB inspections.
After
SEC issued new disclosure requirements to Chinese companies seeking to list on Nasdaq, SEC approved the Public Company Accounting Oversight
Board’s (PCAOB) Rule 6100 establishing framework for determinations under the HFCAA. On December 20, 2021, the SEC’s Division of
Corporation Finance (the “Division”) posted an illustrative letter containing sample comments that the Division may issue to
China-based companies describing 15 areas where the agency encourages existing and future China-based listings to increase disclosures.
On December 20, 2021, the PCAOB issued a report on its determinations that the PCAOB is unable to inspect or investigate completely
PCAOB-registered public accounting firms headquartered in mainland because of positions taken by PRC authorities in those jurisdictions.
Our
independent registered public accounting firm that issued the audit report for our financial statements for 2021, as an auditor of companies
that are traded publicly in the United States and a firm registered with the PCAOB, is subject to laws in the United States pursuant
to which the PCAOB conducts regular inspections to assess our auditor’s compliance with the applicable professional standards.
Our auditor is based on the U.S. and has been inspected by the PCAOB on a regular basis. However, the recent U.S. legislative and evolving
regulatory environments as related to PRC companies listing or seeking to list stock on U.S. exchanges would add uncertainties to the
trading and price volatility of our common shares. The rules and guidelines applicable in the future are unclear and may affect the progress
of our application. We cannot be certain whether SEC or other U.S. regulatory authorities would apply additional and more stringent criteria
to Chinese issuers including us as related to the audit of our financial statements. These additional requirements and more stringent
criteria to be applied could add potential risks to our business and share price. Investigations under more strict scrutiny brought significant
impact to the Company that may materially and adversely affect your stock holdings value, reduces the value of your investment.
Additional
factors outside of our control related to doing business in China could negatively affect our business.
Additional
factors that could negatively affect our business include a potential significant revaluation of the Renminbi, which may result in an
increase in the cost of commodity or products in the PRC supply chain industry, labor shortages and increases in labor costs in China
as well as difficulties in moving products manufactured in China out of the country, whether due to infrastructure inadequacy, labor
disputes, slowdowns, PRC regulations and/or other factors. Prolonged disputes or slowdowns can negatively impact both the time and cost
of goods. Natural disasters or health pandemics impacting China can also have a significant negative impact on our business. Further,
the imposition of trade sanctions or other regulations against products supplied or sold in the supply chain industry transactions for
which we provide solutions or the loss of “normal trade relations” status with China could significantly affect our operating
results and harm our business.
The
risk related to products quality responsibility and personal claims.
The
Company’s subsidiaries and related parties’ business scope involve the operation and distribution of medical device, in product
liability claims we should be liable for compensation according to the Civil Law, the Product Quality Law and the Tort Liability Law
in below circumstances: (1)Where physical injury is caused to a person or damage to another person’s property by a product’s defect resulting
from the seller’s fault; (2) Where the seller can identify neither the producer of the defective product nor the supplier thereof; (3)
Where a defective product causes physical injury to a person or damage to another person’s property, the victim may claim compensation
from the producer or from the seller of such product. We may be involved in any litigation regarding the products we sold or distributed
due to our contractual relationship with other companies. If we lose the lawsuit, the damages can be very substantial, even if we are
found not liable, the costs of litigation can be quite substantial. Additional, product liability dispute litigation may cause adversely
affect on our business reputation and efficiency, further, affect or interrupt the company’s operations and revenue.
Risks
arising from reliance on third-party service providers and intellectual property rights risk.
The
Company’s subsidiaries have co-operation agreements with technology enterprises that have patent or other independent intellectual
property rights which have been properly registered with regulatory agencies such as the State Intellectual Property Office and Trademark
Office of China’s State Administration for Industry and Commerce (SAIC). Our service and reputation significantly rely on the third-party
suppliers mentioned above. If (i) the PRC authorities invalidate these agreements for violation of PRC laws, rules, and regulations,
(ii) the agreements are valid but can not be performed, or (iii) any parties fail to perform their obligations under these agreements,
our business operations in China would be materially and adversely affected, and the value of your stock would substantially decrease.
If a third party fails to perform or defective perform its contractual obligations, it will lead to a failure to provide products or
services according to meet our consumers’ requirements, we may have to take legal action to compel them to fulfill their contractual
obligations. The Company depends on third parties to a large extent that it could not enable us to feasibly monitor the behavior of third
parties to reasonably avoid contractual risks. Further, because intellectual property rights are owned by a third party, it is difficult
for the company to restrain third parties from intellectual property infringement or default disclosure of trade secrets. This could
harm our reputation and business position.
Federal
and state privacy laws, and equivalent laws of third countries, may increase our costs of operation and expose us to civil and criminal
sanctions.
The
Health Insurance Portability and Accountability Act of 1996, as amended, and the regulations that have been issued under it, or collectively
HIPAA, and similar laws outside the United States, contain substantial restrictions and requirements with respect to the use and disclosure
of individuals’ protected health information. The HIPAA privacy rules prohibit “covered entities,” such as healthcare
providers and health plans, from using or disclosing an individual’s protected health information, unless the use or disclosure
is authorized by the individual or is specifically required or permitted under the privacy rules. Under the HIPAA security rules, covered
entities must establish administrative, physical and technical safeguards to protect the confidentiality, integrity and availability
of electronic protected health information maintained or transmitted by them or by others on their behalf. While we do not believe that
we will be a covered entity under HIPAA, we believe many of our customers will be covered entities subject to HIPAA. Such customers may
require us to enter into business associate agreements, which will obligate us to safeguard certain health information we obtain in the
course of our relationship with them, restrict the manner in which we use and disclose such information and impose liability on us for
failure to meet our contractual obligations.
In
addition, under The Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, which was signed into law
as part of the U.S. stimulus package in February 2009, certain of HIPAA’s privacy and security requirements are now also directly
applicable to “business associates” of covered entities and subject them to direct governmental enforcement for failure to
comply with these requirements. We may be deemed as a “business associate” of some of our customers. As a result, we may
be subject as a “business associate” to civil and criminal penalties for failure to comply with applicable privacy and security
rule requirements. Moreover, HITECH created a new requirement obligating “business associates” to report any breach of unsecured,
individually identifiable health information to their covered entity customers and imposes penalties for failing to do so.
In
addition to HIPAA, most U.S. states have enacted patient confidentiality laws that protect against the disclosure of confidential medical
information, and many U.S. states have adopted or are considering adopting further legislation in this area, including privacy safeguards,
security standards, and data security breach notification requirements. These U.S. state laws, which may be even more stringent than
the HIPAA requirements, are not preempted by the federal requirements, and we are therefore required to comply with them to the extent
they are applicable to our operations.
These
and other possible changes to HIPAA or other U.S. federal or state laws or regulations, or comparable laws and regulations in countries
where we conduct business, could affect our business and the costs of compliance could be significant. Failure by us to comply with any
of the standards regarding patient privacy, identity theft prevention and detection, and data security may subject us to penalties, including
civil monetary penalties and in some circumstances, criminal penalties. In addition, such failure may damage our reputation and adversely
affect our ability to retain customers and attract new customers.
The
protection of personal data, particularly patient data, is subject to strict laws and regulations in many countries. The collection and
use of personal health data in the EU is governed by the provisions of Directive 95/46/EC of the European Parliament and of the Council
of 24 October 1995 on the protection of individuals with regard to the processing of personal data and on the free movement of such data,
commonly known as the Data Protection Directive. The Directive imposes a number of requirements including an obligation to seek the consent
of individuals to whom the personal data relates, the information that must be provided to the individuals, notification of data processing
obligations to the competent national data protection authorities of individual EU Member States and the security and confidentiality
of the personal data. The Data Protection Directive also imposes strict rules on the transfer of personal data out of the EU to the U.S.
Failure to comply with the requirements of the Data Protection Directive and the related national data protection laws of the EU Member
States may result in fines and other administrative penalties and harm our business. We may incur extensive costs in ensuring compliance
with these laws and regulations, particularly if we are considered to be a data controller within the meaning of the Data Protection
Directive.
Once
we commercialize our product, if ever, security breaches, loss of data and other disruptions could compromise sensitive information related
to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business
and our reputation.
We
face four primary risks relative to protecting this critical information: loss of access risk, inappropriate disclosure risk, inappropriate
modification risk and the risk of our being unable to identify and audit our controls over the first three risks.
We
will be highly dependent on information technology networks and systems, including the Internet, to securely process, transmit and store
this critical information. Security breaches of this infrastructure, including physical or electronic break-ins, computer viruses, attacks
by hackers and similar breaches, can create system disruptions, shutdowns or unauthorized disclosure or modification of confidential
information. The secure processing, storage, maintenance and transmission of this critical information will be vital to our operations
and business strategy, and we plan to devote significant resources to protecting such information. Although we will take measures to
protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure, and that of our
third-party providers, may be vulnerable to attacks by hackers or viruses or breached due to employee error, malfeasance or other disruptions.
A
security breach or privacy violation that leads to disclosure or modification of or prevents access to consumer information (including
personally identifiable information or protected health information) could harm our reputation, compel us to comply with disparate state
breach notification laws, require us to verify the correctness of database contents and otherwise subject us to liability under laws
that protect personal data, resulting in increased costs or loss of revenue. If we are unable to prevent such security breaches or privacy
violations or implement satisfactory remedial measures, our operations could be disrupted, and we may suffer loss of reputation, financial
loss and other regulatory penalties because of lost or misappropriated information, including sensitive consumer data. In addition, these
breaches and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the
type described above.
Any
such breach or interruption could compromise our networks or those of our third-party providers, and the information stored there could
be inaccessible or could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such interruption in access, improper
access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy
of personal information, such as HIPAA, and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations,
including our ability to perform tests, provide test results, bill payers or patients, process claims and appeals, provide customer assistance
services, conduct research and development activities, collect, process and prepare company financial information, provide information
about our current and future products and other patient and clinician education and outreach efforts through our website, and manage
the administrative aspects of our business and damage our reputation, any of which could adversely affect our business. Any such breach
could also result in the compromise of our trade secrets and other proprietary information, which could adversely affect our competitive
position.
In
addition, the interpretation and application of consumer, health-related, privacy and data protection laws in the U.S., the EU and elsewhere
are often uncertain, contradictory and in flux. It is possible that these laws may be interpreted and applied in a manner that is inconsistent
with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could
adversely affect our business. Complying with these various laws could cause us to incur substantial costs or require us to change our
business practices and compliance procedures in a manner adverse to our business.
Risks
Related to our Operations as a Public Company and our Securities
If financial performance do not meet the
expectations of investors, shareholders or financial analysts, the market price of the Company’s securities may be volatile and
decline .
If our business and/or financial performance
do not meet the expectations of investors or securities analysts, the market price of the Company’s securities may decline. If
an active market for the Company’s securities develops and continues, the trading price of our securities could be volatile and
subject to wide fluctuations in response to various factors, some of which are beyond our control. Any of the factors listed below could
have a material adverse effect on your investment in the Company’s securities which may trade at prices significantly below the
price you paid for them. In such circumstances, the trading price of our securities may not recover and may experience a further decline.
Factors affecting the trading price of the Company’s securities
may include:
|
● |
actual or anticipated fluctuations in our quarterly financial results or the quarterly financial results of companies perceived to be similar to us; |
|
|
|
|
● |
changes in the market’s expectations about our operating results; |
|
|
|
|
● |
success of competitors; |
|
|
|
|
● |
our operating results failing to meet the expectation of securities analysts or investors in a particular period; |
|
|
|
|
● |
changes in financial estimates and recommendations by securities analysts concerning the Company or the lending market in general; |
|
|
|
|
● |
operating and stock price performance of other companies that investors deem comparable to the Company; |
|
|
|
|
● |
our ability to market new and enhanced services on a timely basis; |
|
● |
changes in laws and regulations affecting our business; |
|
|
|
|
● |
commencement of, or involvement in, litigation involving the Company; |
|
|
|
|
● |
the Company’s ability to access the capital markets as needed; |
|
|
|
|
● |
changes in the Company’s capital structure, such as future issuances of securities or the incurrence of additional debt; |
|
|
|
|
● |
the volume of ordinary shares available for public sale; |
|
|
|
|
● |
any major change in our board or management; |
|
|
|
|
● |
sales of substantial amounts of ordinary shares by our directors, executive officers or significant shareholders or the perception that such sales could occur; and |
|
|
|
|
● |
general economic and political conditions such as recessions, interest rates, fuel prices, international currency fluctuations and acts of war or terrorism. |
Broad market and industry factors may materially
harm the market price of the Company’s securities irrespective of our operating performance. The stock market in general, has experienced
price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of the particular companies
affected. The trading prices and valuations of these stocks, and of our securities, may not be predictable. A loss of investor confidence
in the market for retail stocks or the stocks of other companies which investors perceive to be similar to the Company could depress
our stock price regardless of our business, prospects, financial condition or results of operations. A decline in the market price of
our securities also could adversely affect our ability to issue additional securities and our ability to obtain additional financing
in the future.
The
Company’s business and share and warrant prices may suffer as a result of the Company’s insufficient public company operating
experience and if securities or industry analysts do not publish or cease publishing research or reports about the Company, its business,
or its market, or if they change their recommendations regarding our ordinary shares adversely, the price and trading volume of our ordinary
shares and warrants could decline.
The Company has been a public company for a limited number of years.
The Company’s insufficient public company operating experience may make it difficult to forecast and evaluate its future prospects.
If the Company is unable to execute its business strategy, either as a result of its inability to effectively manage its business in a
public company environment or for any other reason, the Company’s business, prospects, financial condition and operating results
may be harmed.
The trading market for our ordinary shares and
warrants will be influenced by the research and reports that industry or securities analysts may publish about us, our business, our
market, or our competitors. Securities and industry analysts do not currently, and may never, publish research on the Company. If no
securities or industry analysts commence coverage of the Company, our ordinary share and warrant prices and trading volume would likely
be negatively impacted. If any of the analysts who may cover the Company change their recommendation regarding our shares adversely,
or provide more favorable relative recommendations about our competitors, the price of our ordinary shares and warrants would likely
decline. If any analyst who may cover the Company were to cease coverage of the Company or fail to regularly publish reports on it, we
could lose visibility in the financial markets, which could cause our share and warrant prices or trading volume to decline.
The Company has only registered a small
number of our ordinary shares issuable upon exercise of our warrants, and has not registered any of our ordinary shares underlying the
preferred shares under the Securities Act of 1933, as amended (the “Securities Act”) or state securities laws at this time,
and such registration may not be in place when an investor desires to exercise such warrants.
The Company has only registered a small number
of the ordinary shares issuable upon exercise of our warrants, and has not registered any of our ordinary shares underlying the preferred
shares under the Securities Act or any state securities laws at this time. We have agreed to use our best efforts to file with the SEC
a registration statement for the registration, under the Securities Act, covering these securities as soon as practicable after the closing
of the Business Combination and cause the same to become effective and to maintain the effectiveness of such registration statement, and
a current prospectus relating thereto.
Warrants we sold will become exercisable
for the Company’s ordinary shares, which would increase the number of shares eligible for future resale in the public market and
result in dilution to our shareholders.
In addition to the warrants issued before January
1, 2018, at an exercise price of $6.00 per one-half of one share ($12.00 per whole share), the Company issued in July 2018 Series A Warrants
at an exercise price of $2.6 per one share and adjusted to $1.18 per one share on January 19, 2019. All warrants are subject to adjustments.
Warrants may be exercised only for a whole number of the Company’s ordinary shares. No fractional shares will be issued upon exercise
of warrants. To the extent such warrants are exercised, additional ordinary shares will be issued, which will result in dilution to the
then existing holders of ordinary shares of the Company and increase the number of shares eligible for resale in the public market. Sales
of substantial numbers of such shares in the public market could adversely affect the market price of our ordinary shares.
The Company’s charter permits the
Board by resolution to amend our charter, including to create additional classes of securities, including shares with rights, preferences,
designations and limitations as they determine which may have an anti-takeover effect.
The Company’s charter permits the Board
by resolution to amend the charter including designating rights, preferences, designations and limitations attaching to the preferred
shares as they determine in their discretion, without shareholder approval with respect to the terms or the issuance. When issued, the
rights, preferences, designations and limitations of the preferred shares are set by the Board and can operate to the disadvantage of
the outstanding ordinary shares the holders of which would not have any pre-emption rights in respect of such an issue of preferred shares.
Such terms could include, among others, preferences as to dividends and distributions on liquidation, or can be used to prevent possible
corporate takeovers.
The Company is no longer a Nasdaq listed
company and, as a result, the Company may not be required to, and may choose not to, obey certain corporate governance requirements of
Nasdaq.
The Company’s ordinary shares have not been listed on the Nasdaq
since September 2019. As a result, the Company is no longer subject to Nasdaq rules. While the Company plans to continue following certain
corporate governance requirements of Nasdaq, it has the discretion not to and may elect to not obey any Nasdaq rules. Its shareholders
will not be afforded the same protections generally as shareholders of Nasdaq-listed companies for so long as the Company is not a Nasdaq
listed company.
The
Company may not be able to timely and effectively implement controls and procedures required by Section 404 of the Sarbanes-Oxley Act
of 2002.
The
Company is required to establish and maintain internal controls over financial reporting and disclosure controls and procedures and to
comply with other requirements of the Sarbanes-Oxley Act and the rules promulgated by the SEC. The Company is required to provide management’s
attestation on internal controls. The standards required for a public company under Section 404 of the Sarbanes-Oxley Act of 2002 are
significantly more stringent than those required of a privately held company. Management may not be able to effectively and timely implement
controls and procedures that adequately respond to the regulatory compliance and reporting requirements, especially considering the new
corporate structure after the Lixin Acquisition. If we are not able to implement the additional requirements of Section 404 in a timely
manner or with adequate compliance, we may not be able to assess whether our internal controls over financial reporting are effective,
which may subject us to adverse regulatory consequences and could harm investor confidence and the market price of our ordinary shares.
The
Company has material weaknesses in its controls and procedures required by Section 404 of the Sarbanes-Oxley Act of 2002. This material
weakness may call into question the accuracy of our financial statements which could harm our business and adversely affect the trading
price of our ordinary shares.
The Company is required to establish and maintain
internal controls over financial reporting and disclosure controls and procedures and to comply with other requirements of the Sarbanes-Oxley
Act and the rules promulgated by the SEC. The Company is required to provide management’s attestation on internal controls. The
standards required for a public company under Section 404 of the Sarbanes-Oxley Act of 2002 are significantly more stringent than those
required of a privately held company. Based on our assessment, as of December 31, 2021, we determined that there were material weaknesses
in our internal control over financial reporting. We believe these material weaknesses mainly resulted from our not having sufficient
personnel with appropriate levels of accounting knowledge and experience to address complex U.S. GAAP accounting issues and to prepare
and review financial statements and related disclosures under U.S. GAAP. There can be no assurance that the steps we have taken to remedy
these material weaknesses will be effective. Any continued material weakness may result in investors believing they may not rely on the
accuracy in our financial statements. This could cause our stock price to decline and any resulting material errors could cause us to
have to restate our financial statements which would be costly and could further erode investor confidence.
There
is no guarantee that our warrants will ever be in the money, and they may expire worthless and the terms of our warrants may be amended.
In
addition to the warrants issued before January 1, 2018, at an exercise price of $6.00 per one-half of one share ($12.00 per whole
share), A Warrants at an exercise price of $2.60 per one share which was adjusted to $1.18 per one share on January 19, 2019. All
warrants are subject to adjustments. Warrants may be exercised only for a whole number of the Company’s ordinary shares. No
fractional shares will be issued upon exercise of the warrants. There is no guarantee that the warrants will ever be in the money
prior to their expiration, and they may expire worthless. The Series A Warrants are the Company’s only outstanding warrants
prior to the Reverse Split and such warrants will expire on July 9, 2022.
A
market for the Company’s securities may not continue, which would adversely affect the liquidity and price of our securities.
The
price of the Company’s securities may fluctuate significantly due to the market’s reaction and general market and economic
conditions. An active trading market for our securities may never develop or, if developed, it may not be sustained. In addition, the
price of the Company’s securities can vary due to general economic conditions and forecasts, our general business condition and
the release of our financial reports. Additionally, because the Company’s ordinary shares were delisted from the Nasdaq Capital
Market in September 2019, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities
that is not a national securities exchange, the liquidity and price of our securities are more limited than when we were listed on the
Nasdaq Capital Market. You may be unable to sell your securities unless a market can be established or sustained.
Because
the Nasdaq Capital Market delisted the Company’s ordinary shares from trading on its exchange due to our failure to meet the Nasdaq
Capital Market’s initial and/or continued listing standards, we and our security holders face significant material adverse consequences
including:
| ● | a
limited availability of market quotations for our securities; |
| ● | a
determination that our ordinary shares are a “penny stock,” which requires brokers
trading in our ordinary shares to adhere to more stringent rules, resulting in a reduced
level of trading activity in the secondary trading market for our ordinary shares; |
| ● | a
limited amount of analyst coverage; and |
| ● | a
decreased ability to issue additional securities or obtain additional financing in the future. |
Although
we are making significant efforts to help our ordinary shares be listed on the Nasdaq Capital Market again, there can be no assurance
that we will succeed or, if listed, that we will be able to comply with the continued listing standards of Nasdaq.
Our
ordinary shares were delisted from the Nasdaq Capital Market in September 2019. To list the Company’s securities on the Nasdaq
Capital Market again, among other conditions, we will be required to demonstrate compliance with Nasdaq’s initial listing standards,
which are more rigorous than Nasdaq’s continued listing requirements. For instance, the Company must maintain a minimum number
of holders (300 round-lot holders). While we are working hard and spending significant resources on applying for listing on Nasdaq again,
we cannot assure you that we will be able to meet those initial listing standards and/or any other conditions.
Risks
Related to Our Ordinary Shares, the Warrants and this Offering
An
active trading market for our ordinary shares and warrants has not developed on the OTCQB and may not develop in the
future regardless of where our stock is quoted or listed. As a result, our shareholders may not be able to resell their ordinary
shares.
Although
our ordinary shares are quoted on the OTCQB, an active trading market for our ordinary shares has not developed. While we
intend to apply to have our ordinary shares and warrants listed on The Nasdaq Capital Market, any such uplisting would likely
require that we conduct a substantial financing which we may be unable to do. If we are unsuccessful in our uplisting, we would
remain on the OTCQB which could inhibit our ability to cause an active trading market to develop. Even if we are successful in
listing on the Nasdaq Capital Market, an active trading market for our shares may never develop or be sustained. We cannot predict
the extent to which an active market for our ordinary shares or warrants will develop or be sustained if we are able to list such
securities on Nasdaq. If an active market for our ordinary shares or warrants does not develop, it may be difficult for you to sell
securities you own without depressing the market price for the shares or warrants, or at all.
Future
issuance of our ordinary shares could dilute the interests of existing shareholders.
We
may issue additional ordinary shares in the future. The issuance of a substantial number of ordinary shares could have the effect of
substantially diluting the interests of our shareholders. In addition, the sale of a substantial amount of ordinary shares in the public
market, in the initial issuance, in a situation in which we acquire a company and the acquired company receives ordinary shares as consideration
and the acquired company subsequently sells its ordinary shares, or by investors who acquired such ordinary shares in a private placement,
could have an adverse effect on the market price of our ordinary shares.
We have some warrants outstanding, and while
these warrants are outstanding, it may be more difficult to raise additional equity capital.
As of December 31, 2021, we had outstanding warrants
to purchase 623,078 ordinary shares. The holders
of these warrants have the opportunity to profit from a rise in the market price of our ordinary shares. We may find
it more difficult to raise additional equity capital while these warrants are outstanding. At any time during which these warrants are
likely to be exercised, we may be unable to obtain additional equity capital on more favorable terms from other sources. Additionally,
the exercise of these warrants will cause the increase of our outstanding ordinary shares, which could have the effect of substantially
diluting the interests of our current shareholders.
Sales
of a substantial number of shares of our ordinary shares in the public market by our existing shareholders could cause our share
price to fall.
Sales of a substantial
number of our ordinary shares in the public market, or the perception that these sales might occur, could depress the market price of
our ordinary shares and could impair our ability to raise capital through the sale of additional equity securities. We are unable to
predict the effect that sales may have on the prevailing market price of our ordinary shares. All of the shares owned by our directors,
officers and shareholders that own over 5% of our ordinary shares on a fully diluted basis are subject to lock-up agreements with the
underwriters of this offering that restrict such shareholders’ ability to transfer our ordinary shares for at least six months
from the date of this prospectus. All of our outstanding shares held by our directors, officers and shareholders that own over 5% of
our ordinary shares on a fully diluted basis will become eligible for unrestricted sale upon expiration of the lockup period, as described
in the sections of this prospectus entitled “Shares Eligible for Future Sale” and “Underwriting.” In addition,
shares issued or issuable upon exercise of options and warrants vested as of the expiration of the lock-up period will be eligible for
sale at that time. Sales of shares by these shareholders could have a material adverse effect on the trading price of our ordinary shares.
We intend to register the offering, issuance, and sale of all ordinary shares that we may issue under our equity compensation plans.
Once we register these shares, they can be freely sold in the public market upon issuance, subject to volume limitations applicable to
affiliates and the lock-up agreements described in the “Underwriting” section of this prospectus. Also,
we have granted “piggyback” registration rights to certain investors concurrently with the consummation of our IPO, in October
2014, pursuant to a Registration Rights Agreement. Upon the effectiveness of a future registration statement in which their shares are
included pursuant to the exercise of these piggyback rights, these stockholders will be able to freely sell their ordinary shares in
the public market without restriction, which sales could materially and adversely affect the trading price of our ordinary shares.
We
are a foreign private issuer and, as a result, we are not subject to U.S. proxy rules and are subject to reporting obligations that,
to some extent, are more lenient and less frequent than those applicable to a U.S. issuer.
Because
we qualify as a foreign private issuer under the Exchange Act, we are exempt from certain provisions of the Exchange Act that are applicable
to U.S. publicly reporting companies, including (i) the sections of the Exchange Act regulating the solicitation of proxies, consents
or authorizations in respect of a security registered under the Exchange Act, (ii) the sections of the Exchange Act requiring insiders
to file public reports of their stock ownership and trading activities and liability for insiders who profit from trades made in a short
period of time, and (iii) the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing
unaudited financial and other specified information, or current reports on Form 8-K, upon the occurrence of specified significant events.
In addition, while U.S. domestic issuers that are not large accelerated filers or accelerated filers are required to file their annual
reports on Form 10-K within 90 days after the end of each fiscal year, foreign private issuers are not required to file their annual
report on Form 20-F until 120 days after the end of each fiscal year. Foreign private issuers are also exempt from the Regulation Fair
Disclosure, aimed at preventing issuers from making selective disclosures of material information.
We
have not paid cash dividends on our capital stock since 2017 and we do not anticipate paying any further dividends in the
foreseeable future. Consequently, any gains from an investment in our ordinary shares will likely depend on whether the price of our
ordinary shares increases, which may not occur.
We have not paid cash dividends our ordinary
shares since 2017 and we currently intend to retain our future earnings, if any, to fund the development and growth of our business.
In addition, the BVI Law imposes restrictions on our ability to declare and pay dividends. As a result, capital appreciation, if any,
of our ordinary shares will be your sole source of gain for the foreseeable future. Consequently, in the foreseeable future, you will
likely only experience a gain from your investment in our ordinary shares if the price of our ordinary shares increases beyond the price
in which you originally acquired the ordinary shares.
The
current and potential future application of the SEC’s “penny stock” rules to our ordinary shares could limit
trading activity in the market, and our shareholders may find it more difficult to sell their shares.
If
our ordinary shares continue to trade at less than $5.00 per share we will continue to be subject to the SEC’s penny stock
rules. Penny stocks generally are equity securities with a price of less than $5.00. Penny stock rules require a broker-dealer,
prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document that
provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer
with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the
transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. The
broker-dealer must also make a special written determination that the penny stock is a suitable investment for the purchaser and
receive the purchaser’s written agreement to the transaction. These requirements may have the effect of reducing the level of
trading activity, if any, in the secondary market for a security that becomes subject to the penny stock rules. The additional
burdens imposed upon broker-dealers by such requirements may discourage broker-dealers from effecting transactions in our
securities, which could severely limit their market price and liquidity of our securities. These requirements may restrict the
ability of broker-dealers to sell our ordinary shares and may affect our shareholders’ ability to resell their ordinary
shares.
In
the event a market develops for our ordinary shares, the market price of our ordinary shares may be volatile.
In
the event a market develops for our ordinary shares, the market price of our ordinary shares may be highly volatile. Some of the factors
that may materially affect the market price of our ordinary shares are beyond our control, such as changes in financial estimates by
industry and securities analysts, conditions or trends in the industry in which we operate or sales of our ordinary shares. These factors
may materially adversely affect the market price of our ordinary shares, regardless of our performance. In addition, the public stock
markets have experienced extreme price and trading volume volatility. This volatility has significantly affected the market prices of
securities of many companies for reasons frequently unrelated to the operating performance of the specific companies. These broad market
fluctuations may adversely affect the market price of our ordinary shares.
If
we are or become classified as a passive foreign investment company, our U.S. shareholders may suffer adverse tax consequences as
a result.
Generally,
for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable
to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as
a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For purposes of these tests, passive income includes
dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets
which produce passive income (including amounts derived by reason of the temporary investment of funds raised in offerings of our shares)
and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct
of a trade or business. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having
gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential
rate applicable to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to
distributions by us and gains from the sales of our shares.
Our status as a PFIC will depend on the nature
and composition of our income and the nature, composition and value of our assets (which, assuming we are not a “controlled foreign
corporation,” or a CFC, under Section 957(a) of the Internal Revenue Code of 1986, as amended, or the Code, for the year being tested,
may be determined based on the fair market value of each asset, with the value of goodwill and going concern value determined in large
part by reference to the market value of our common shares, which may be volatile). Our status may also depend, in part, on how quickly
we utilize the cash proceeds from this offering in our business. Based upon the value of our assets, including any goodwill, and the nature
and composition of our income and assets, we do not believe that we were classified as a PFIC for the taxable year ended December 31,
2020 and we do not believe that we will be classified as a PFIC for the taxable year ending December 31, 2021 or in the immediately foreseeable
future. Because the determination of whether we are a PFIC for any taxable year is a factual determination made annually after the end
of each taxable year, there can be no assurance that we will not be considered a PFIC in any taxable year. Accordingly, our legal counsel
expresses no opinion with respect to our PFIC status for our taxable year ended December 31, 2018, and also expresses no opinion
with regard to our expectations regarding our PFIC status in the future.
The
tax consequences that would apply if we were classified as a PFIC would also be different from those described above if a U.S. shareholder
were able to make a valid qualified electing fund, or QEF, election. At this time, we do not expect to provide U.S. shareholders with
the information necessary for a U.S. shareholder to make a QEF election. Prospective investors should assume that a QEF election will
not be available.
The
intended tax effects of our corporate structure and intercompany arrangements depend on the application of the tax laws of various
jurisdictions and on how we operate our business.
Significant
judgment is required in evaluating our tax positions and determining our provision for income taxes. During the ordinary course of business,
there are many transactions and calculations for which the ultimate tax determination is uncertain. For example, our effective tax rates
could be adversely affected by changes in foreign currency exchange rates or by changes in the relevant tax, accounting and other laws,
regulations, principles and interpretations. As we intend to operate in numerous countries and taxing jurisdictions, the application
of tax laws can be subject to diverging and sometimes conflicting interpretations by tax authorities of these jurisdictions. It is not
uncommon for taxing authorities in different countries to have conflicting views, for instance, with respect to, among other things,
the manner in which the arm’s length standard is applied for transfer pricing purposes, or with respect to the valuation of intellectual
property. In addition, tax laws are dynamic and subject to change as new laws are passed and new interpretations of the law are issued
or applied. For example, on December 22, 2017, the Tax Cuts and Jobs Act was enacted, which introduced a comprehensive set of tax reforms.
We continue to assess the impact of such tax reform legislation on our business and may determine that changes to our structure, practice
or tax positions are necessary in light of the Tax Cuts and Jobs Act. Certain impacts of this legislation have been taken into account
in our financial statements, including the reduction of the U.S. corporate income tax rate from the previous 35 percent to 21 percent.
The Tax Cuts and Jobs Act in conjunction with the tax laws of other jurisdictions in which we operate, however, may require consideration
of changes to our structure and the manner in which we conduct our business. Such changes may nevertheless be ineffective in avoiding
an increase in our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.
If
tax authorities in any of the countries in which we operate were to successfully challenge our transfer prices as not reflecting arms’
length transactions, they could require us to adjust our transfer prices and thereby reallocate our income to reflect these revised transfer
prices, which could result in a higher tax liability to us. In addition, if the country from which the income is reallocated does not
agree with the reallocation, both countries could tax the same income, potentially resulting in double taxation. If tax authorities were
to allocate income to a higher tax jurisdiction, subject our income to double taxation or assess interest and penalties, it would increase
our consolidated tax liability, which could adversely affect our financial condition, results of operations and cash flows.
If
securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or
if they adversely change their recommendations or publish negative reports regarding our business or our shares, our share price
and trading volume could decline.
The
trading market for our ordinary shares will be influenced by the research and reports that industry or securities analysts may publish
about us, our business, our market or our competitors. We do not have any control over these analysts, and we cannot provide any assurance
that analysts will cover us or provide favorable coverage. If any of the analysts who may cover us adversely change their recommendation
regarding our shares, or provide more favorable relative recommendations about our competitors, our share price would likely decline.
If any analyst who may cover us were to cease coverage of our company or fail to regularly publish reports on us, we could lose visibility
in the financial markets, which in turn could cause our share price or trading volume to decline.
ITEM
4. INFORMATION ON THE COMPANY
A. |
History
and Development of the Company |
Corporate
History and Structure of our PRC Operation
Roan
Holdings Group Co., Ltd. (formerly DT Asia Investments Limited, or “DT Asia,” and subsequently China Lending Corporation)
(the “Company,” “Roan,” “we,” “us” or “our”) is a British Virgin Islands
company limited by shares. The Company was established on April 8, 2014 under the laws of the British Virgin Islands (“BVI”)
as a shell company with the purpose of acquiring, engaging in share exchange, share reconstruction and amalgamation, purchasing all or
substantially all of the assets of, entering into contractual arrangements, or engaging in any other similar business combination with
one or more businesses or entities. The address of our principal executive offices is 147 Ganshui Lane, Yuhuangshannan Fund Town,
Shangcheng District, Hangzhou, Zhejiang, China. Our current agent is SCS Secretarial Services Limited and its address is Room 703, 7th
Floor, Beautiful Group Tower, 77 Connaught Road Central, Hong Kong.
The SEC maintains an Internet site that contains reports,
proxy and information statements, and other information regarding issuers that file electronically with the SEC and state the address
of that site (http://www.sec.gov). Our website is www.roanholdingsgroup.com. The information contained on our website is not incorporated
by reference and does not form part of this annual report on Form 20-F.
We refer to “Item
5. Operating and Financial Review and Prospects” for the description of our recent investments. Apart from these investments, there
have been no material capital expenditures in the last three years. The material divestitures are listed below under the title “Dispositions
of China Roan Industrial-Financial Holdings Group Co., Limited and subsidiaries”.
On
July 6, 2016, the Company consummated a business combination (the “First Business Combination”) with Adrie Global Holdings
Limited (“Adrie”) and its subsidiaries and variable interest entity (“VIE”) by acquiring from the shareholders
of Adrie all of outstanding equity interests of Adrie in exchange for 20 million ordinary shares of DT Asia and a purchase price of $200.0
million. Adrie, through its subsidiaries and VIE, was engaged in the business of providing loan facilities to micro, small and medium
sized enterprises (“MSMEs”) and sole proprietors in Xinjiang Uyghur Autonomous Region (“XUAR”) of
the People’s Republic of China (“PRC”). As a result of the business combination, shareholders of Adrie became the controlling
shareholders of the Company, and Adrie became a subsidiary of the Company. For financial reporting purpose, the consolidated assets,
liabilities and results of operations of Adrie became the historical financial statements of the Company, and the Company’s assets,
liabilities and results of operations were consolidated with that of Adrie beginning on the acquisition date. Immediately following the
First Business Combination, the Company’s name was changed from DT Asia to China Lending Corporation (“CLDC”).
In
June through December 2019, the Company consummated a second business combination with Lixin Financial Holdings Group Limited (“Lixin
Cayman”) and its subsidiaries, pursuant to which the Company acquired a majority interest in Lixin Cayman (the “Second Business
Combination” or “Lixin Acquisition”) (discussed below). In connection with the Second Business Combination, the Company
was renamed Roan Holdings Group Co., Ltd. (“Roan”) in November 2019. Roan is a holding company and conducts business operations
through its direct and indirect subsidiaries.
ADRIE
Global Holding Limited (“Adrie”) was established under the laws of the BVI as a company limited by shares on November 19,
2014 and became a wholly-owned subsidiary of the Company after the First Business Combination. Adrie is a holding company that has no
substantial operations and has no assets other than its ownership of a wholly-owned subsidiary.
China Roan Industrial-Financial Holdings Group Co., Ltd. (中国融安产融控股集团有限公司)
(“Roan HK” or “RAHK”) (formerly China Feng Hui Financial Holding Group Co., Ltd, and subsequently, China Fenghui Industrial-Financial
Holding Group Co. Ltd.) is a wholly-owned subsidiary of Adrie. It was established on February 11, 2015 under the laws of the Hong Kong
Special Administrative Region (“Hong Kong”) of the PRC. It is a holding company and conducts business through its direct and
indirect subsidiaries. On September 30, 2021, the Company disposed Roan HK and its subsidiaries, Xinjiang Feng Hui Jing Kai Direct Lending
Limited (新疆丰汇经开小额贷款有限公司) (“Jing
Kai”).
Fortis
Industrial Group Limited (富通产业集团有限公司) (“Fortis” or
“FIG”,formerly called Fortis Health Industrial Group Limited or 富通健康产业集团有限公司)
was established on December 30, 2019 under the laws of Hong Kong. It is a wholly owned subsidiary of Adrie. It is a holding
company and conducts business through its direct and indirect subsidiaries.
Yifu Health Industry (Ningbo) Co., Ltd. (怡福健康产业(宁波)有限公司)
(“Yi Fu”) is a wholly-owned subsidiary of Fortis and is engaged in healthcare related professional services business. Prior
to August 7, 2020, Yi Fu conducted financial leasing business under its prior corporate name of Ningbo Ding Tai Financial Leasing Co.,
Ltd. (宁波鼎泰融资租赁有限公司)
(“Ding Tai”). Ding Tai was established in December 19, 2016 under the laws of the PRC for the purpose of engaging in financial
leasing business. In July 2020, Roan HK transferred 100% of YiFu’s equity interest to Fortis, which is 100% owned by the Company.
Hangzhou
Zeshi Investment Partnership (Limited Partnership)
(杭州泽时投资合伙企业(有限合伙) (“Hangzhou
Zeshi”) was formed on November 29, 2018 under the laws of the PRC. It is a limited partnership with 98.04% of its interest
owned by Yi Fu, its general partner, and the remaining 1.96% is owned by Zeshi Insurance (discussed below). It is primarily engaged in asset
management business.
Through
Hangzhou Zeshi, we provide new supply chain financing services, including a business factoring program, financing products design,
related corporate financing solutions, investments and asset management, as part of our restructuring plan implemented in
2019.
Ningbo
Zeshi Insurance Technology Co., Ltd. (宁波泽时保险科技有限公司)
(“Zeshi Insurance”) was incorporated on February 28, 2020 under the laws of the PRC. Yi Fu owns 99% of Zeshi Insurance equity
interest with the remaining 1% owned by Hangzhou Zeshi. Its principal business is providing insurance technology services and related
services.
Zeshi
(Hangzhou) Health Management Co., Ltd. (泽时(杭州)健康管理有限公司)
(“Zeshi Health”) was incorporated on March 3, 2020 under the laws of the PRC. Hangzhou Zeshi and Yi Fu own 99% and 1%, respectively,
of its interest. Zeshi Health provides services in health management, health big data management and blockchain technology-based health
information management.
A
joint venture, Yijia Travel (Hangzhou) Digital Technology Co. Ltd.
(易佳行旅(杭州)数字科技有限公司)
(“Yijia Travel”), was incorporated on August 2, 2021 under the laws of the PRC. The Company and the Company’s
business partner, Shuzhiyun Holdings (Beijing) Co., Ltd. (“Shuzhiyun”), who signed an agreement with the Company to
vote in concert, own 35% and 30%, respectively, of its interest. Yijia Travel (Hangzhou) Digital Technology Co. Ltd. (“Yijia
Travel”) owns the remaining 30% equity in the joint venture. Yijia Travel provides business travel services.
A
joint venture, Fine C+ Health (Hangzhou) Technology Limited (乐享未来健康科技(杭州)有限公司)
(“FINE C+ Health”), was incorporated on October 14, 2021 under the laws of the PRC. The Company’s subsidiary, Yi Fu
and the Company’s business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert, own 40% and 30%, respectively,
of its interest. Shanghai Jingmu Information Technology Co. Ltd. (“Jingmu”) owns the remaining 30% equity in the joint
venture. FINE C+ Health provides online medical consultation and traditional Chinese medicine.
A
joint venture, FINE C+ Digital Technology (Hangzhou) Limited (乐享未来数字科技(杭州)有限公司)
(“FINE C+ Digital”), was incorporated on November 8, 2021 under the laws of the PRC. The Company and the Company’s
business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert, own 45% and 30%, respectively, of its interest.
Shenzhen Geile Information Technology Co., Ltd. (“Harvest”, formerly called “Shenzhen Harvest Business Ltd., Co.”),
owns the remaining 25% equity in the joint venture. FINE C+ Digital offers lifestyle consumer services including cross-platform
clearing and settlement services for consumer reward rights and interests.
A joint venture, FINE C+ Interactive Technology
(Hangzhou) Limited (乐享未来互动科技(杭州)有限公司)
(“FINCE C+ Interactive”) was incorporated on November 8, 2021 under the laws of the PRC. The Company and the Company’s
business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert, own 35% and 14%, respectively, of its interest.
Flourishing Technology Inc. (“Flourishing”) and media interactive technology experts owns the remaining 51% equity in
the joint venture. FINE C+ Interactive provides cultural and tourism services, education development industry business and personal financial
services.
A
joint venture, FINE C+ Entertainment Technology (Hangzhou) Limited
(乐享未来娱乐科技(杭州)有限公司)
(“FINE C+ Entertainment”) was incorporated on December 22, 2021 under the laws of the PRC. FINE C+ Interactive and the
Company’s business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert, own 35% and 35%,
respectively, of its interest. Harvest Horn (Beijing) Marketing Co., Ltd. (“Harvest Horn”) owns the remaining 30%
equity in the joint venture. FINE C+ Entertainment provides theme park designing service
As of the date of this report, the Company has not paid
for this investment of RMB 2,000,000 (approximately $313,844).
Dispositions of China Roan Industrial-Financial
Holdings Group Co., Ltd. and subsidiaries
Prior to September 30, 2020, Feng Hui Ding Xin (Beijing) Financial
Consulting Co., Ltd. (“Ding Xin”) was a wholly-owned subsidiary of Roan HK licensed to provide financial advisory services,
and its Urumqi branch office primarily provided financial services to third-party direct lending companies in Xingjiang. Zhiyuan Commercial
Factoring (Guangzhou) Co., Ltd. (“Zhiyuan”) was a 99%-owned subsidiary of Ding Xin which had engaged in business factoring
program, financing products design, related corporate financing solutions, investments and asset management.
Due to the slowdown of the Chinese economy and
policy changes related to loans to MSMEs, the direct loan business to MSMEs became difficult in China and the Company determined to exit
that business. On September 30, 2020, Roan HK entered into an agreement (the “Agreement”) with Urumqi Fengxunhui
Management Consulting Co., Ltd. (“Fengxunhui” or the “Purchaser”), pursuant to which Roan HK transferred 100%
of the equity of Ding Xin, including Ding Xin’s interests in its Urumqi branch office and Zhiyuan, in exchange for a total consideration
of approximately $15,326 (RMB 100,000). As a result of the disposition, the Company no longer conducted direct loan business. When Roan
HK was disposed on September 30, 2021, the purchase price had not been paid.
Xinjiang
Xin Quan Financial Leasing Co., Ltd. (“Xin Quan”) was a 60%-owned subsidiary of Roan HK engaged in financial leasing service
before its dissolution on April 28, 2021. During the 2020 fiscal year, Xin Quan ceased its operations.
On September 17, 2021, the Company signed an equity
transfer agreement to sell 100% of the equity interest it held in Roan HK, a holding company that has no business operations, to
Yuanjia Asset Management Co. Ltd. (“Yuanjia”), a BVI company, for a total of approximately $282 (HK$2,200). The transaction
was closed on September 30, 2021. The net assets of Roan HK were negative $492,495 as of September 30, 2021, resulting in a gain on deconsolidation
of $492,777 and other comprehensive loss of $2,494. Roan HK’s subsidiary, Jing Kai was disposed at the same time.
Lixin
Financial Holdings Group Limited and Subsidiaries
Lixin
Financial Holdings Group Limited (“Lixin Cayman”) was established on October 25, 2017 under the laws of the Cayman Islands
as an exempt company. It is a holding company and does not have substantial operations. It conducts its business through its direct and
indirect subsidiaries.
In
January 2019, the Company acquired 1% of the equity interest in Zhejiang Lixin (defined below) for RMB 2,858,600. On June 14, 2019, the
Company entered into a Share Purchase Agreement (the “SPA”) with Lixin Cayman and certain shareholders of Lixin Cayman to
acquire a controlling interest in Lixin Cayman. Pursuant to the SPA, the Company acquired a 65.0177% interest in Lixin Cayman from its
selling shareholders in exchange for ordinary shares of the Company to be issued to the selling shareholders for a total value of RMB
276.00 million (later adjusted to $31.09 million (RMB 217.88 million) (“Lixin Acquisition”). On August 23, 2019, the
parties entered into a supplementary agreement to amend the form of payment of the purchase price. Pursuant to the supplementary agreement,
Lixin shareholders agreed to receive non-voting preferred shares that will have the right to be converted into common shares after two
years from the closing date of the acquisition. The transaction was closed on December 20, 2019 upon the Company’s issuance of
291,795,150 Class B convertible preferred shares to the selling shareholders. These convertible preferred shares are embedded with liquidation
preference and dividend preference but with no voting rights. Following the second anniversary of the closing date, preferred shares
may be convertible to the equal number of ordinary shares or can be redeemed at a conversion price calculated at the average closing
price per share for ninety consecutive trading days before the conversion date. On December 22, 2021, the Board of Directors passed
the resolution which changed 2 years to 30 months. As of the date of this report, there was no shares redeemed or converted.
Lixin Cayman, through its subsidiaries, provides
a wide range of financing solutions and related peripheral services, including financial leasing, commercial factoring, private funding,
guarantee and supply chain management, to individuals and MSMEs in the Yangtze River Delta Region of China. Lixin Cayman conducts its
business through the following direct and indirect subsidiaries.
Lixin
Financial Holdings (BVI) Limited (“Lixin BVI”) is a wholly-owned subsidiary of Lixin Cayman. It was established on November
29, 2017 under the laws of the BVI as a company limited by shares. It is a holding company and does not have business operations.
Lixin
Financial Holdings Group Limited (励信金融控股集团有限公司) (“Lixin
HK”) was established on January 15, 2018 under the laws of Hong Kong as a wholly-owned subsidiary of Lixin BVI. It is a holding
company and does not have business operations.
Zhejiang
Lixin Enterprise Management Holding Group Co., Ltd. (浙江励信企业管理集团有限公司)
(“Zhejiang Lixin”) was incorporated on July 3, 2015 under the laws of the PRC. Lixin HK owns 99% of Zhejiang Lixin equity
interest and Fortis owns the remaining 1%. Following its reorganization completed in 2018, it became the controlling shareholder of Zhejiang
Jingyuxin (discussed below). It is a financial service company providing comprehensive financial solutions and services including guarantee
services and related assessment and management services.
Zhejiang
Jing Yu Xin Financing Guarantee Co., Ltd. (浙江京虞信融资担保有限公司)
(“Zhejiang Jingyuxin”) was incorporated on January 5, 2013 under the laws of the PRC. Zhejiang Lixin owns 93.4% of Zhejiang
Jingyuxin equity interest, with the remaining 6.6% interest owned by an unrelated third party individual. It provides guarantee services
and related assessment and management services.
Lixin
(Hangzhou) Asset Management Co., Ltd. (励信(杭州)资产管理有限公司)
(“LAM”) is a wholly-owned subsidiary of Zhejiang Jingyuxin. It was incorporated on March 21, 2017 under the laws of the PRC.
LAM provides consulting and assessment services to customers and facilitates financial guarantee services between customers and guarantors.
Lixin
Supply Chain Management (Tianjin) Co., Ltd. (励信供应链管理(天津)有限公司)
(“(“Lixin Supply Chain”) is a wholly-owned subsidiary of LAM. It was incorporated on December 19, 2017 under the laws
of the PRC and its principal business is providing supply chain management services.
Our
Business
We
are a financial, insurance and healthcare related solutions company serving individuals and micro-, small- and medium-sized enterprises
(“MSMEs”) in China. In 2021, the Company expanded its business to provide industrial operation services
based on the Company’s past experience, capability, customer resources, market channels, relationships with institutional organizations
and government relations.
Our
business has experienced substantial changes in the recent years. Following our business combination with Adrie, the original China Lending
Group was a PRC-based group of companies specializing in providing loan facilities to MSMEs and sole proprietors in Xinjiang. Due to the slowdown of the Chinese economy and policy changes
related to loans to MSMEs, since 2018,
we have adjusted our business models and substantially reduced direct loan business starting in 2018 and didn’t renew any pre-existing
loans in 2019. In September 2020, we disposed the direct lending business from the company.
In 2019, the Company acquired a 65.0177% interest in Lixin Financial
Holdings Group Limited (“Lixin Cayman”), through its subsidiaries, provides a wide range of financing solutions and related
peripheral services, including financial management, assessment and consulting services, debt collecting services, and financial guarantee
services to individuals and MSMEs in China. After the Lixin Acquisition closed in December 2019, our customers were MSMEs and individual
proprietors located in Zhejiang Province and Guangdong Province. Those customers were involved in the commerce and service, real estate,
technology promotion and application services, construction, finance, wholesale and retail and other industries.
For the year ended December 31, 2021, the Company
conducted management and assessment services, financial guarantee, financial consulting business, healthcare service and industrial operation
services.
As of December 31, 2021, the Company had cash
balance of $1,947,142 and a positive working capital of $51,940,172. In addition to the cash balance, the working capital was mainly comprised
of restricted cash of $29,693,689, accounts receivable of $6,929,529, loan receivable due from third parties of $23,751,471 and other
receivables of $656,835. The balances of these assets are expected to be repaid on maturity dates and will also be used for working capital.
COVID-19
Impact Update
In
December 2019, a novel strain of coronavirus (COVID-19) was first identified in China and has since spread rapidly globally and
resulted in new variants. The outbreak of COVID-19 has resulted in quarantines, travel restrictions, and the temporary closure of offices
and business facilities globally. In March 2020, the World Health Organization declared the COVID-19 a pandemic. In 2020 and 2021, COVID-19
had a material impact on our business, financial condition, and results of operations, including, but not limited to, the following:
| ● | We
temporarily closed our offices from late January to March 2020, as required by relevant PRC
regulatory authorities. Our offices were subsequently reopened pursuant to local guidelines.
In the first half of 2020, the pandemic caused disruptions in our operations, which resulted
in delays in our services to certain of our customers. |
| ● | Our
customers were negatively impacted by the pandemic, which reduced the demand for our services.
As a result, our revenue and income were negatively impacted in the first half of 2020. |
| ● | In
December 2021, Shangyu District, Shaoxing City, Zhejiang Province, where the subsidiary company
Zhejiang Jingyuxin Financing Guarantee Co., Ltd. is located, was closed and suspended due
to the epidemic, resulting in delays in our services to some customers. After the lockdown
was lifted on December 31, 2021, operations resumed. |
After
the second quarter of 2020, the COVID outbreak in China was gradually controlled. Our business initially returned to normal operations,
although management assessed that our results of operations had been negatively impacted for the year. In 2021, Omicron variants emerged,
resulting in continued disruption to our business and the global economy and supply chain. COVID-19 could continue to adversely affect
our business and results of operations in 2022 if any COVID resurgence causes significant disruptions to our operations or the business
of our customers, logistics and service providers. If any new outbreak of COVID-19 is not effectively and timely controlled, or if government
responses to outbreaks or potential outbreaks are severe or long-lasting, our business operations and financial condition may be materially
and adversely affected as a result of the deteriorating market outlook, the slowdown in regional and national economic growth, weakened
liquidity and financial condition of our customers or other factors that we cannot foresee. Any of these factors and other factors beyond
our control could have a material adverse effect on the overall business environment, cause uncertainties in the regions where we conduct
business, and could materially and adversely impact our business, financial condition and results of operations.
Our
Major Services
The followings are the major services and products
provided by the Company during fiscal year 2021:
1. Loans to third parties
Zhejiang Lixin, LAM, Hangzhou Zeshi and Yi Fu
provide loans to third parties and charge a fixed rate interest on the loans. The Company recorded interest on third parties loans
of $2,113,918, and $2,131,447 for fiscal year 2021 and 2020, respectively.
2. Guarantee and consulting services: financial
and non-financial
(1) Guarantee services: financial and non-financial
These services are mainly conducted by Zhejiang Jingyuxin.
Zhejiang Jingyuxin received the commissions from guarantee services either in full at inception or in instalments during the guarantee
period. Its guarantee services are divided into financial guarantee and non-financial guarantee.
Financial guarantee service contracts provide guarantees
which protect the holder of a debt obligation against default in the financing process. Pursuant to such guarantee, the Company makes
payments if the obligor responsible for making payments fails to do so as scheduled. The contract amounts reflect the extent of involvement
Zhejiang Jingyuxin has in the guarantee transaction and also represent the Company’s maximum exposure to credit loss in its guarantee
business.
To mitigate the potential credit risks exposure to
the financial guarantee services, Zhejiang Jingyuxin requires the guarantee service customers to make a deposit to Zhejiang Jingyuxin
of the same amount as the deposit Zhejiang Jingyuxin pledged to the banks for their loans if the customer does not pledge or collateralize
other assets with Zhejiang Jingyuxin. The deposit is returned to the customer after the customer repays the bank loan and the Zhejiang
Jingyuxin’s guarantee obligation expires.
In addition, Zhejiang Jingyuxin also provides non-financial
guarantee services to clients by giving credit guarantee. It is used to improve the contract enforcement. This business includes litigation
preservation guarantee, bid guarantee, project performance guarantee and other contract performance business. This is not its key business
and it does not take the core resources. It has lower risks.
(2) Consulting services for financial guarantee customers
Zhejiang Lixin provided financial consulting services
to financial guarantee customers. Pursuant to the contracts with customers, Zhejiang Lixin facilitated financial guarantee services between
customers and financial guarantors, and charged referral fees at a fixed amount. The performance obligations are completed and control
of the service is transferred at the inception of financial guarantee period. Transaction prices are generally paid upon successful facilitation.
The Company recorded commission and fee income on
guarantee services of $399,527 and $285,606 for fiscal year 2021 and 2020, respectively.
Under the financial guarantee service agreements,
banks, other financial institutions and creditors who provide loans to the Company’s guarantee service customers, generally require
the Company, as the guarantor of the loans, to deposit cash of 10% to 20% of the guaranteed amount into an escrow account which is restricted
from use. The Company records interest received on the restricted cash pledged as revenue. The Company recorded interest on restricted
cash of $300,749 and $348,389 for fiscal year 2021and 2020, respectively.
3. Management and assessment services
Hangzhou Zeshi and
Zhejiang Lixin provided the following management and assessment services for the factoring and
direct loan customers:
|
1) |
Asset management services focused on providing account receivable collection plans, debt collection, due diligence investigation for guaranty, litigation mitigation, and asset preservation and management consultation. |
|
2) |
Financing related services focus on financing plan design and consultation, supply chain transaction participant selection consultation, and financing project due diligence. |
Revenue from management and assessment service was
$440,254, $19,676 for fiscal year 2021 and 2020, respectively.
The company will continuously develop management & assessment
services in 2022. Subsidiaries of both Adrie and Lixin Cayman cooperate closely to expand business territories, share business resources
of each other and strengthen the Company’s competitiveness.
4. Consulting services related to debt collection
Lixin Cayman subsidiaries also provides consulting
services relating to debt collection with certain factoring companies. The debt collection services involved commitments of 1) assisting
the customers to obtain court judgments on outstanding debt, and the Company recognized revenue over period towards completion of the
performance by using input method based on the staff cost incurred, and 2) assisting the customers to receive repayment on outstanding
debt, the Company recognized revenues upon collection of outstanding debts. The transaction price is allocated to each performance obligation
based on the relative standalone selling prices of the services being provided to the customer.
In fiscal year 2021, our consulting services, especially
deb collection related operations, were affected by the pandemic. As a result of the quarantines, office closings and travel restrictions,
asset auctions and the enforcement process presided by the courts, asset valuations by valuation companies, and debt collections were
disrupted and delayed for some of our customers. Our services to those customers and operating results were adversely impacted by the
pandemic related delays.
Revenue from debt collection service was $206,792
and $2,108,477 for fiscal year 2021 and 2020, respectively.
5. Industrial operation services
After nearly 10 years of development, the Company’s
financing service business has served more than 500 companies in various industries, including finance, asset management, supply chain
management and financial advisory. This has enabled the Company to better understand the growth of different industries, the policy environment,
industrial ecology, development trends, the potential problems in operations and their solutions, capital, government cooperation, market
environment and other aspects. The Company has also accumulated a wide range of customers, market resources, financial institutions and
capital service resources, and the Company has significant experience in government liaison and cooperation. At the same time, through
continuous training of the core management team, development of new business entities and team integration, the Company has been able
to set up an experienced management team with experience in international companies, listed companies, and top institutions in the field
of science, technology and consumer services.
In 2021, the Company expanded its business to provide
industrial operation services based on the Company’s past experience, capability, customer resources, market channels, relationships
with institutional organizations and government relations.
On December 31, 2021, Hangzhou Zeshi, a
wholly-owned subsidiary of the Company, entered into an agreement with ZhongTan Future New Energy Industry Development (Zhejiang)
Co., Ltd. (“ZhongTan Future”), which has an advanced international scientific and technological R&D team in the
field of new energy and semiconductor materials for the marketing and growth of these products. Pursuant to the agreement, Hangzhou
Zeshi will provide supply chain financial services, financial leasing services and industrial operation services, etc.
Revenue of $146,245 was recognized during the year ended December 31, 2021 after the target customer was located, due diligence and
initial negotiation was completed and requirements of ZhongTan Future were met.
6.
Health management, health insurance and other health related services
In 2020, the Company began and expanded the provision
of health management, innovation insurance, healthcare and consumer financing services to the employees of large institutions.
On
December 30, 2019, we incorporated Fortis Industrial Group Limited (former name Fortis Health Industrial Group Limited) (“Fortis”
or “FIG”,) in Hong Kong. On February 28, 2020, we incorporated Zeshi Insurance to conduct insurance technology business.
On March 3, 2020, we incorporated Zeshi Health to conduct health management, health big data management, and health information management
based on blockchain technology.
During 2020, the Company established
long-term partnerships for innovative insurance services, smart health medical services, data mining, and operations with a variety
of insurance service partners, medical service partners, and technology and big data partners. The Company also signed
several cooperation agreements with its business partners to jointly develop health insurance products and markets for fetal
and neonatal congenital heart diseases, middle-aged and older adult cardiovascular and cerebrovascular diseases, stroke and other
diseases, newborn deformity insurance
Due to the negative impact of Covid-19 pandemic,
many of the Company’s health projects was suspended or delayed. During 2021, the Company continuously improved the accuracy of
the algorithm model for the artificial intelligence screening auxiliary system for the diagnose of fetal and neonatal congenital heart
disease. The Company also optimized the newborn deformity insurance products for these diseases.
On December 30, 2020, Zehshi Health, the 100% subsidiary of the Company,
signed an exclusive distribution agreement with Furuikang to sell FuruiKang is a related party with the Company whose shareholder is
a beneficial owner of the Company. The products are expected to launch in the second half year of 2022.
On October 14, On June 8, 2021, the Company entered
a ten-year cooperation agreement with Furui Health Industry Development (Zhejiang) Co, Ltd. (“Furui Health”) and Furuikang
Biomedical Technology (Zhejiang) Co, Ltd. (“Furuikang”) to promote the transformation and industrialization of Furuikang’s
technical achievements in tumor adjuvant therapy and postoperative rehabilitation of tumor patients in the Chinese market.
On June 20, 2021, the Company entered a
ten-year cooperation agreement with Shuzhiyun Holdings (Beijing) Co., Ltd. (“Shuzhiyun”) to promote the transformation
and industrialization of Shuzhiyun’s birth defect screening technology achievements in the Chinese market.
2021, the Company’s
subsidiary, Yi Fu signed a cooperation agreement with Shuzhiyun and Shanghai
Jingmu Information Technology Co. Ltd. (“Jingmu”), to set up a joint venture to provide online medical consultation and
traditional Chinese medicine, FINE C+ Health (Hangzhou) Technology Limited (“FINE C+ Health”). In January 2022, FINE
C+ Health obtained the “drug information services on the internet certificate” issued by the State Food and Drug
Administration of China and set up the Wechat service application.
Business
Strategies
The Company
acquired 65.0177% shares of Lixin Cayman in December 2019, which provides financial services and disposed Roan HK in September 2021,
which was mainly involved in the direct lending business. They were mainly involved in the direct lending business. The Company now provides
various financial services to its MSME customers. The Company will continue focusing on capital advisory services which require less assets,
less capital investment and lower-risk.
In 2021, the Company further optimized its strategic
planning and business layout based on the Company’s past experience, capability, customer resources, market channels, relationships
with institutional organizations and government relations. The Company also completed the restructuring of its operations, established
a new management team, optimized the decision-making ability of the board of directors, integrated all resources, and upgraded the businesses
services and products to meet the needs for the Company’s future development.
Through continuous optimization and improvement, the Company has combined
its industrial capital service experience, resources, and its capabilities to industries which have good growth prospects.
We intend to implement the following three strategies to expand and grow the size of
our businesses:
a.
Continue to expand our financial services to different regions
We start from Zhejiang Province. Zhejiang
Province is the frontline of internet development in China and an economically active area. We are based in Hangzhou, the capital
city of Zhejiang and are developing the new business in Zhejiang. We plan to continue to expand our regional coverage. While based
upon the Zhejiang market, the Company plans to actively expand to economically developed regions such as the Yangtze River Delta and
the Pearl River Delta.
b. Explore
opportunities in industrial operation services
We are relying on our advantages in the
financial services to expand our industrial operation services. While providing financial services to our customers, our management
team has built up managing experience in the fields of different industries. We have also accumulated a wide range of
customers, market resources, financial institutions and capital service resources. Management’s experience in customer
relationships, government cooperation, the management of resources and their ability to take an innovative approach to products and
services have enabled us to provide better solutions and services to our partners, including companies and the government.
We plan to provide industrial operation
services to the companies in technology industries with high growth and global market demand and the urban life service industry
which is closely related to improving the quality of people’s life. The technology industry focuses on the needs of the local
government for industrial economic development and the needs of the companies for the commercialization of leading scientific and
technological products in the field of new energy and semiconductors, We believe this will help further develop long-term and
sustainable industrial capital service customers and projects.
While firmly focusing on the target industries
and maintaining revenue growth, we will share operating income and industry development opportunities through joint ventures and
equity participation, and will look for any listing opportunity for any relevant projects in the capital markets.
Through the two strategic business sectors,
we have obtained the long-term operating rights for some new technologies, products and services in the fields of new energy,
health services, semiconductor, culture and tourism. Our goal is to realize any gains form capital and resource appreciation,
and improve revenue and profit sharing from operations
The Company’s financial service sales team
works closely with other financial institutions to provide financing services to its customers. For loans to third parties, the Company
receives monthly interest. For guarantee and consulting services, the Company receives fees and commissions either in full at inception
or in instalments during the guarantee period. For the management and assessment services and consulting services related to debt collection,
the Company receives instalments service fees based on the project progress and results.
The Company’s management team actively explores industrial operation
service opportunities while providing financial services to its customers. Through long-term cooperation agreements, the Company locks
in close and long-term cooperation with its customer and charges services fees according to project progress and achievements;
The Company sells its health products directly to its customers. The
Company plans to sell the products through direct on-line marketing and through off-line sales distributors in the future.
Intellectual
Property
We
own and have the right to use the domain name “www.roanholdingsgroup.com”.
We
have registered the following trademarks:
Owner |
|
Trademark |
|
Issuance
Entity |
|
Term |
Lixin
Cayman |
|
|
|
Trademark
Office of PRC State Administration for Industry and Commerce |
|
March
7, 2019 – March 6, 2029 |
|
|
|
|
|
|
|
Lixin
HK |
|
|
|
HK
Trade Marks Registry Intellectual Property Department |
|
February
2, 2018 – February 1, 2028 |
|
|
|
|
|
|
|
Zhejiang
Jingyuxin |
|
|
|
Trademark
Office of PRC State Administration for Industry and Commerce |
|
July
28, 2016 – July 27, 2026 |
Certificates
Our
subsidiary Zhejiang Jingyuxin was issued a PRC Financing Guarantee Organization Operation Permit by Zhejiang Commission of Economy and
Informatization on May 17, 2016 with a term of five years. We had renewed and received the new permit in September 2021. The permit authorizes
Zhejiang Jingyuxin to operate the guarantee business, and related financial consulting and consulting agent business in China.
Competition
The
Company faces competition in the financial industry. We believe that the financial industry is becoming more competitive as this industry
matures and begins to consolidate, especially under the heavy regulation by policies and macroeconomic downturn. The Company competes
with other financial guarantee companies, other financial consulting companies, and some cash-rich state-owned companies or individuals
that provide financial services to MSMEs. Some of these competitors have larger and more established customer bases and substantially
greater financial, marketing and other resources than we have. As a result, we could lose market share and our revenues could decline,
thereby adversely affecting our earnings and potential for growth.
While
we plan to achieve a competitive advantage by adopting various business strategies including exploring business in the Internet +
Healthcare area, we face the competition from the companies much bigger than us and with a longer history. For example,
Ping’an good doctor service offering focuses on online diagnosis, consumption diagnosis, health mall, health management and
health interaction. Ali Health started from online medicine, and is building a big health closed loop by developing internet
diagnosis, intelligent treatment, consumption diagnosis and source tracking service. Huarun Medicine, as a top medicine enterprise,
has strong supply chain and rich client resources and is developing its platform by applying internet technology.
Seasonality
Our
main business does not have significant seasonality.
Government
Regulation
The
Company’s operations are subject to extensive and complex state, provincial and local laws, rules and regulations. We are supervised
by a variety of provincial and local government authorities, including CBRC, PBOC, local tax bureaus, local Administration for Market
Regulation, local Bureau of Finance, local Administration of Foreign Exchange and local employment departments. The areas include Zhejiang
Province and Tianjin City.
Summaries
of Certain Key PRC Laws
Below
are summaries of the material terms of PRC laws applicable to our businesses.
No. |
|
Regulation
name |
|
Main
regulatory content |
1 |
|
Civil
Code |
|
Article
577 If a party fails to perform its obligations under a contract, or its performance fails
to satisfy the terms of the contract, it shall bear the liabilities for breach of contract
such as to continue to perform its obligations, to take remedial measures, or to compensate
for losses.
Article
610. Where the subject matter does not meet quality requirements, and as a result it is impossible to realise the objectives of the
contract, the purchaser may refuse to accept the subject matter or may dissolve the contract. Where the buyer refuses to accept the
subject matter or rescinds the contract, the risk of damage to or missing of the subject matter shall be borne by the seller. |
|
|
|
|
|
2 |
|
Company
Law |
|
Article
6 To establish a company, an application for establishment registration shall be filed with
the company registration authority. If the application meets the establishment requirements
of this Law, the company registration authority shall register the company as a limited liability
company or joint stock limited company. If the application does not meet the establishment
requirements of this Law, it shall not be registered as a limited liability company or joint
stock limited company.
If
any law or administrative regulation provides that the establishment of a company shall be subject to approval, and relevant approval
formalities shall be gone through prior to the registration of the company.
The
general public may go to a company registration authority to search and consult the registration information filed by a company and
the authority shall provide the research services for the public. |
|
|
|
|
|
3 |
|
Labor
Contract Law |
|
Article
4 Employers shall establish and perfect labor bylaws so as to ensure that workers can enjoy
labor rights and perform labor obligations.
Where
employers constitute, modify or determine such bylaws or significant matters in direct relation to the real benefits of workers as
the remuneration, working time, rest and vacation, work safety and health care, social insurance and welfare, job training, job discipline
or quota management, the draft thereof shall be discussed at the workers’ congress or by all the workers, which shall bring
forward schemes and opinions. The aforesaid bylaws and significant matters shall be determined after equal consultation by employers
and labor union or representatives of workers.
During
the process of the implementation of the aforesaid bylaws and significant matters, the labor union or the workers is/are entitled
to require the employer to modify or improve them through consultations if it/they find them improper.
The
employers shall publicize the bylaws and significant matters in direct relation to the real benefits of the workers or inform the
workers.
Article
38 In the case of any of the following circumstances occurring to an employer, workers may discharge the labor contract:
(3)
It fails to pay social security premiums for the workers according to law;
Article
46 In the case of any of the following circumstances, employers shall make an economic compensation to the workers:
(1)
Any worker discharges the labor contract according to Article 38 of this Law; |
4 |
|
Product
Quality Law |
|
Article
43 If damages are done to the person or properties of others due to the defects of products, the victims may claim for compensation
either from the producers or sellers. If the responsibility rests with the producers and the compensation is paid by the sellers,
the sellers have the right to recover their losses from the producers. If the responsibility rests with the sellers and the compensation
is paid by the producers, the producers have the right to recover their losses. |
|
|
|
|
|
5 |
|
Foreign
Investment Law |
|
Article
21 Foreign investors’ capital contribution, profits, capital gains, assets disposal income,
intellectual property license fees, legally obtained damages or compensation, liquidation
proceeds, etc., may be freely remitted to overseas in RMB or foreign exchange according to
law.
Article
28 Foreign investors shall not invest in the areas where investment is prohibited under the negative list for the admission of foreign
investment.
Foreign
investors shall meet the conditions set forth in the negative list for the admission of foreign investment to invest in the areas
where investment is restricted under the negative list.
Management
of foreign investment in the areas beyond the negative list shall be implemented in accordance with the principle of equality between
domestic and foreign investment.
Article
34 The State establishes a system for foreign investment information reporting. Foreign investors or foreign-invested enterprises
shall submit investment information to the competent commerce departments through the enterprise registration system and the enterprise
credit information publicity system.
The
content and scope of the foreign investment information report shall be determined in accordance with the principle of necessity;
the investment information that can be obtained through the inter-department information sharing system shall not be required to
be submitted again.
Article
36 Where a foreign investor invests in the areas, which are specified by the negative list for the admission of foreign-investment
as prohibited areas, the relevant competent department shall order it to stop the investment activities, and dispose of the shares,
assets or take other necessary measures within a specified time limit, and restitute to the status before the investment was made;
If there is illegal income, it shall be confiscated.
Where
the investment activities of a foreign investor violates the special management measures for the admission of foreign-investment
regarding restricted areas in the negative list, the relevant competent department shall order the correction within a specified
time limit and take necessary measures to meet the conditions set forth by the special management measures for the admission of foreign-investment;
if no corrections have been made within the time limit, the provisions of the preceding paragraph shall be applied.
Where
the investment activities of a foreign investor violates the special management measures for the admission of foreign-investment
in the negative list, in addition to the provisions of the preceding two paragraphs, it shall also bear corresponding legal liabilities
under the law.
Article
37 If a foreign investor or a foreign-invested enterprise violates the provisions of this Law and fails to submit investment information
in accordance with the requirements of the foreign investment information reporting system, the competent commerce department shall
order it to make corrections within a specified time limit; if no corrections have been made within the time limit, a fine of more
than 100,000 yuan and less than 500,000 yuan shall be imposed. |
6 |
|
Circular
of the SAFE on Issues Related to Foreign Exchange Administration in Terms of Overseas Investment
and Financing via Special Purpose Companies and Return Investment by Domestic Residents
(Huifa
No.37〔2014〕) |
|
XV.
If domestic residents or the domestic companies that they control, directly or indirectly,
remit capital to SPVs through false or structured transactions, they shall be punished by
the SAFE in accordance with Article 39 of the Regulations on Foreign Exchange Administration
of the People’s Republic of China.
Domestic
residents who fail to carry out the foreign exchange registration, to truthfully disclose information on the actual controller of
the companies that make the round-trip investments, or make false commitments shall be punished by the SAFE in accordance with Paragraph
5 of Article 48 of the Regulations on Foreign Exchange Administration of the People’s Republic of China.
Domestic
residents who fail to carry out the foreign exchange registration, to truthfully disclose information on the actual controller of
the companies that make the round-trip investments, or make false commitments but have capital outflows shall be punished by the
SAFE in accordance with Article 39 of the Regulations on Foreign Exchange Administration of the People’s Republic of China. If these
residents have capital inflows or foreign exchange settlements, they shall be punished by the SAFE in accordance with Article 41
of the Regulations on Foreign Exchange Administration of the People’s Republic of China.
Domestic
residents and SPVs that fail to declare the required BOP statistics for cross-border receipts and payments shall be punished by the
SAFE in accordance with Paragraph 1 of Article 48 of the Regulations on Foreign Exchange Administration of the People’s Republic
of China. |
|
|
|
|
|
7 |
|
Circular
on Further Simplifying and Improving Policies for Foreign Exchange Administration for Direct
Investment
(Huifa
No.13〔2015〕) |
|
II.
Simplifying procedures for some transactions of foreign exchange for direct investment
(I)
Simplifying registration management for confirmation of capital contribution by a foreign investor under domestic direct investment.
The registration for confirmation of non-monetary capital contribution by a foreign investor under domestic direct investment and
registration for confirmation of capital contribution by a foreign investor for acquisition of a Chinese shareholder’s equity are
cancelled. The registration for confirmation of monetary contribution by a foreign investor is replaced with registration for
accounting entry of monetary contribution for domestic direct investment. If the foreign investor makes capital contributions in
cash (including cross-border spot exchange and RMB), the opening bank can handle registration for accounting entry of monetary
contribution for domestic direct investment upon receipt of relevant capital funds directly through the capital accounting formation
system of the SAFE, and the capital funds can be used only after the registration.
(II)
Canceling filing of foreign exchange for overseas reinvestment. Foreign exchange filing will no longer be required for overseas
reinvestment for establishment of or control over another overseas enterprise by an overseas enterprise established or controlled by
a domestic investment entity.
(III)
Canceling annual check of foreign exchange for direct investment and replacing it with registration for accumulated equity. Data on
accumulated equity in domestic direct investment and/or overseas direct investment (collectively, the accumulated equity in direct
investment) as at the end of the last year shall be reported through the capital account information system of the SAFE by relevant
market entity itself or by an accounting firm or a bank before and on September 30 every year. |
|
|
|
|
|
8 |
|
Measures
for Registration for the Record of Foreign Trade Operators |
|
Article
2 Foreign trade operators that engage in the import and export of goods or technology
shall handle record filing and registration with the Ministry of Commerce of the People’s
Republic of China (MOFCOM) or an authority appointed by MOFCOM, except where
laws, administrative regulations and MOFCOM stipulate that no record filing or registration
is required.
If
a foreign trade operator fails to handle record filing and registration in accordance with these Procedures, customs shall not carry
out the procedures for declaration, and inspection and release of the imports and exports. |
9 |
|
Guidelines
for Business Cooperation between Banking Financial Institutions and Financial Guarantee Companies |
|
Article
9 both parties of banks and financial guarantee companies may agree to carry out business
cooperation within the following scope:
(1)
Financial guarantee business: including loan guarantee, bill acceptance guarantee, letter of credit guarantee and other financial
guarantee business;
(2)
Non-financial guarantee business: including bid guarantee, project performance guarantee, litigation preservation guarantee and other
non-financial guarantee business;
(3)
Other legal compliance business. |
|
|
|
|
|
10 |
|
Regulations
on the Supervision and Administration of Medical Devices |
|
Article
40. To engage in medical device business activities, there should be business premises and
storage conditions commensurate with the business scale and scope, and a quality management
system and personnel.
Article
41. For Class II medical device business, the business enterprise shall file with the food and drug regulatory department of the
municipal people’s government at the districted level and submit the certification materials that it meets the conditions specified
in Article 40 of these regulations.
Article
45. When purchasing medical devices, the medical device business enterprises and users shall check the qualification of suppliers
and the qualification certificates of medical devices, and establish a record system for purchase inspection. The enterprises engaged
in wholesale business of class II and class III medical devices and retail business of class III medical devices shall also establish
a sales record system. The record items include: (1) name, model, specification and quantity of medical devices, (2) the production
batch number, validity period and sales date of medical devices, (3) the name of the production enterprise, (4) the name, address
and contact information of the supplier or the buyer, (5) relevant license document number, etc. Purchase inspection records and
sales records shall be true and shall be kept within the time limit specified by the Food and Drug administration under the State
Council. The State encourages the use of advanced technical means for recording.
Article
47. The transportation and storage of medical devices shall meet the requirements of the instructions and labels of medical devices.
If there are special requirements for temperature, humidity and other environmental conditions, corresponding measures shall be taken
to ensure the safety and effectiveness of medical devices. |
|
|
|
|
Article
55. The medical device business enterprises and users shall not operate or use medical devices that have not been registered in accordance
with the law, have no qualification certificates, and have expired, invalid or eliminated. |
|
|
|
|
Article 60 The medical device advertisements
shall be true and legal, and shall not contain false, exaggerated or misleading contents.
The medical device advertisement shall be
examined and approved by the Food and Drug Administration Department of the People’s Government of the province, autonomous region
or municipality directly under the central government where the medical device manufacturer or the imported medical device agent
is located and the approval document for the medical device advertisement shall be obtained. When the advertisement publisher publishes
advertisement for medical device, it shall check the approval document and its authenticity in advance. It shall not publish advertisement
for medical device that has not been approved, the authenticity of the approval document has not been verified, or the content of
the advertisement is inconsistent with the approval document. The Food and Drug Administration Departments of the People’s Governments
of provinces, autonomous regions and municipalities directly under the central government shall publish and timely update the approved
medical device advertisement catalogue and the approved advertisement content.
The Food and Drug Administration Department
of the People’s Government at or above the provincial level shall order to suspend the production, sale, import and use of medical
devices, and shall not publish advertisements involving the medical devices during the period of suspension. |
|
|
|
|
The measures for the examination of medical
device advertisements shall be formulated by the Food and Drug Administration Department of the State Council and Administration
Department for Industry and Commerce of the State Council.
Article 62. Medical device manufacturers
and users shall monitor the adverse events of the medical devices they produce, operate or use. If any adverse event or suspicious
adverse event of medical devices is found, it shall be reported to the technical institution for monitoring adverse events of medical
devices in accordance with the provisions of the Food and Drug Administration Department of the State Council.
Article 81. Under any of the following circumstances,
the Food and Drug Administration Department of the People’s Government at or above the county level shall confiscate the illegal
income, the medical devices illegally produced and operated, and the tools, equipment, raw materials and other goods used for illegal
production and operation. If the value of medical devices illegally produced and operated is less than RMB 10,000, a fine of not
less than RMB 50,000 but not more than RMB 100,000 shall be imposed. If the value of the goods is more than RMB10,000 yuan, a fine
of not less than 15 times but not more than 30 times the value of the goods shall be imposed. If the circumstances are serious, the
medical device license applications submitted by relevant responsible persons and enterprises will not be accepted within 10 years
confiscate the income of the legal representative, the primary person in charge, the directly responsible person in charge, and other
liable persons of the illegal entity obtained from the entity during the period of the illegal act, impose a fine of not less
than 30% of but not more than 3 times the income obtained, and prohibit them from engaging in production and operation of medical
devices for life: (1) Producing or operating class II or class III medical devices without medical device registration certificate,
(2) Engaging in the production of class II or class III medical devices without permission, and (3) Engaging in the business activities
of class III medical devices without permission. In case of serious circumstances mentioned in the first item of the preceding paragraph,
the original license issuing department shall revoke the medical device production license or the medical device operation license.
Article 84 Under any of the following circumstances,
the department in charge of drug supervision and administration shall public the name of the entity and its products, and order it
to make corrections within a time limit; if the entity fails to take corrective actions within the time limit, its illegal gains
and illegally produced and traded medical devices shall be confiscated; impose a fine of not less than RMB 10,000 nor more than RMB
50,000 if the amount of the value of the medical devices produced or distributed in violation of laws is less than RMB 10,000, or
impose a fine of not less than five times nor more than 20 times the amount of the value if the amount of the value of medical devices
is RMB 10,000 or more; and, if the circumstances are serious, confiscate the income of the legal representative, the primary person
in charge, the directly responsible person in charge, and other liable persons of the illegal entity obtained from the entity during
the illegal act, impose a fine of not less than 30% of nor more than twice the income obtained, and prohibit them from engaging in
production and operation of medical devices within five years:
(1) Production and operation of unrecorded
Class I medical devices;
(2) Engaging in the production of Class I
medical devices without filing;
(3) The business of Class II medical devices
shall be filed but not filed;
(4) The materials that have been filed fail
to meet the requirements.
|
|
|
|
|
Article 85 Where any entity provides false materials during filing, the department in charge of drug supervision and administration shall public the name of the entity and its products, and confiscate the illegal income and the medical devices produced or distributed illegally; impose a fine of not less than RMB 20,000 nor more than RMB 50,000 if the amount of the value of the medical devices produced or operated illegal is less than RMB 10,000, or impose a fine of not less than five times nor more than 20 times the amount of the value of the medical devices if the amount of the value of the medical devices is RMB 10,000 or more; and, if the circumstances are serious, it shall be ordered to suspend production and business, confiscate the income of the legal representative, main responsible person, directly responsible person in charge, and other liable persons of the illegal entity obtained from the entity during the illegal act, impose a fine of not less than 30% of nor more than three times the income obtained, and prohibit them from engaging in medical devices production and operation within 10 years.
|
|
|
|
|
Article 86. Under any of the following circumstances,
the Food and Drug Administration Department of the People’s Government at or above the county level shall order the enterprise to make
corrections and confiscate the medical devices illegally produced, operated and used. If the value of medical devices illegally produced
and operated is less than RMB 10,000, a fine of not less than RMB 20,000 but not more than RMB 50,000 shall be imposed. If the value of
the goods is more than RMB 10,000, a fine of not less than 5 times but not more than 20 times the value of the goods shall be imposed.
If the circumstances are serious, it shall be ordered to suspend production until the original license issuing department revokes the
registration certificate, production license and operation license of medical devices confiscate the income of the legal representative,
the primary person in charge, the directly responsible person in charge, and other liable persons of the illegal entity obtained from
the entity during the period of the illegal act, impose a fine of not less than 30% of nor more than three times the income obtained,
and prohibit them from engaging in production and distribution of medical devices within ten years: (1) Producing, operating or using
medical devices that do not meet the mandatory standards or the registered or filed product technical requirements; and (3) Operating
or using medical devices without qualification certificate, expired, invalid or eliminated, or using medical devices not registered according
to law.
Article 89. Under any of the following
circumstances, the department in charge of drug supervision and administration and the health department shall order correction and
give a warning according to their respective duties. The enterprise refuse to make corrections shall be fined not less than RMB
10,000 but not more than RMB 100,000. If the circumstances are serious, it shall be ordered to suspend production until the original
license issuing department revokes the registration certificate, production license and operation license of medical devices and
impose a fine of not less than RMB 10,000 nor more than RMB 30,000 on the legal representative, the primary person in charge, the
directly responsible person in charge, and other liable persons of the illegal entity: (4) The enterprise engaged in the wholesale
business of the class II or class III of medical devices and the retail business of the class III medical devices fails to establish
and implement the sales record system in accordance with the regulations.
Article 97 Anyone who violates the regulations
on the administration of medical device advertisements shall be punished in accordance with the provisions of the Advertising Law of the
People’s Republic of China. |
11 |
|
Measures
for the Supervision and Administration of Medical Device Operation |
|
Article 4. According to the risk degree of
medical devices, the operation of medical devices is managed by classification. The operation of class I medical devices does not
need making a license and filing. The operation of class II medical devices is subject to filing management, and the operation of
class III medical devices is subject to licensing management.
Article 7. The enterprise engaging in the
business of medical devices shall meet the following conditions: (1) it shall have a quality management organization or quality management
personnel suitable for the business scope and scale. And the quality management personnel shall have relevant professional qualifications
or professional titles recognized by the state. It shall have business and storage sites suitable for its business scope and scale.
(2) It shall have business and storage place suitable for the business scope and scale. (3) It shall have the storage conditions
suitable for the business scope and scale. If all the medical devices are entrusted to other medical device business enterprises
for storage, the storage room may not be set up. (4) It shall have a quality management system suitable for the medical devices.
(5) It shall have the ability of professional guidance, technical training and after-sales service corresponding to the medical devices
operation, or agree to provide technical support by relevant institutions. The enterprise engaged in the operation of class III medical
devices shall also have a computer information management system that meets the quality management requirements for the operation
of medical devices, so as to ensure the traceability of products. Enterprises engaged in the operation of class I and class II medical
devices are encouraged to establish computer information management systems that meet the quality management requirements of medical
device business.
Article 8. For those engaged in the operation
of class III medical devices, the enterprise shall apply to the Food and Drug Administration Department of the city divided into
districts where it is located, and submit the following materials: (1) Copies of business license. (2) Copies of identification certificate,
education or title certificate of legal representative, leading cadres and quality director. (3) Organization and department setting
up description. (4) Description of Operation scope and Operation mode. (5) Copies of the geographical location map, plan and house
property certificate or lease agreement (with the certificate of the property right of the house attached) of the business place
and warehouse. (6) Catalogue of business facilities and equipment. (7) Catalogue of business quality management system, working procedures
and other documents. (8) Introduction and function description of computer information management system. (9) Authorization certificate
of the operator. and (10) Other supporting materials.
Article 12. The enterprises engaged in the
business of class II medical devices shall file with the Food and Drug Administration Department of the city divided into districts
where it is located, and fill in the business record form of class II medical devices. Meanwhile, it shall submit the materials specified
in Article 8 of these measures (except item 8).
Article 23. If the enterprise name, legal
representative, leading cadres, residence, business place, business mode, business scope, warehouse address and other record items
change in the business record certificate of medical devices, the record shall be changed in time.
Article 30. Medical device business enterprises
shall establish an operation and management system covering the whole process of quality management in accordance with the requirements
of medical device operation quality management standards, and make relevant records to ensure that the operation conditions and operation
behaviors continue to meet the requirements. |
|
|
|
|
Article 31. The medical device business enterprise
shall bear legal responsibility for the purchase and sale of medical devices undertaken by its offices or sales personnel in the
name of the enterprise. Sales personnel of medical device business enterprises selling medical devices shall provide an authorization
letter with the official seal of the enterprise. The authorization letter shall specify the type, region, and time limit for authorized
sales, and indicate the ID number of the sales personnel.
Article 32. The medical device business enterprise
shall establish and implement a record system for purchase inspection. The enterprise engaged in the wholesale business of the class
II or class III of medical devices and the retail business of the class III medical devices shall establish the sales record system.
Purchase inspection records and sales records shall be true, accurate and complete. For the enterprise engaged in the wholesale business
of medical devices, its purchase, storage, and sales records shall meet the traceability requirements. The purchase inspection record
and sales record shall be kept for 2 years after the validity period of medical devices. If there is no validity period, it shall
not be less than 5 years. Purchase inspection records and sales records of implantable medical devices shall be kept permanently.
Other medical device enterprises shall be encouraged to establish a sales record system.
Article 33. The medical device business enterprises
shall purchase medical devices from qualified manufacturing enterprises or trading enterprises. The medical device business enterprise
shall agree on the quality responsibility and after-sales service responsibility with the supplier to ensure the safe use of the
medical device after-sales. The medical device business enterprise that has agreed with the supplier or the corresponding organization
to be responsible for product installation, maintenance, and technical training services may not have a department for technical
training and after-sales service, but shall have corresponding management personnel.
Article 34. The medical device business enterprise
shall take effective measures to ensure that the transportation and storage of medical devices meet the requirements of medical device
instructions or labels, and make corresponding records to ensure the quality and safety of medical devices. If the instructions and
labels require low temperature and cold storage, it shall be transported and stored with low temperature and cold storage facilities
and equipment in accordance with relevant regulations.
Article 35. If the medical device business
enterprise entrusts other carriers to transport the medical devices, it shall conduct an assessment of the carrier’s quality
assurance ability to transport medical devices, clarify the quality responsibility in the process of transportation, and ensure the
quality and safety in the process of transportation.
Article 36. If the medical device business
enterprise provides storage and distribution services for other medical device production and business enterprises, it shall sign
a written agreement with the entrusting party to clarify the rights and obligations of both parties, It shall also have equipment
and facilities suitable for the conditions and scale of product storage and distribution, and a computer information management platform
and technical means to carry out real-time electronic data exchange with the entrusting party and realize the traceability of the
whole process of product operation.
Article 37. The business enterprise engaged
in wholesale business of medical devices shall sell them to qualified business enterprises or users.
Article 38. The medical device business enterprise
shall be equipped with full-time or part-time personnel responsible for after-sales management. The quality problems of the customer
complaints shall be identified. And it shall be take effective measures to deal with and feedback in time, and make records. If necessary,
the supplier and medical device manufacturer shall be informed.
Article 53. Under any of the following circumstances,
the Food and Drug Administration Department at or above the county level shall order the enterprise to make corrections within a
time limit and give a warning. If the enterprise refuses to make corrections, it shall be fined not less than RMB 5,000 but not more
than RMB 20,000: (1)The medical device business enterprise fails to change the registration items in accordance with the measures.
(2) The medical device business enterprise sends sales personnel to sell medical devices, but fails to provide authorization letters
in accordance with the requirements of the measures. (3) The class III medical device business enterprise fails to submit the annual
self-inspection report to the Food and Drug Administration Department before the end of each year. |
|
|
|
|
Article 54. Under any of the following circumstances,
the Food and Drug Administration Department at or above the county level shall order the enterprise to make corrections. And the
enterprise shall be fined not less than RMB 10,000 but not more than RMB 30,000: (1) The operating conditions of the medical device
business enterprise have changed, no longer meet the requirements of the medical device business quality management standards, and
the rectification has not been carried out in accordance with the provisions. (2) The medical device business enterprise changes
the business site or warehouse address, expands the business scope or establishes the warehouse without authorization. (3) The business
enterprise engaged in the wholesale business of medical devices sells product to an unqualified business enterprise or user. (4)
The medical device business enterprise purchases medical devices from an unqualified production or business enterprise.
Article 55. If the enterprise engages in
the business activities of medical devices without permission, or fails to renew the medical device operating license and continue
to engage in medical device business after the expiry of the validity period, it shall be punished in accordance with Article 63
of the regulations on the supervision and administration of medical devices.
Article 58. If the enterprise fails to file
or provides false information in accordance with the measures, it shall be punished in accordance with Article 65 of the regulations
on the supervision and administration of medical devices.
Article 59. Under any of the following circumstances,
the Food and Drug Administration Department at or above the county level shall order the enterprise to make corrections within a
time limit, and punish the enterprise in accordance with Article 66 of the regulations on the supervision and administration of medical
devices: (1) The enterprise operates medical devices that do not meet the mandatory standards or meet the technical requirements
of the products registered or filed. (2) The enterprise operates medical devices that are qualified, expired, invalid or eliminated.
(3) The enterprise still refuses to stop the operation of medical devices after being ordered to stop operation by the Food and Drug
Administration Department.
Article 60. Under any of the following circumstances,
the Food and Drug Administration Department at or above the county level shall order the enterprise to make corrections, and punish
the enterprise in accordance with Article 67 of the regulations on the supervision and administration of medical devices: (1) The
instructions and labels of the medical devices are not in conformity with the relevant provisions. (2) Failing to transport and store
the medical device according to the requirements of the instructions and labels of the medical device.
Article 61. Under any of the following circumstances,
the Food and Drug Administration Department at or above the county level shall order the enterprise to make corrections, and punish
the enterprise in accordance with Article 68 of the regulations on the supervision and administration of medical devices: (1) The
business enterprise fails to establish and implement the record system for the purchase inspection of medical devices in accordance
with the provisions of the measures. (2) The business enterprise engages in the wholesale business of the class II or class III of
medical devices and the retail business of the class III medical devices fail to establish and implement the sales record system
in accordance with the measures. |
C. |
Organizational
Structure |
The following is an organizational chart setting
forth our corporate structure as of December 31, 2021 and as of the date of this report:
The following table lists the major holders of our Ordinary Shares:
|
|
Record
Holder |
|
Ownership
Percentage |
|
|
Beneficial
Owner* |
|
Beneficial
Ownership in Record Holder |
|
1 |
|
Ruiheng
Global Limited |
|
|
24.7590 |
% |
|
Yuan
Shen |
|
|
40.637 |
% |
2 |
|
Yangwei
Global Limited |
|
|
13.7746 |
% |
|
Qian
Li |
|
|
87.291 |
% |
3 |
|
Jiyi
Global Investments Limited |
|
|
8.0453 |
% |
|
Qian
Li |
|
|
75.05 |
% |
4 |
|
Zhan
Zhao Limited |
|
|
5.0927 |
% |
|
|
|
|
|
|
* |
Beneficial
owners of 30% or more of applicable record holders, where record holder is not an individual. |
D. |
Property,
Plants and Equipment |
A summary of our leased properties as of the
date of this report is shown below:
Subsidiary
Name |
|
City |
|
Address |
|
Size
(m2) |
|
Usage |
|
Term |
|
LAM |
|
Hangzhou,
Zhejiang |
|
First
floor of No. 147 Ganshui lane, Shangcheng District |
|
330.60
|
|
Office |
|
April
1, 2022-March 31, 2023 |
|
|
|
|
|
|
|
|
|
|
|
|
|
LAM |
|
Hangzhou,
Zhejiang |
|
Room
802, Unit 1, Building 5, Puyuewan, Binjiang District |
|
88.59 |
|
Staff Apartment |
|
July
15, 2021-July 14,2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
LAM |
|
Hangzhou,
Zhejiang |
|
Hangzhou
Poly NPUB Qianjiang New Town United Community, Building 11, Intersection of Tonggu Road and Wenchao Road, Hangzhou |
|
|
|
Staff Apartment |
|
August
15, 2021-August 14,2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Zhejiang
Jingyuxin |
|
Shaoxing,
Zhejiang |
|
48th
floor of Baiguan Square, Baiguan Street |
|
1,700 |
|
Office |
|
May
1, 2020-April 30, 2022 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Zheshi
Health |
|
Hangzhou,
Zhejiang |
|
First
floor of No. 147 Ganshui Lane, Shangcheng District |
|
148.78 |
|
Office |
|
April
1, 2022-March 31, 2023 |
|
The Company does not have any plants, but has
office equipment in each office.
We believe that the facilities that we currently
lease are adequate to meet our needs for the foreseeable future and we will be able to obtain adequate facilities, principally through
leasing of additional properties, to accommodate our future expansions when needed.
ITEM 4A. UNRESOLVED STAFF COMMENTS
None.
Item 5. OPERATING AND
FINANCIAL REVIEW AND PROSPECTS
You should read the following discussion and
analysis of our financial condition and results of operations in conjunction with our consolidated financial statements and the related
notes included elsewhere in this annual report on Form 20-F. This discussion may contain forward-looking statements based upon current
expectations that involve risks and uncertainties. Our actual results may differ materially from those anticipated in these forward-looking
statements as a result of various factors, including those set forth under “Item 3. Key Information—D. Risk Factors”
or in other parts of this annual report on Form 20-F.
Overview
Roan Holdings Group Co., Ltd. (formerly known
as China Lending Corporation or DT Asia Investments Limited) (“Roan”, or the “Company”) is a holding company
incorporated on April 8, 2014, under the laws of the British Virgin Islands. The Company historically engaged in providing loan facilities
to individuals, micro, small and medium-sized enterprises (“MSMEs”) and sole proprietors in the Xinjiang province in China.
Due to the slowdown of the Chinese economy and policy changes related to loans to MSMEs, the Company has transformed its business from
a direct loan business, to a financial, insurance and healthcare related solutions company serving MSMEs in China. The Company also provides
health management, asset management, insurance services, healthcare and consumer financing services to the employees of large institutions.
In 2019, the Company acquired a 65.0177% interest
in Lixin Financial Holdings Group Limited (“Lixin Cayman”), through its subsidiaries, provides a wide range of financing
solutions and related peripheral services, including financial management, assessment and consulting services, debt collecting services,
and financial guarantee services to individuals and MSMEs in China.
In 2020, the Company began and expanded its services
in the health industry. The Company plans to provide a variety of health care related services, including health management, health big
data management, and health information management based on blockchain technology, innovation insurance, health products and healthcare
services. Due to the negative impact of Covid-19 pandemic, many of the Company’s health projects was suspended or delayed.
In 2021, the Company expanded its business to
provide industrial operation services based on the Company’s past experience, capability, customer resources, market channels, relationships
with institutional organizations and government relations.
On December 31, 2021, Hangzhou Zeshi
Investment Partnership (Limited Partnership) (“Hangzhou Zeshi”), a wholly-owned subsidiary of the Company, entered
into an agreement with ZhongTan Future New Energy Industry Development (Zhejiang) Co., Ltd. (“ZhongTan Future”).
Pursuant to the agreement, Hangzhou Zeshi will provide supply chain financial services, financial leasing services and industrial
operation services, etc.
Among the Company’s subsidiaries,
Zhejiang Lixin Enterprise Management Holding Group Co., Ltd.
(浙江励信企业管理集团有限公司) (“Zhejiang
Lixin”), Lixin (Hangzhou) Asset Management Co., Ltd.
(励信(杭州)资产管理有限公司) (“LAM”) and
Hangzhou Zeshi Investment Partnership (Limited Partnership)
(杭州泽时投资合伙企业(有限合伙))
(“Hangzhou Zeshi”) are financial service companies, which provide comprehensive financial solutions and services
including financial consulting services, consulting services relating to debt collection, management and assessment and financial
guarantee services.
Financial Consulting Services
The Company provides financial consulting services
to its customers who have financing needs. The Company designs financing plans for its customers, facilitates the financing services
between customers and financing providers, and charges a fixed referral fee for its services.
For the year ended December 31, 2021, 2020 and
2019, the Company generated $nil, $nil and $9,503 in consulting services for financial guarantee customers.
Consulting services relating to debt collection
The Company provides consulting services relating
to debt collection to its customers. The debt collection services involved commitments of 1) assisting the customers to obtain court
judgments on outstanding debt, and 2) assisting the customers to receive repayment on outstanding debt.
For the year ended December 31, 2021 and 2020, the Company generated
consulting services relating to debt collections of $206,792 and $ 2,108,477. For the period from the closing of Lixin Acquisition on
December 20, 2019 to December 31, 2019, the Company generated consulting services relating to debt collections of $176,984 through Lixin.
In addition, the Company’s another
subsidiary, Hangzhou Zeshi Investment Partnership (Limited Partnership) (“Hangzhou Zeshi”) was involved in consulting service
relating to debt collection with one factoring company. The debt collection service involved one performance obligation which is to
assist the customer to receive repayment on outstanding debt, and the Company recognized revenues upon completion of the performance
obligation. For the year ended December 31, 2021, 2020 and 2019, Hangzhou Zeshi recognized revenue of $nil, $nil and $316,795
respectively.
Management and assessment services
The Company commenced its management and assessment
services in December 2018. The Company provided management and assessment services during the loan period to its customers who borrowed
direct loans from the Company.
|
1) |
Asset
management services focus on providing account receivable collection plans, collection, investigation on assets such as guaranty,
assisting litigation mitigation, process assets and asset supervision; |
|
2) |
Financing
services focus on designing financing plans, recommending fund sources and assisting funds to arrange project due diligence; and |
|
|
|
|
3) |
Factoring
business focuses on financing invoices from businesses that have cash flow problems due to slow-paying customers. The client gets
immediate funds for the receivable. We hold the invoice and make certain profit when the invoice is paid by the clients’ customers.
In this process, we also provide related services such as assessing the buyers’ credit risks. |
For the years ended December 31, 2021, 2020 and 2019, we provided management
and assessment services to four customers, generating revenues of $440,254, $19,676, and $135,938, respectively. Revenue for the year
ended December 31, 2020, were mainly for the contracts obtained in 2019 which were recognized during fiscal year 2020. In the year ended
December 31, 2021, we entered into some new contracts with our customers and the revenue increased as compared to the previous year.
Financial guarantee services
The Company’s subsidiary, Zhejiang Jing
Yu Xin Financing Guarantee Co., Ltd. (浙江京虞信融资担保有限公司)
(“Zhejiang Jingyuxin”), which the Company owns 93.4% of the equity, provides financial guarantee services to its customers.
The Company receives financial guarantee commission
by providing a financial guarantee service to customers. Pursuant to the financial guarantee service contracts, the Company is obligated
to make payments if the customers fail to make payments to financial institutions as scheduled. Accordingly, the financial institutions
providing capital to customers and will claim the defaulted amount against the Company if any customer default occurs. The contract amounts
reflect the extent of credit losses to which the Company is exposed.
Credit risk is controlled by the application
of credit approvals, limits and monitoring procedures including due-diligence visits and post-lending visits to the clients. The Company
manages credit risk through in-house research and analysis of the Chinese economy, the underlying obligors and transaction structures.
To minimize credit risk, the Company requires collaterals in the form of cash or pledges of securities or property and equipment.
As part of its financial guarantee services, the Company provides loan
guarantees. The customer’s cash deposits or other assets are held as collaterals for the repayment of each loan. As of December
31, 2021 and 2020, the amount of outstanding loans and related interest that the Company has guaranteed was approximately $47,020,055
and $51,318,310, respectively.
The Company generated financial guarantee commissions
of $456,944 and $375,471 for December 31, 2021 and 2020, respectively. For the period from acquisition of Lixin on December 20, 2019
to December 31, 2019, the Company generated financial guarantee commission of $8,797.
Revenue from Interest and fees
Zhejiang Lixin, LAM, Hangzhou Zeshi, Zeshi Insurance and
Yi Fu provide
loans to third parties and charge a fixed rate interest on the loans. For the year ended December 31, 2021, 2020 and 2019, the Company
recorded interest on third parties loans of $2,113,918, $2,131,447, and 34,707, respectively.
Under the financial guarantee service agreements,
banks, other financial institutions and creditors who provide loans to the Company’s guarantee service customers, generally require
the Company, as the guarantor of the loans, to deposit cash of 10% to 20% of the guaranteed amount into an escrow account which is restricted
from use. The Company records interest received on the restricted cash pledged as revenue. For the year ended December 31, 2021, 2020
and 2019, the Company recorded interest on restricted cash of $300,749, $348,389, and $64,636, respectively.
Prior to September 30, 2020, through Feng Hui
Ding Xin (Beijing) Financial Consulting Co., Ltd. (“Ding Xin”), which was sold on September 30, 2020, we also entered into
financing arrangements with our customers through Zhiyuan Commercial Factoring (Guangzhou) Co., Ltd. (“Zhiyuan”), which
is engaged in business factoring program. We earned interest income from these financing arrangements. For the years ended December 31,
2020 and 2019, we earned interest income from factoring programs of $nil and $2,782,332.
Healthcare service packages
On December 30, 2019, the Company incorporated
Fortis Health Industrial Group Limited (former name Fortis Health Industrial Group Limited) (“Fortis” or “FIG”,)
in Hong Kong. On February 28, 2020, the Company incorporated Zeshi Insurance to conduct insurance technology business. On March 3, 2020,
the Company incorporated Zeshi Health to conduct health management, health big data management, and health information management based
on blockchain technology.
In April 2020, the Company officially launched
a one-stop internet insurance and health care service platform after nearly eight months of preparation and systems development. The platform
aims to provide modern households with one-stop systematic “customized insurance + health management + family doctor + home medical
testing” health management service solutions. This platform will enable households and employees of medium to large-sized enterprises
to access cost-effective, customized health care and insurance solutions, customized insurance products, as well as data management and
operational services.
In July 2020, the Company changed the principal
business operations of Ningbo Ding Tai Financial Leasing Co., Ltd. in order to expand and enhance its services in the health industry
in Zhejiang Province and renamed it Yifu Health Industry (Ningbo) Co., Ltd.
The Company has established long-term partnerships
for innovative insurance services, smart health medical services, data mining, and operations with a variety of insurance service partners,
medical service partners, and technology and big data partners.
The Company had initially planned to officially
launch our newborn deformity diagnosis and treatment insurance project at the end of 2020 or early 2021. Due to a COVID outbreak in Hebei
province in early 2021, the project was temporarily suspended. The revenue generated from the health care service was minimal during
the year ended December 30, 2021 and 2020.
Industrial
operation services
In
the year ended December 31, 2021, the Company began to provide industrial operations services to its customers, which includes transformation,
incubation and commercialization of scientific and technological achievements; investment and development of projects for new technology,
products and related operating service.
On
December 31, 2021, Hangzhou Zeshi investment partnership (Limited Partnership) (“Hangzhou Zeshi”), a wholly-owned
subsidiary of the Company, entered into an agreement with ZhongTan Future New Energy Industry Development (Zhejiang) Co., Ltd.
(“ZhongTan Future”). Pursuant to the agreement, Hangzhou Zeshi will provide supply chain financial services,
financial leasing services and industrial operation services, etc. Revenue of $146,245 was recognized during the year ended December
31, 2021 after the target customer was located, due diligence and initial negotiation was completed and requirements of ZhongTan
Future were met.
COVID-19 Impact
Our business operations
have been affected and may continue to be affected by the ongoing COVID-19 pandemic. After the second quarter of 2020, the COVID outbreak
in China was gradually controlled. Our business initially returned to normal operations, although management assessed that our results
of operations had been negatively impacted for the year. In 2021, Omicron variants emerged, resulting in continued disruption to our
business and the global economy and supply chain. If any new outbreak of COVID-19 is not effectively and timely controlled, or if government
responses to outbreaks or potential outbreaks are severe or long-lasting, it could negatively affect the execution of customer contracts,
the collection of customer payments, or disrupt our supply chain, and the continued uncertainties associated with COVID 19 may cause
our revenue and cash flows to underperform in the next 12 months. The extent of the future impact of the COVID-19 pandemic on our business
and results of operations is still uncertain.
Recent developments
Dispositions of China Roan Industrial-Financial Holdings
Group Co., Ltd. and subsidiaries
On September 17, 2021, the Company signed an
equity transfer agreement to sell 100% of the equity interest it held in Roan HK, a holding company that has no business operations,
to Yuanjia Asset Management Co. Ltd. (“Yuanjia”), a BVI company, for a total of approximately $282 (HK$2,200). The transaction
was closed on September 30, 2021. The net assets of Roan HK were negative $492,495 as of September 30, 2021, resulting in a gain on deconsolidation
of $492,777 and other comprehensive loss of $2,494. Roan HK’s subsidiary, Jing Kai was disposed at the same time.
Setup of joint ventures
On July 27, 2021, the Company signed a cooperation
agreement with Beijing Auvgo International Travel Technology Co. Ltd. (“Auvgo International”), to form a joint venture, Yijia
Travel (Hangzhou) Digital Technology Co. Ltd. (“Yijia Travel”), to jointly develop business travel services. Pursuant to
the agreement, the Company and Auvgo International will invest and hold 35% of the equity in the joint venture, respectively, and the
Company’s business partner, Shuzhiyun Holdings (Beijing) Co., Ltd. (“Shuzhiyun”), who signed an agreement with the
Company to vote in concert, will make capital contributions for the remaining 30% equity in the joint venture.
On September 30, 2021, the Company signed a cooperation
agreement with Shenzhen Geile Information Technology Co., Ltd. (“Harvest”, formerly called “Shenzhen Harvest Business
Ltd., Co.”), to jointly set up a consumer payment technology joint venture, FINE C+ Digital Technology (Hangzhou) Limited (“FINE
C+ Digital”), to offer lifestyle consumer services including cross-platform clearing and settlement services for consumer reward
rights and interests. Pursuant to the agreement, the Company and Harvest will invest and hold 45% and 25% of the equity in the joint
venture, respectively, and the Company’s business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert,
will make capital contributions for the remaining 30% equity in the joint venture.
On October 14, 2021, the Company’s subsidiary,
Yifu Health Industry (Ningbo) Co., Ltd. (“Yi Fu”) signed a cooperation agreement with Shuzhiyun and Shanghai Jingmu Information
Technology Co. Ltd. (“Jingmu”), to set up a joint venture to provide online medical consultation and traditional Chinese
medicine, FINE C+ Health (Hangzhou) Technology Limited (“FINE C+ Health”). Pursuant to the agreement, Yi Fu and Shuzhiyu will
invest and hold 40% and 30% of the equity in the joint venture, respectively, and Jingmu will make capital contributions for the remaining
30% equity in the joint venture. Shuzhiyun signed an agreement with the Company to vote in concert.
On October 18, 2021, the Company signed a cooperation
agreement with Flourishing Technology Inc. (“Flourishing”) and media interactive technology experts to set up a joint venture,
FINE C+ Interactive Technology (Hangzhou) Limited (“FINE C+ Interactive”), to jointly develop cultural and tourism services,
education development industry business and personal financial services. Pursuant to the agreement, the Company and Flourishing and media
interactive technology experts will invest and hold 35% and 51 % of the equity in the joint venture, respectively, and the Company’s
business partner, Shuzhiyun, who signed an agreement with the Company to vote in concert, will make capital contributions for the remaining
14% equity in the joint venture.
As of the date of this report, the Company had
not paid the investment.
On November 18, 2021, the Company signed a
cooperation agreement with Harvest Horn (Beijing) Marketing Co., Ltd. (“Harvest Horn”) to set up an entertainment
technology joint venture focusing on the theme park industry. Pursuant to the agreement, the Company’s subsidiary, FINE C+
Interactive and Roan’s partners will hold 70% equity jointly, and Harvest Horn’s subsidiary, Beijing Liuxinghuoyu
Technology Co., Ltd. (“Liuxinghuoyu”), will hold the remaining 30% equity. As of the date of this report, the Company
has not paid for this investment.
On November 24, 2021, Hangzhou Zeshi Shuzhhiyun and another individual
set up Hangzhou Future New Energy Enterprise Management Partnership (Limited Partnership) (“Future New Energy”). Hanzhou Zeshi
held 1% of the equity of Future New Energy. The registered capital of Future New Energy is RMB 10,000,000 (approximately $1,569,218).
As of the date of this report, Hangzhou Zeshi has not paid for this investment of RMB100,000 (approximately $15,692).
On December 16, 2021, Hangzhou Zeshi, Future
New Energy Partnership (Limited Partnership) and another four unrelated parties set up Zhongtan Future New Energy Industry
Development (Zhejiang) Co., Ltd., (“Zhongtan Future”). Hangzhou Zeshi held 2% its equity and Future New Energy
held 20% its equity. The registered capital of Zhongtan Future is RMB 100,000,000 (approximately $15,692,182). As of the date
of this report, the Company has not paid for this investment of RMB 2,000,000 (approximately $313,844).
Key Factors Affecting Our Results of Operation
We have a limited operating history of our current
businesses. We commenced management and assessment consulting services in December 2018, and acquired financial guarantee and consulting
business in late December 2019. We believe our future success depends on our ability to significantly expand financial market and channels,
and apply latest technology related to healthcare big data, artificial intelligence and block chain to the combination of medical and
healthcare management and insurance. Our limited operating history makes it difficult to evaluate our business and future prospects.
You should consider our future prospects in light of the risks and challenges encountered by a company with a limited operating history
in an emerging and rapidly evolving industry. These risks and challenges include, among other things,
|
● |
our
ability to integrate financial guarantee and financial consulting business; |
|
● |
our
ability to expand financial market and channels, especially in individual financial area services: insurance + consumption finance;
and |
|
● |
our
ability to build the insurance technology and health management platform. |
In addition, our business requires a significant
amount of capital in large part due to needing to continuously grow financial guarantee services, and expand our business in existing
markets and to additional markets where we currently do not have operations. We do not know if we will receive the amount of capital
needed for our business growth and expansion.
Results of Operations
The following table sets forth a summary of our
consolidated results of operations for the periods presented. This information should be read together with our consolidated financial
statements and related notes included elsewhere in this annual report. The results of operations in any period are not necessarily indicative
of our future trends.
|
|
For the Years Ended
December 31, |
|
|
|
2021 |
|
|
2020 |
|
|
2019 |
|
|
|
|
|
|
|
|
|
|
|
Revenues from services |
|
$ |
793,291 |
|
|
$ |
2,128,153 |
|
|
$ |
639,220 |
|
Revenues from healthcare service package |
|
|
- |
|
|
|
55,301 |
|
|
|
- |
|
Cost of revenues |
|
|
- |
|
|
|
(50,774 |
) |
|
|
(8,080 |
) |
Net revenues of services |
|
|
793,291 |
|
|
|
2,132,680 |
|
|
|
631,140 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commissions and fees on financial guarantee services |
|
|
456,944 |
|
|
|
375,471 |
|
|
|
8,797 |
|
Provision for financial guarantee services |
|
|
(57,417 |
) |
|
|
(89,865 |
) |
|
|
(5,008 |
) |
Commission and fee income on guarantee services, net |
|
|
399,527 |
|
|
|
285,606 |
|
|
|
3,789 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and fees income |
|
|
|
|
|
|
|
|
|
|
|
|
Interest and fees on direct loans |
|
|
- |
|
|
|
- |
|
|
|
1,153 |
|
Interest income on loans due from third parties |
|
|
2,113,918 |
|
|
|
2,131,447 |
|
|
|
34,707 |
|
Interest income from factoring business |
|
|
- |
|
|
|
- |
|
|
|
2,782,332 |
|
Interest income on deposits with banks |
|
|
300,749 |
|
|
|
348,389 |
|
|
|
64,636 |
|
Total interest and fee income |
|
|
2,414,667 |
|
|
|
2,479,836 |
|
|
|
2,882,828 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest expense |
|
|
|
|
|
|
|
|
|
|
|
|
Interest expenses and fees on secured loans |
|
|
- |
|
|
|
- |
|
|
|
(2,218,815 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net interest income |
|
|
2,414,667 |
|
|
|
2,479,836 |
|
|
|
664,013 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Provision for loan losses |
|
|
- |
|
|
|
- |
|
|
|
(2,244,601 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net interest (loss) income after provision for loan losses |
|
|
2,414,667 |
|
|
|
2,479,836 |
|
|
|
(1,580,588 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating (loss) income |
|
|
3,607,485 |
|
|
|
4,898,122 |
|
|
|
(945,659 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
Salaries and employee surcharge |
|
|
(1,054,509 |
) |
|
|
(1,116,482 |
) |
|
|
(512,314 |
) |
Other operating expenses |
|
|
(2,241,069 |
) |
|
|
(2,995,098 |
) |
|
|
(1,385,259 |
) |
Changes in fair value of warrant liabilities |
|
|
(3,021 |
) |
|
|
5,961 |
|
|
|
530,863 |
|
Total operating expenses |
|
|
(3,298,599 |
) |
|
|
(4,105,619 |
) |
|
|
(1,366,710 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expenses) |
|
|
|
|
|
|
|
|
|
|
|
|
Deconsolidation gain (loss) |
|
|
490,283 |
|
|
|
(1,953,248 |
) |
|
|
- |
|
Other income (expense) |
|
|
554,167 |
|
|
|
76,406 |
|
|
|
- |
|
Interest income (expenses), net |
|
|
(267,184 |
) |
|
|
- |
|
|
|
- |
|
Total other expenses |
|
|
777,266 |
|
|
|
(1,876,842 |
) |
|
|
- |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes |
|
|
1,086,152 |
|
|
|
(1,084,339 |
) |
|
|
(2,312,369 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Income tax (expenses) recovery |
|
|
(328,851 |
) |
|
|
229,733 |
|
|
|
(244,741 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from continuing operations |
|
|
757,301 |
|
|
|
(854,606 |
) |
|
|
(2,557,110 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) from discontinued operations, net of income tax |
|
|
- |
|
|
|
- |
|
|
|
26,846,018 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) |
|
$ |
757,301 |
|
|
$ |
(854,606 |
) |
|
$ |
24,288,908 |
|
Year ended December 31, 2021 compared to year ended December 31,
2020
Revenues
Our revenues from services decreased by $1,334,862 or 63%, from $2,128,153
for the year ended December 31, 2020, to $793,291 for the year ended December 31, 2021. The following table sets forth a breakdown of
our revenue by services offered for the years ended December 31, 2021 and 2020:
|
|
For the years ended
December 31, |
|
|
Variance |
|
|
|
2021 |
|
|
2020 |
|
|
Amount |
|
|
% |
|
Management and assessment services |
|
$ |
440,254 |
|
|
$ |
19,676 |
|
|
$ |
420,578 |
|
|
|
2138 |
% |
Consulting services relating to debt collection |
|
|
206,792 |
|
|
|
2,108,477 |
|
|
|
(1,901,685 |
) |
|
|
(90 |
)% |
Industrial operation services |
|
|
146,245 |
|
|
|
- |
|
|
|
146,245 |
|
|
|
100 |
% |
Revenues from services |
|
$ |
793,291 |
|
|
$ |
2,128,153 |
|
|
$ |
(1,334,862 |
) |
|
|
(63 |
)% |
Management and assessment services
Revenue from management and assessment services
was $440,254 and $19,676 for the year ended December 31, 2021 and 2020, respectively. Revenue for the year ended December 31, 2020,
were mainly for the contracts obtained in 2019 which were recognized during fiscal year 2020. In the year ended December 31, 2021, we
entered into some new contracts with our customers and the revenue increased as compared to the previous year.
Consulting services relating to debt collection
The Company provides consulting services
relating to debt collection with certain factoring companies, through the subsidiary of Lixin Cayman which were acquired in late
December 2019. The debt collection services involved two performance obligations and the service fee for each performance obligation
are fixed and reflected the stand-alone selling price. In addition, a collected-amount based incentive is rewarded to the Company
upon collection of outstanding debt.
|
1) |
assisting
the customers to get court judgements on outstanding debt, and the Company recognized revenues over the period towards the completion
of the performance obligation; and |
|
2) |
assisting
the customers to receive repayment on outstanding debt, and the Company recognized revenues upon completion of the performance obligation. |
Revenue from consulting services relating to debt collection $206,792
for the year ended December 31, 2021, a decrease of 1,901,685, or 90%, as compared to and $2,108,477 for the year ended December 31, 2020,
which was mainly due to the negative impact of the COVID pandemic. We had less contracts for debt collection service during the year ended
December 31, 2021.
Industrial operation services
On December 31, 2021, Hangzhou Zeshi
Investment Partnership (Limited Partnership) (“Hangzhou Zeshi”), a wholly-owned subsidiary of the Company, entered into an
agreement with ZhongTan Future New Energy Industry Development (Zhejiang) Co., Ltd. (“ZhongTan Future”). Pursuant to the
agreement, Hangzhou Zeshi will provide supply chain financial services, financial leasing services and industrial
operation services, etc. Revenue of $146,245 was recognized during the year ended December 31, 2021 after the target customer was
located, due diligence and initial negotiation was completed and requirements of ZhongTan Future were met.
Commissions and fees on financial guarantee
services
Commission and fees on financial guarantee services was $456,944 for
the year ended December 31, 2021, an increase of $81,473, or 22% as compared to $375,471 for fiscal year 2020, reflecting an increase
for business development.
Provision for financial guarantee services
The provisions for financial guarantee services are related to financial
guarantee service business as per the requirement of local government. Provisions for financial guarantee services was $57,417 for the
year ended December 31, 2021, as compared to $89,865 for last fiscal year.
Interest and fees income
Interest and fee income primarily consisted of interest and fee income
generated from loans due from third parties. Interest and fee income was $2,414,667, a decrease of $65,169, or 3% for the year ended December
31, 2021 as compared to $2,479,836 for fiscal year 2020. The decrease was mainly due to a decrease of $17,529 in interest income from
loans due from third parties and a decrease of $47,640 in interest income on deposits with banks.
Operating expenses
Operating expense mainly consisted of salary and employee surcharges,
office expenses, travel costs, entertainment expenses, depreciation of equipment, current expected credit losses, write-off of receivables,
professional fees and office supplies. Operating expenses in total decreased by $807,020, or 20% to $3,298,599 for year ended December
31, 2021 compared to $4,105,619 for the year ended December 31, 2020. The decrease was primarily attributable by a decrease of $61,973
in salaries and employee surcharges and a decrease of $754,029 in other operating expenses. The decreases in both of these expenses were
primarily the result of our cost control strategies. Operating expenses also include change in fair value of warrant liabilities. The
loss from the fair value change in warrant liabilities was $3,021 during the year ended December 31, 2021, as compared to a gain of $5,961
for last fiscal year.
Income tax expenses
We had income tax expenses of $328,851 for the
year ended December 31, 2021 as compared to a recovery of $229,733 for the year ended December 31, 2020.
Current income tax expenses decreased by $177,367
from $ 771,639 for the year ended December 31, 2020 to $594,272 for the year ended December 31, 2021. The decrease was primarily
caused by the reversal of the accrued tax payables in the previous years.
Deferred income tax recovery was $265,421 or
the year ended December 31, 2021 as compared to $ 1,001,372 for the ended December 31, 2020. The higher tax recovery in 2020 was
mainly due to the reversal of deferred income tax liabilities in connection with the changes in temporary differences.
Net income (loss) from discontinued operations,
net of income tax
During the year ended December 31, 2020, the net
income from discontinued corporation, net of income tax was $Nil. The Company, however, recorded a derecognition loss of $1,953,248 from
the disposition of Ding Xin in September 2020.
Net income
As a result of the foregoing, we had a net income
of $757,301 for the year ended December 31, 2021, as compared to a net loss of $854,606 for the year ended December 31, 2020.
Year ended December 31, 2020 compared to year ended December 31,
2019
Revenues
Our revenues from services increased by $1,488,933 or 233%, from $639,220 for
the year ended December 31, 2019, to $2,128,153 for the year ended December 31, 2020. The following table sets forth a breakdown of our
revenue by services offered for the years ended December 31, 2020 and 2019:
| |
For the years ended December 31, | | |
Variance | |
| |
2020 | | |
2019 | | |
Amount | | |
% | |
Management and assessment services | |
$ | 19,676 | | |
$ | 135,938 | | |
$ | (116,262 | ) | |
| (86 | )% |
Consulting services relating to debt collection | |
| 2,108,477 | | |
| 493,779 | | |
| 1,614,698 | | |
| 327 | % |
Consulting services relating to financial guarantee services | |
| - | | |
| 9,503 | | |
| (9,503 | ) | |
| (100 | )% |
Revenues from services | |
$ | 2,128,153 | | |
$ | 639,220 | | |
$ | 1,488,933 | | |
| 233 | % |
Management and assessment services
Revenues from management and assessment services decreased by $116,262 or
86%. The primary reason of the decrease was due to a majority of revenues from the contracts obtained in 2018 were recognized in the year
ended December 31, 2019. In the year ended December 31, 2020, we did not engage in much management and assessment services due to the
change of our business focus. Therefore, there was minimal revenue from Management and assessment services.
Consulting services relating to debt collection
The Company provides consulting services relating
to debt collection with certain factoring companies, through Lixin group which were acquired in late December 2019. The debt collection
services involved two performance obligations, and the service fee for each performance obligation are fixed and reflected the stand-alone
selling price. In addition, a collected-amount based incentive is rewarded to the Company upon collection of outstanding debt.
|
1) |
assisting
the customers to get court judgements on outstanding debt, and the Company recognized revenues over the period towards the completion
of the performance obligation; and |
|
2) |
assisting
the customers to receive repayment on outstanding debt, and the Company recognized revenues upon completion of the performance obligation. |
The significant increase of $1,614,698 or 327%
was due to we consolidated a full year of Lixin’s operations in 2020, whereas in 2019, we only consolidated Lixin’s operation
from December 20, 2019 to December 31, 2019.
Commissions and fees on financial guarantee
services
Commissions and fees on financial guarantee services increased by $366,674
or 4,168% for the year ended December 31, 2020 compared to the same period of 2019. This was due to we consolidated a full year of Lixin’s
operations in 2020, whereas in 2019, we only consolidated Lixin’s operation from December 20, 2019 to December 31, 2019.
Interest and fees income
Interest and fee income primarily consisted of
interest and fee income generated from factoring business and from loans due from third parties. Interest and fee income decreased by
$402,992 or 14% for the year ended December 31, 2020 compared to the same period of 2019. The decrease was mainly due to our subsidiary,
Zhiyuan, which provided our only factoring business did not conduct any factoring business due to the Company’s change of business
plan. Zhiyuan was later disposed of in September 2020. As a result, interest income and fee from factoring business decreased by $2,782,332.
The decrease in interest income from factoring business was offset by the increase of $2,131,447 in interest income from loans advanced
to third parties through our Lixin’s operations after our acquisition of Lixin in December 2019.
Interest expenses and fees on secured loans
Interest expenses and fees on secured loans decreased
by $2,218,815 or 100% from $2,218,815 for the year ended December 31, 2019 to $Nil for the year ended December 31, 2020.
The significant decrease of interest expenses
and fees on secured loans was due to all secured loans were repaid during the year ended December 31, 2019. Our secured loans were issued
through Zhiyuan in previous years. There were no new secured loans issued in fiscal 2020 and we later disposed of Zhiyuan in September
2020.
Provision for loan losses
The provisions for loan losses related to our
direct loan and secured loan lending business conducted through Ding Xin before 2020. There were no new direct loans and secured loans
issued in fiscal 2020 and we disposed of Ding Xing in September 30, 2020. Therefore, provisions for loan losses decreased by $2,244,601,
or 100%, from $2,244,601 for the year ended December 31, 2019 to $Nil for the year ended December 31, 2020.
Operating expenses
Operating expense mainly consisted of salary and
employee surcharges, office expenses, travel costs, entertainment expenses, depreciation of equipment, current expected credit losses,
write-off of receivables, professional fees and office supplies. Operating expenses in total increased by $2,738,909, or 200% for year
ended December 31, 2020 compared to $1,366,710 for the year ended December 31, 2019. The increase was primarily attributable by
an increase of $604,168 in salaries and employee surcharges and an increase of $ 1,609,839 in other operating expenses. The
increases in both of these expenses were primarily due to the consolidation of Lixin’s operating expenses for the full year in 2020,
whereas the consolidation Lixin’s operating expenses was only from December 20, 2019 to December 31, 2019. Operating expenses also
include change in fair value of warrant liabilities. There was a minimal change in fair value in 2020 compared to 2019, resulting in a
decrease of $524,902 in gain from fair value change in warrant liabilities.
Income tax expenses
We had income tax recovery of $229,733 for the
year ended December 31, 2020, as compared with income tax expense of $244,741 for the year ended December 31, 2019.
Current income tax expenses increased by
$526,898 from $187,067 for the year ended December 31, 2019 to $771,639 for the year ended December 31, 2020. The increase was
primarily caused by the full year consolidation of Lixin’s operations in 2020 compared to the consolidation of Lixin’s
operations for only a small stub period in 2019.
Deferred income tax expenses changed from deferred
tax expense of $57,674, for the year ended December 31, 2019 to deferred tax recovery of $1,001,372 for the ended December 31, 2020. The
change was mainly due to the reversal of deferred income tax liabilities in connection with the changes in temporary differences.
Net income (loss) from discontinued operations,
net of income tax
During the year ended December 31, 2020, the net
income from discontinued corporation, net of income tax is $nil. The Company, however, recorded a derecognition loss of $1,953,248 from
the disposition of Ding Xin in September 2020.
During the year ended December 31, 2019, the net
income was comprised of a net loss of $27,904,790 from discontinued operations of Feng Hui and a gain of $54,750,808 from disposal of
the discontinued operations of Feng Hui.
Net income
As a result of the foregoing, we had a net loss of $854,606 for the
year ended December 31, 2020, as compared to a net income of $24,288,908 for the year ended December 31, 2019.
Taxation
British Virgin Islands
Under the current tax laws of the British Virgin Islands, the Company
is not subject to tax on income or capital gains. Additionally, upon payments of dividends to the shareholders, no British Virgin Islands
withholding tax will be imposed.
Cayman Islands
Under the current tax laws of the Cayman Islands,
the Company’s subsidiary incorporated in the Cayman Islands is not subject to tax on income or capital gain.
Hong Kong
Roan HK and Lixin HK are incorporated in Hong
Kong and are subject to Hong Kong Profits Tax on the taxable income as reported in its statutory financial statements adjusted in accordance
with relevant Hong Kong tax laws. The applicable tax rate for the first HKD$2 million of assessable profits is 8.25% and assessable profits
above HKD$2 million will continue to be subject to the rate of 16.5% for corporations in Hong Kong, effective from the year of assessment
2018/2019. Before that, the applicable tax rate was 16.5% for corporations in Hong Kong. The Company did not make any provisions for
Hong Kong profit tax as there were no assessable profits derived from or earned in Hong Kong since inception. Under Hong Kong tax laws,
Roan HK and Lixin HK are exempted from income tax on its foreign-derived income and there are no withholding taxed in Hong Kong on remittance
of dividends.
PRC
PRC subsidiaries are subject to PRC Enterprise
Income Tax (“EIT”) on the taxable income in accordance with the relevant PRC income tax laws. The EIT rate for companies
operating in the PRC is 25%.
Critical Accounting Policies
We prepare our consolidated financial statements
in accordance with U.S. GAAP, which requires us to make judgments, estimates and assumptions that affect (i) the reported amounts of
assets and liabilities, (ii) disclosure of contingent assets and liabilities at the end of each reporting period and (iii) the reported
amounts of revenues and expenses during each reporting period. We continually evaluate these estimates and assumptions based on historical
experience, knowledge and assessment of current business and other conditions, expectations regarding the future based on available information
and reasonable assumptions, which together form a basis for making judgments about matters not readily apparent from other sources. The
use of estimates is an integral component of the financial reporting process, though actual results could differ from those estimates.
Some of our accounting policies require higher degrees of judgment than others in their application. Please refer to Note 3 of consolidated
financial statements included in this 20-F annual report for the accounting policies critical to an understanding of our consolidated
financial statements as their application places the most significant demands on the judgment of our management.
Recent Accounting Pronouncements
A list of recently issued accounting pronouncements
that are relevant to us is included in Note 3(ll) of our audited consolidated financial statements included elsewhere in this annual
report.
B. |
Liquidity
and capital resources |
In assessing our liquidity, we monitor and analyze
our cash on-hand and our operating and capital expenditure commitments. To date, we have financed our operations primarily through cash
flows from operations, bank borrowings, and equity financing.
In assessing the Company’s liquidity, the
Company monitors and analyzes its cash and its ability to generate sufficient cash flow in the future to support its operating and capital
expenditure commitments. The Company’s liquidity needs are to meet its working capital requirements and operating expenses obligations.
As of December 31, 2021, the Company had cash
balance of $1,947,472 and a positive working capital of $51,940,172. In addition to the cash balance, the working capital was mainly comprised
of restricted cash of $29,693,689, accounts receivable of 6,629,529, loan receivable due from third parties of $23,751,471 and other receivables
of $656,835. The balances of these assets are expected to be repaid on maturity dates and will also be used for working capital.
In addition, the management estimated the operating
expenses obligation for the next twelve months after issuance of the consolidated financial statements to be $3,786,344, which will be
covered by the cash flows of $4,185,518 generated from financial guarantee services, financial services and interest income.
The Company’s shareholder also committed to provide continuous financial support to the Company whenever necessary.
The Company plans to fund its operations through
revenue generated from its revenues of management and assessment services, financial guarantee services and financial consulting services,
private placements from investors, and financial support commitments from the Company’s shareholders.
Based on above operating plan, the management
believes that the Company will continue as a going concern in the following 12 months.
The Company’s ability to support its operating
and capital expenditure commitments will depend on its future performance, which will be subject in part to general economic, competitive
and other factors beyond its control. The impacts of COVID-19 may cause lockdowns, quarantines, travel restrictions, and closures of
businesses and schools. As a result, the Company may experience delay of outstanding receivables from customers and limited access to
cash to expand its operations. The extent to which the coronavirus impacts the Company’s operation results for year 2022 will depend
on certain future developments, including the duration of the COVID-19 pandemic, emerging information concerning the severity of the
coronavirus and the actions taken by governments and private businesses to attempt to contain the coronavirus, all of which is uncertain
at this point.
Current foreign exchange and other regulations
in the PRC may restrict our PRC entities in their ability to transfer their net assets to the Company and its subsidiaries in Cayman
Islands, and Hong Kong. However, these restrictions have no impact on the ability of these PRC entities to transfer funds to us as we
have no present plans to declare dividend which we plan to retain our retained earnings to continue to grow our business. In addition,
these restrictions have no impact on the ability for us to meet our cash obligations as all of our current cash obligations are due within
the PRC.
A majority of our future revenues are likely
to continue to be in the form of Renminbi. Under existing PRC foreign exchange regulations, Renminbi may be converted into foreign exchange
for current account items, including profit distributions, interest payments and trade-and service-related foreign exchange transactions.
We expect that a substantial majority of our
future revenues will be denominated in Renminbi. Under existing PRC foreign exchange regulations, payments of current account items,
including profit distributions, interest payments and trade and service-related foreign exchange transactions, can be made in foreign
currencies without prior SAFE approval as long as certain routine procedural requirements are fulfilled. Therefore, our PRC subsidiaries
are allowed to pay dividends in foreign currencies to us without prior SAFE approval by following certain routine procedural requirements.
However, approval from or registration with competent government authorities is required where the Renminbi is to be converted into foreign
currency and remitted out of China to pay capital expenses such as the repayment of loans denominated in foreign currencies. The PRC
government may at its discretion restrict access to foreign currencies for current account transactions in the future.
Cash Flows
The following table sets forth a summary of our
cash flows for the years ended December 31, 2021, 2020 and 2019.
| |
For the Years Ended December 31, | |
| |
2021 | | |
2020 | | |
2019 | |
Net Cash Provided by (Used in) Operating Activities | |
$ | 8,717,975 | | |
$ | (7,461,511 | ) | |
$ | (1,101,143 | ) |
Net Cash (Used in) Provided by Investing Activities | |
| (5,684,489 | ) | |
| 6,332,631 | | |
| 85,965,056 | |
Net Cash (Used in) Provided by Financing Activities | |
| (3,114,478 | ) | |
| 7,853,152 | | |
| (64,138,838 | ) |
Effect of exchange rate changes on cash and cash equivalents | |
| 914,219 | | |
| 1,937,807 | | |
| 119,326 | |
Net increase in cash and cash equivalents, and restricted cash in banks | |
$ | 833,227 | | |
$ | 8,662,079 | | |
$ | 20,844,401 | |
Operating activities
Years Ended December 31, 2021 and 2020
Net cash provided by operating activities was
$8,717,975 for the year ended December 31, 2021, an increase of $16,179,486 from net cash used in operating activities of $7,461,511 for
the year ended December 31, 2020. Net income for the year ended December 31, 2021 was $757,301, an increase of 1,611,907 from a net loss
of $854,606 for the year ended December 31, 2020. The increase was primarily due to an increase in net income.
In addition to the increase in net income,
the increase in net cash provided by operating activities was the result of the following major changes in our working capital and
non-cash items:
|
● |
A cash outflow of $7,495 from change in accounts receivable for the year ended December 31, 2021, as compared with a cash outflow of $3,116,533 for the year ended December 31, 2020. |
|
|
|
|
● |
A cash inflow of $3,431,640 from changes in other current assets for the year ended December 31, 2021, as compared with a cash outflow of $3,215,702 for the year ended December 31, 2020. |
|
|
|
|
● |
A cash inflow of $2,425,003 in other receivable for the year ended December 31, 2021, as compared with a cash outflow of 3,268,571 for the year ended December 31, 2020. |
|
|
|
|
● |
A cash inflow of $411,015 from change in pledged deposits and other non-current assets for the year ended December 31, 2021, as compared with a cash inflow of $328,854 for the year ended December 31, 2020. |
|
|
|
|
● |
A cash inflow of $847,043 from change in tax payable for the year ended December 31, 2021, as compared with a cash inflow of $1,029,919 for the year ended December 31, 2020. |
|
|
|
|
● |
A cash inflow of $449,971 from change in other liabilities for the year ended December 31, 2021, as compared with a cash outflow of $1,079,811 for the year ended December 31, 2020. |
Years Ended December 31, 2020 and 2019
Net cash used in operating activities was $7,461,511
for the year ended December 31, 2020, an increase of $6,360,368 from net cash used in operating activities of $1,101,143 for the year
ended December 31, 2019.
For the year ended December 31, 2020, we generated
a net income of $Nil from discontinued operation and had net cash used in discontinued operation of $Nil, a change of $26,846,018 and
$26,564 from net income of $26,846,018 and net cash used in discontinued operation of $26,564 for the year ended December 31, 2019.
We had net cash used in operating activities from
continuing operations of $7,461,511 for the year ended December 31, 2020, an increase of $6,386,932 from $1,074,579 for the year ended
December 31, 2019. We incurred a net loss from continuing operations of $854,606 for the year ended December 31, 2020, a decrease of $1,702,504
from a net loss of $2,557,110 for the year ended December 31, 2019. The decrease was primarily due to the full year consolidation of Lixin’s
positive net income in 2020 compared to consolidation of Lixin’s positive net income only for the period from December 20, 2019
to December 31, 2019.
In addition to the change in net loss, the increase
in net cash used in operating activities was the result of the following major changes in our working capital and non-cash items:
|
● |
A cash outflow of $ 3,116,533 from change in accounts receivable for the year ended December 31, 2020, as compared with a cash outflow of $206,442 for the same period ended December 31, 2019. |
|
|
|
|
● |
A cash outflow of $3,215,702 in other current assets for the year ended December 31, 2020, as compared with a cash outflow of $289,604 for the same period ended December 31, 2019. |
|
|
|
|
● |
A cash outflow of $3,268,571 from change in other receivable for the year ended December 31, 2020, as compared with a decrease of $Nil for the same period ended December 31, 2019. |
|
|
|
|
● |
A cash inflow of $359,202 from change in pledged deposits and other non-current assets for the year ended December 31, 2020, as compared with an increase of $Nil for the same period ended December 31, 2019. |
|
|
|
|
● |
A cash inflow of $1,029,919 from change in tax payable for the year ended December 31, 2020, as compared with a cash inflow of $273,589 for the same period ended December 31, 2019. |
|
|
|
|
● |
A cash outflow of $1,079,811 from change in other liabilities for the year ended December 31, 2020, as compared with a decrease of $Nil for the same period ended December 31, 2019. |
Holding Company Structure
Roan Holdings Group Co., Ltd. (“Roan”)
is a holding company with no material operations of its own. We conduct our operations primarily through our PRC subsidiaries. As a result,
Roan’s ability to pay dividends depends upon dividends paid by our PRC subsidiaries. If our existing PRC subsidiaries or any newly
formed ones incur debt on their own behalf in the future, the instruments governing their debt may restrict their ability to pay dividends
to us. In addition, our wholly foreign-owned subsidiaries in China are permitted to pay dividends to us only out of its retained earnings,
if any, as determined in accordance with PRC accounting standards and regulations. Under PRC law, each of our subsidiaries in China is
required to set aside at least 10% of its after-tax profits each year, if any, to fund certain statutory reserve funds until such reserve
funds reach 50% of their registered capital. In addition, our wholly foreign-owned subsidiaries in China may allocate a portion of their
after-tax profits based on PRC accounting standards to enterprise expansion funds and staff bonus and welfare funds at their discretion.
The statutory reserve funds and the discretionary funds are not distributable as cash dividends. Remittance of dividends by a wholly
foreign-owned company out of China is subject to examination by the banks designated by SAFE. Our PRC subsidiaries have not paid dividends
and will not be able to pay dividends until they generate accumulated profits and meet the requirements for statutory reserve funds.
C. |
Research
and development, Patents and License, etc. |
As a financial company, our business does not
rely on research and development. Accordingly, we have not incurred research and development expenses for the years ended December 31,
2021, 2020 and 2019.
For our intellectual property and license, please
see “Item 4. Information on the Company-B. Business Overview.”
Other than as disclosed elsewhere in this Form
20-F, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material effect
on our net revenues, income from continuing operations, profitability, liquidity or capital resources, or that would cause reported financial
information not necessarily to be indicative of future operating results or financial condition.
E. |
Off-balance
Sheet Arrangements |
We have not entered into any derivative contracts
that are indexed to our shares and classified as shareholders’ equity or that are not reflected in our consolidated financial statements.
Furthermore, we do not have any retained or contingent interest in assets transferred to an unconsolidated entity that serves as credit,
liquidity or market risk support to such entity. We do not have any variable interest in any unconsolidated entity that provides financing,
liquidity, market risk or credit support to us or that engages in leasing, hedging or research and development services with us.
F. |
Tabular
Disclosure of Contractual Obligations |
Contingencies
From time to time, the Company may be subject
to certain legal proceedings, claims and disputes that arise in the ordinary course of business. Although the outcomes of these legal
proceedings cannot be predicted, the Company does not believe these actions, in the aggregate, will have a material adverse impact on
its financial position, results of operations or liquidity.
Lease
commitments
As of December 31,
2021, only Zhejiang Jingyuxin had an operating lease, which had 0.33 years. . The Company considers those renewal or termination options
that are reasonably certain to be exercised in the determination of the lease term and initial measurement of right of use assets and
lease liabilities. Lease expense for operating lease is recognized on a straight-line basis over the lease term. The Company’s lease
agreements do not contain any material residual value guarantees or material restrictive covenants.
In calculating
the initial values of right of use assets and liabilities at inception date, the Company uses the rate implicit in the lease, when available
or readily determinable, to discount lease payments to present value. When the leases do not provide a readily determinable implicit
rate, the Company discount lease payments based on an estimate of its incremental borrowing rate.
The table below
presents the operating lease related assets and liabilities recorded on the balance sheets.
|
|
December 31,
2021 |
|
|
|
|
|
Right of use assets |
|
$ |
37,313 |
|
|
|
|
|
|
Operating lease liabilities, current portion |
|
$ |
65,498 |
|
Operating lease liabilities, noncurrent portion |
|
|
- |
|
Total operating lease liabilities |
|
$ |
65,498 |
|
As of December 31, 2021, the weighted average
remaining lease term was 0.33 years, and discount rates were 4.75% for the operating lease.
Rental expense for the years ended December 31,
2021, 2020 and 2019 was $146,498, 134,457 and $78,756, respectively.
The following is a schedule, by years, of maturities
of lease liabilities as of December 31, 2021:
Twelve months ended December 31, 2022 |
|
$ |
65,758 |
|
Total lease payments |
|
|
65,758 |
|
Less: imputed interest |
|
|
(260 |
) |
Present value of lease liabilities |
|
$ |
65,498 |
|
This annual report on Form 20-F contains forward-looking
statements. These statements are made under the “safe harbor” provisions of Section 21E of the Securities Exchange Act
of 1934, as amended. These forward-looking statements can be identified by terminology such as “will,” “expects,”
“anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,”
“may,” “intend,” “is currently reviewing,” “it is possible,” “subject to”
and similar statements. Among other things, the sections titled “Item 3. Key Information—D. Risk Factors,” “Item
4. Information on the Company,” and “Item 5. Operating and Financial Review and Prospects” in this annual report on
Form 20-F, as well as our strategic and operational plans, contain forward-looking statements. We may also make written or oral forward-looking
statements in our filings with the SEC, in our annual report to shareholders, in press releases and other written materials and in oral
statements made by our officers, directors or employees to third parties. Statements that are not historical facts, including statements
about our beliefs and expectations, are forward-looking statements and are subject to change, and such change may be material and may
have a material and adverse effect on our financial condition and results of operations for one or more prior periods. Forward-looking
statements involve inherent risks and uncertainties. A number of important factors could cause actual results to differ materially from
those contained, either expressly or impliedly, in any of the forward-looking statements in this annual report on Form 20-F. All
information provided in this annual report on Form 20-F and in the exhibits is as of the date of this annual report on Form 20-F,
and we do not undertake any obligation to update any such information, except as required under applicable law.
ITEM 6. DIRECTORS, SENIOR MANAGEMENT AND EMPLOYEES
A. |
Directors
and senior management |
Below are the names of and certain information
regarding the Company’s current executive officers and directors.
Name |
|
Age |
|
Position |
Junfeng
Wang |
|
43 |
|
Chairman
of the Board of Directors |
Guiling
Sun |
|
47 |
|
Director |
Xiaoliang
Liang |
|
49 |
|
Independent
Director |
John
Chen |
|
50 |
|
Independent
Director |
Yiguo
Xu |
|
49 |
|
Independent
Director |
Zhiyong
Tang |
|
46 |
|
Chief
Executive Officer |
Wenhao
Wang |
|
34 |
|
Chief
Financial Officer |
The principal occupation and business experience
during the past five years for our executive officers and directors is as follows:
Mr. Junfeng Wang was appointed as the
Company’s Chairman of the Board, effective August 10, 2021. He was appointed as the Company’s Chief Executive Officer from
August 10, 2020 to August 10, 2021. Mr. Wang served as a Technical Director with Beijing Chenglianxin Technology Co., Ltd., Internet
in Logistics Platform section from 2016 to July 2020. From 2015 to 2016, he held the technical director position with Juewei Group Beijing
Digital Marketing Center in the Food Processing Department. Mr. Wang holds an MBA degree from Beijing University of Posts and Telecommunications.
Ms. Guiling Sun was appointed as an executive
director of the Company on December 20, 2021. Ms. Sun was the Deputy General Manager of the Beijing Ming De Ya Xing Cultural Development
Co., Ltd. from September 2019 to September 2021. As the Deputy General Manager of Operations, she was in charge of the company’s
public affairs responsible for education consulting and facilitating cultural and artistic exchanges. From September 2019, Ms. Sun serves
as a Rural Education Support Project Consultant for the Holt International Foundation of China, and Guangxi Holt Philanthropic Foundation.
As the Rural Education Support Project Consultant, Ms. Sun is responsible for project design, training, and education consulting. Prior
to that position, she was Vice-Chancellor at Canvard College, Beijing Technology and Business University, from October 2013 to September
2019. Ms. Sun holds a Master’s degree in business management from Xiamen University, Xiamen, China.
Mr. Xiaoliang Liang was appointed as an
independent director of the Company on December 20, 2021 and serves as the Chairman of our Corporate Governance and Nominating Committee.
Mr. Liang is the General Manager of Chongqing Yuhong Chuangneng IOT Technology Co., Ltd. and has held that position since July 2021.
As the General Manager, he is responsible for the hydrogen fuel cell truck demonstration application, renewable energy hydrogen production,
hydrogen refueling station construction and operation, vehicle big data platform construction and operation, and carbon finance and business
related matters. Prior to that position, he was the General Manager of Beijing Qingshui Youyang New Energy Technology Co., Ltd. from
January 2020 to July 2021. Mr. Liang was the Chief Financial Officer of Zhejiang Yuhui Sola Energy Resource Co., Ltd. from January 2018
to December 2019. Mr. Liang served as a Vice President of Tunghsu Azure Renewable Energy Co., Ltd. from May 2015 to December 2017. Mr.
Liang holds a postgraduate degree in engineering management from the Beijing Graduate Institute of North China University of Water Resources
and Electric Power, Beijing, China.
Mr. John Chen is an independent
director and serves as Chairman of the Company’s Audit Committee. Mr. Chen is California Certified Public Accountant. Mr. Chen
is Executive President of Zhangjiagang Zhongbaojin Enterprise Management Consulting Co., Ltd. and was the Chief Financial Officer of
General Steel Holding Inc. (OTCBB: GSIH) from 2004 to 2019. From 1997 to 2003, Mr. Chen was a Senior Accountant at Moore Stephens
Frazer and Torbet. Mr. Chen received his Bachelor of Science degree in Business Administration, Accounting from California State
Polytechnic University.
Mr. Yiguo Xu is an independent director
appointed on March 26, 2019, and serves as Chairman of our Compensation Committee. Mr. Xu is the Secretary General of the National
Institution for Finance and Development, the Dean of the Finance Faculty of the Graduate School of Chinese Academy of Social Sciences,
the Deputy Director of the Finance Policy Research Centre of the Chinese Academy of Social Sciences and the Secretary General of Beijing
CBD International Finance Research Academy. He writes extensively on finance policies and conducts researches in various topics. He earned
his master’s degree from the School of Finance of Renmin University of China and his PhD in finance from the Graduate School of
Chinese Academy of Social Sciences.
Mr. Zhiyong Tang was appointed as the
Company’s Chief Executive Officer, effective August 25, 2021. Mr. Tang is currently serving as President of Zhejiang Lixin Enterprise
Management Group Co., Ltd. Prior to that, Mr. Tang served as General Manager of Zhejiang Jing Yu Xin Financing Guarantee Co., Ltd. from
2015 to 2018; President of Zhongchuang International Finance Leasing Co., Ltd. from 2013 to 2015; Executive Vice President of China Financial
Services Holdings Ltd. from 2010 to 2012; General Manager of Huale Tongda (Beijing) International Investment Management Registrant from
2004 to 2010. In addition, Mr. Tang worked in the Northern Investment Group Co., Ltd. from 1999 to 2004. Mr. Tang earned a master’s
degree in accounting and finance science from Hongkong Baptist University in 2015 and a master’s degree in public administration
from Liaoning University in 2012.
Mr. Wenhao Wang was appointed as the Company’s
Acting Chief Financial Officer, effective August 25, 2021. Mr. Wang served as a managing director of investment banking of Southwest
Securities Co., Ltd. from 2015 to 2021. Before joining the Company, he has worked in securities brokerage, equity investment and banking
businesses. His experience includes leadership roles in internal control and compliance practices in the process of corporate operations
and proficiency in China’s capital market and financing practices. Prior to joining us, Mr. Wang served 33 large-scale companies
in the financial field over 11 years and managed more than RMB 4 billion in equity investment and RMB 500 million in fund investment
as a financial advisor. Mr. Wang earned his bachelor’s degree in economics from Southwest University of Science and Technology
in 2014.
Arrangements Concerning Election of Directors;
Family Relationships
Our current board of directors consists of five
directors. We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family
relationships among our executive officers and directors.
The aggregate compensation paid and
share-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended
December 31, 2021 was $95,438. Due to the negative impact of Covid-19, the Company did not reach its performance goal for the year
ended December 31, 2021. The Company did not pay the wage for the Chief Executive Officer, Chief Financial Officer, Senior
Executive President and Senior Vice President for the months from August to December 2021 as agreed by the management. This amount
does not include business travel, professional and business association dues and expenses reimbursed to office holders, and other
benefits commonly reimbursed or paid by companies in our industry. We do not currently have a stock option or other equity incentive
plan. We may adopt one or more such programs in the future. We do not have any written agreements with any director providing for
benefits upon the termination of such director’s relationship with us.
Board of Directors
Our Board of Directors consists of five (5) members. Previously
we had a practice of appointing Directors to staggered three (3) year terms. On March 17, 2020, with the shareholders’ consent,
we changed all the directors’ terms to one year. Each director holds office for one year, or until his or her earlier death, resignation
or removal.
Director Independence
Even if we elect to be a controlled company,
a majority of our Board is independent. An “independent director” is defined under the Nasdaq rules generally as a person
other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which in the opinion
of the company’s board of directors, would interfere with the director’s exercise of independent judgment in carrying out
the responsibilities of a director. Our Board has determined that John Chen, Yiguo Xu and Jianfeng Yin (term ended on December 20, 2021)
and Xiaoliang Liang (newly elected on December 20, 2021) are “independent directors” as defined in the Nasdaq listing standards
and applicable SEC rules. Our independent directors will have regularly scheduled meetings at which only independent directors are present.
Leadership Structure and Risk Oversight
The Board does not have a lead independent director.
Mr. Junfeng Wang has been the Chairman of the Board since August 10, 2021. Mr. Liu Zhigang was the Chairman of the Board from March 18.
2020 to August 10, 2021 and was a co-chair of the Board and authorized to execute documents on behalf of the Company on December 15,
2019.
Policy Regarding Board Attendance
Our directors are expected to attend Board meetings
as frequently as necessary to properly discharge their responsibilities and to spend the time needed to prepare for each meeting. Our
directors are expected to attend annual meetings of shareholders, but we do not have a formal policy requiring them to do so.
Committees of the Board of Directors
The standing committees of our Board currently
consists of an Audit Committee, a Compensation Committee and a Nominating and Corporate Governance Committee.
Audit Committee
We have established an Audit Committee of the
board of directors. As of December 31, 2021, Messrs. John Chen, Yiguo Xu, and Xiaoliang Liang served as members of our Audit Committee
and they are all independent. Dr. Jianfeng Yin’s term ended on December 20, 2021 and succeeded by Mr. Xiaoliang Liang on December
20, 2021. Mr. John Chen served as chairman of the Audit Committee.
Each member of the Audit Committee is financially
literate and our board of directors has determined that Mr. John Chen qualifies as an “Audit Committee financial expert”
as defined in applicable SEC rules.
We have adopted an Audit Committee charter, which
details the responsibilities of the Audit Committee, including:
|
● |
the
appointment, compensation, retention, replacement, and oversight of the work of the independent auditors and any other independent
registered public accounting firm engaged by us; |
|
|
|
|
● |
pre-approving
all audit and non-audit services to be provided by the independent auditors or any other registered public accounting firm engaged
by us, and establishing pre-approval policies and procedures; |
|
|
|
|
● |
reviewing
and discussing with the independent auditors all relationships the auditors have with us in order to evaluate their continued independence; |
|
|
|
|
● |
setting
clear hiring policies for employees or former employees of the independent auditors; |
|
|
|
|
● |
setting
clear policies for audit partner rotation in compliance with applicable laws and regulations; |
|
|
|
|
● |
obtaining
and reviewing a report, at least annually, from the independent auditors describing (i) the independent auditor’s internal
quality-control procedures and (ii) any material issues raised by the most recent internal quality-control review, or peer review,
of the audit firm, or by any inquiry or investigation by governmental or professional authorities, within, the preceding five years
respecting one or more independent audits carried out by the firm and any steps taken to deal with such issues; |
|
|
|
|
● |
reviewing
and approving any related party transaction required to be disclosed pursuant to Item 404 of Regulation S-K promulgated by the SEC
prior to us entering into such transaction; and |
|
|
|
|
● |
reviewing
with management, the independent auditors, and our legal advisors, as appropriate, any legal, regulatory or compliance matters, including
any correspondence with regulators or government agencies and any employee complaints or published reports that raise material issues
regarding our consolidated financial statements or accounting policies and any significant changes in accounting standards or rules
promulgated by the Financial Accounting Standards Board, the SEC or other regulatory authorities. |
Compensation Committee
As of December 31, 2021, the members of our Compensation
Committee were Messrs. John Chen, Yiguo Xu and Xiaoliang Liang, succeeding Dr. Jianfeng Yin whose term ended on December 20, 2021. Mr.
Yiguo Xu served as Chairman of the Compensation Committee. We have adopted a Compensation Committee charter, which details the principal
functions of the Compensation Committee, including:
|
● |
reviewing
and approving on an annual basis the corporate goals and objectives relevant to our Chief Executive Officer’s compensation,
evaluating our Chief Executive Officer’s performance in light of such goals and objectives and determining and approving the
remuneration (if any) of our Chief Executive Officer’s based on such evaluation in executive session at which the Chief Executive
Officer is not present; |
|
|
|
|
● |
reviewing
and approving the compensation of all of our other executive officers; |
|
|
|
|
● |
reviewing
our executive compensation policies and plans; |
|
|
|
|
● |
implementing
and administering our incentive compensation equity-based remuneration plans; |
|
|
|
|
● |
assisting
management in complying with our proxy statement and annual report disclosure requirements; |
|
|
|
|
● |
approving
all special perquisites, special cash payments and other special compensation and benefit arrangements for our executive officers
and employees; |
|
|
|
|
● |
producing
a report on executive compensation to be included in our annual proxy statement; and |
|
|
|
|
● |
reviewing,
evaluating and recommending changes, if appropriate, to the remuneration for directors. |
The charter also provides that the Compensation
Committee may, in its sole discretion, retain or obtain the advice of a compensation consultant, legal counsel or other adviser and will
be directly responsible for the appointment, compensation and oversight of the work of any such adviser. However, before engaging or
receiving advice from a compensation consultant, external legal counsel or any other adviser, the compensation committee will consider
the independence of each such adviser, including the factors required by Nasdaq and the SEC.
Corporate Governance and Nominating Committee
Our Corporate Governance and Nominating Committee
will be responsible for, among other matters:
|
● |
identifying
individuals qualified to become members of our board of directors, consistent with criteria approved by our board of directors; |
|
|
|
|
● |
overseeing
the organization of our board of directors to discharge the board’s duties and responsibilities properly and efficiently; |
|
|
|
|
● |
identifying
best practices and recommending corporate governance principles; and |
|
|
|
|
● |
developing
and recommending to our board of directors a set of corporate governance guidelines and principles applicable to us. |
As of December 31, 2021, our Corporate Governance
and Nominating Committee consisted of Messrs. John Chen, Yiguo Xu and Xiaoliang Liang, with Mr. Xiaoliang Liang serving as the Chairman
of the Corporate Governance and Nominating Committee, succeeding Dr. Jianfeng Yin whose term ended on December 20, 2021.
As of December 31, 2021, the Company had 35 full
time employees, including 4 members of Senior Management Team employed by Roan Holdings Group
Co., Ltd., 6 employees employed by Zeshi Health, and 25 employees employed by Zehjiang Jingyuxin and Zhejiang Lixin. They
have executed employment contracts with its employees in accordance with PRC Labor Law and Labor Contract Law. There are no collective
bargaining contracts covering any of its employees. The Company believes its relationship with its employees is satisfactory.
| |
Number of employees | | |
% of total | |
Sales and marketing | |
| 5 | | |
| 14.29 | % |
Business operation | |
| 8 | | |
| 22.86 | % |
Management and administration | |
| 22 | | |
| 62.85 | % |
Total | |
| 35 | | |
| 100.00 | % |
We are required under PRC law to make contributions
to employee benefit plans at specified percentages of our after-tax profit. In addition, we are required by PRC law to cover employees
in China with various types of social insurance. For the years ended December 31, 2021, 2020 and 2019, we contributed approximately $131,949,
$61,296, and $31,012, respectively, to the employee benefit plans. The effect on our liquidity by the payments for these contributions
is immaterial. We believe that we are in material compliance with the relevant PRC employment laws.
For information concerning the beneficial ownership
of our ordinary shares by our executive officers and directors, see the table in Item 7A. “Major Shareholders and Related Party
Transactions—Major shareholders.”
ITEM 7. MAJOR SHAREHOLDERS AND RELATED PARTY TRANSACTIONS
The following table sets forth information relating to the beneficial
ownership of our Ordinary Shares as of April 22, 2022, by:
|
● |
Each
of our directors and named executive officers; |
|
|
|
|
● |
All
of our directors and executive officers as a group; |
|
|
|
|
● |
each
person, or group of affiliated persons, known by us to beneficially own more than 5% of our outstanding ordinary shares; |
The number of ordinary shares beneficially owned
by each entity, person, director or executive officer is determined in accordance with the rules of the SEC, and the information is not
necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any ordinary shares
over which the individual has sole or shared voting power or investment power as well as any ordinary shares that the individual has the
right to acquire within 60 days of April 22, 2022 through the exercise of any stock options, warrants or other rights. Except as
otherwise indicated, and subject to applicable community property laws, the persons named in the table have sole voting and investment
power with respect to all ordinary shares held by that person.
Ordinary shares that a person has the right to
acquire within 60 days of April 22, 2022 are deemed outstanding for purposes of computing the percentage ownership of the person holding
such rights, but are not deemed outstanding for purposes of computing the percentage ownership of any other person, except with respect
to the percentage ownership of all directors and executive officers as a group. Unless otherwise indicated in the footnotes to the table,
the information presented in this table is based on based on 25,287,851 outstanding ordinary shares on April 22, 2022.
Named
Executive Officers and Directors |
|
Amount
of
Beneficial
Ownership(1) |
|
|
Percentage
Ownership |
|
|
Percentage
Voting
Power(2) |
|
Directors
and Named Executive Officers: |
|
|
|
|
|
|
|
|
|
Junfeng
Wang, Chairman(3) |
|
613,000 |
|
|
2.42 |
% |
|
2.36 |
% |
Guiling,
Sun, Director |
|
- |
|
|
- |
|
|
- |
|
Yiguo
Xu, Director |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Xiaoliang
Liang, Director |
|
|
- |
|
|
|
- |
|
|
|
- |
|
John
Chen, Director |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Jianfeng
Yin, Director |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Zhigang
Liu, Chairman(4) |
|
|
500,000 |
|
|
|
1.98 |
% |
|
|
1.92 |
% |
Qingliang
Yang, Director(5) |
|
|
419,900 |
|
|
|
1.66 |
% |
|
|
1.61 |
% |
Zhiyong
Tang, Chief Executive Officer |
|
|
- |
|
|
|
- |
|
|
|
- |
|
Wenhao
Wang, Chief Financial Officer |
|
|
- |
|
|
|
- |
|
|
|
- |
|
All
directors and executive officers as a group (10 persons) |
|
|
1,532,900 |
|
|
|
6.06 |
% |
|
|
5.89 |
% |
5%
Beneficial Owners: |
|
|
|
|
|
|
|
|
|
|
|
|
Ruiheng
Global Limited(6) |
|
|
6,261,055 |
|
|
|
24.76 |
% |
|
|
24.08 |
% |
Qian
Li (7) |
|
|
6,157,881 |
|
|
|
24.35 |
% |
|
|
23.68 |
% |
Yuan
Shen(8) |
|
|
3,506,732 |
|
|
|
13.87 |
% |
|
|
13.49 |
% |
Yangwei
Global Limited(9) |
|
|
3,483,312 |
|
|
|
13.77 |
% |
|
|
13.40 |
% |
Jiyi
Global Investments Limited(10) |
|
|
2,034,501 |
|
|
|
8.05 |
% |
|
|
1.32 |
% |
Zhan
Zhao Limited(11) |
|
|
1,287,830 |
|
|
|
5.09 |
% |
|
|
4.95 |
% |
* |
Less
than 1%. |
|
|
(1) |
Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to the ordinary
shares. All shares represent only ordinary shares held by shareholders as no options are issued or outstanding. |
|
|
(2) |
Ordinary
Shares have one vote per share, and Class A Convertible Preferred Shares have one vote per share. |
|
|
(3) |
Consists
of 4,467 Ordinary Shares held by Jiyi Global Investments Limited in which Mr. Wang owns a 0.22% interest, 265,533 Ordinary Shares
held by Zhan Zhao Limited in which Mr. Wang owns a 20.619% interest, and 343,000 Ordinary Shares held by Zhong Yun Holdings Limited
in which Mr. Wang owns a 68.125% interest. All of the above shares were acquired in connection with the Business Combinations. |
|
|
(4) |
Consists
of 60,667 Ordinary Shares held by Yangwei Global Limited in which Mr. Liu owns a 1.74% interest, 334,333 Ordinary Shares held by
Jiyi Global Investments Limited in which Mr. Liu owns a 16.43% interest, 105,000 Ordinary Shares held by Ruiheng Global Limited in
which Mr. Liu owns a 1.67% interest. All of the above shares were acquired in connection with the Business Combinations. Mr. Liu
resigned the Chairman of the Board on August 10, 2021. |
(5) |
Consist
of 411,010 Ordinary Shares held by Favour Plus Global Limited in which Mr. Yang owns 40% interest and 8,890 Ordinary Shares held
by Ruiheng Global Limited in which Mr. Yang owns 0.142% interest. Mr. Qingliang Yang was appointed as an executive director on April
2, 2021, succeeding Ms. Shuangping Feng who was a director during the 2020 fiscal year. Prior to Ms. Feng’s resignation effective
on April 2, 2021, she was deemed as beneficially owning 766,410 ordinary shares directly held by Qixiang Global Limited, a company
in which Mr. Mengshi Feng owned 3.03% of the equity interest and 500,000 Class A preferred shares Mr. Feng owned directly because
Mr. Mengshi Feng is the son of Shuangping Feng who may be deemed to beneficially own the 766,410 ordinary shares held by Qixiang
Global Limited and the Class A preferred shares. Mr. Yang resigned the Director on December 20, 2021. |
(6) |
The
Ordinary Shares held by Ruiheng Global Limited, a BVI company, are beneficially owned by Ms. Yuan Shen, the controlling shareholder,
and Mr. Zhisan Yang, Ms. Wen Qi, Ms. Wen Li, Ms. Guixiang Luo, Mr. Quan Zhou, Ms. Shiping Gao, Mr. Qingliang Yang and Mr. Zhigang Liu. |
|
|
(7) |
Consists
of (i) 20,549 ordinary shares directly held by Qixiang Global Limited, a company in which Qian Li owns 2.174% interest;
(ii) 1,526,903 ordinary shares directly held by Jiyi Global Investment Limited, a company in which Qian Li owns 75.05% interest;
(iii) 1,236,907 ordinary shares directly held by Ruiheng Global Limited, a company in which Qian Li owns 19.756% interest; (iv) 3,040,604
ordinary shares directly held by Yangwei Global Limited, a company in which Qian Li owns 87.291% interest; (v) 332,918 ordinary shares
directly held by Zhan Zhao Limited, a company in which Qian Li owns 25.851% interest. The above shares are held by Ms. Shiping Gao
on behalf of Qian Li through a contractual arrangement and Qian Li may be deemed to be the beneficial owner of such shares. |
|
|
(8) |
Consists
of (i) 936,354 ordinary shares directly held by Changman Limited, a company in which Yuan Shen owns 94.6% interest; (ii) 616,515
ordinary shares directly held by Favour Plus Global Limited, a company in which Yuan Shen owns 60.0% interest; (iii) 676,667 ordinary
shares directly held by Xinglin Limited, a company in which Yuan Shen owns 68.1% interest; (iv) 770,000 ordinary shares directly
held by Yimao Enterprises Limited, a company in which Yuan Shen owns 68.1% interest; (v) 158,363 ordinary shares directly held by
Qixiang Global Limited, a company in which Yuan Shen owns 16.8% interest; (vi) 135,333 ordinary shares directly held by Yangwei Global
Limited, a company in which Yuan Shen owns 3.9% interest; and (vii) 213,500 ordinary shares directly held by Zhan Zhao Limited, a
company in which Yuan Shen owns 16.6% interest. |
|
|
(9) |
The
Ordinary Shares held by Yangwei Global Limited, a BVI company, are beneficially owned by Ms. Qian Li, the controlling
shareholder, Ms. Zhihong Zhang, Ms. Yunzhu Chi, Ms. Yuan Shen, Ms. Guifang Li, Ms. Shiping Gao, Mr. Shuai Guo, Mr. Qiang Jin,
and Mr. Zhigang Liu. Ms. Gao exercises voting and dispositive power over the Ordinary Shares held by such
entity. |
|
|
(10) |
The
Ordinary Shares held by Jiyi Global Investments Limited, a BVI company, are beneficially owned by Ms. Shiping Gao, the controlling
shareholder, and Mr. Cheng Sui, Mr. Jianfeng Zhang, Ms. Yuhua Liu, Ms. Cuiping Liu, Mr. Zhigang Liu, Mr. Wei Liu and Mr. Junfeng
Wang. Ms. Gao exercises voting and dispositive power over the Ordinary Shares held by such entity. |
|
|
(11) |
The
Ordinary Shares held by Zhan Zhao Limited, a BVI company, are beneficially owned by Ms. Zhihong Zhang, Ms. Yuquan Zhang, Ms. Xiaolan
Zhao, Ms. Lulu Chen, Mr. Wei Liu, Ms. Yuan Shen, Ms. Shiping Gao and Mr. Junfeng Wang. |
Change of Control
In January 2020, our prior Chief Financial Officer,
Ms. Jingping Li, resigned from such position. In March 2020, Ms. Li ceased to serve on the Board of Directors, and an original shareholder
and former director, Shuangping Feng, was elected to the Board to replace Ms. Li. As a result of such departures, Ms. Li has ceased to
exercise control over our Company. Our current largest shareholders and Board of Directors exercise effective control of our Company
as of the date of this filing. Although we have issued an aggregate of 291,795,150 Class B convertible preferred shares in connection
with our acquisition of Lixin Cayman and its subsidiaries, such shares have no voting rights. Such Class B convertible shares may be
converted into ordinary shares at the holders’ election after June 19, 2022 (revised from December 20, 2021), or the Company could
redeem those Class B convertible shares. If the Class B convertible preferred shares are converted into ordinary shares, the holders
of such ordinary shares would likely control our Company. Except as described in this report, no arrangements or understandings exist
among present or former controlling shareholders with respect to the election of members of our Board and, to our knowledge, no other
arrangements exist that might result in a change of control of the Company.
B. |
Related
Party Transactions |
During fiscal year 2020, the Company advanced a loan of $91,954 to
a shareholder, Mr. Yuan Shen. The loan is interest free and due on demand as of December 31, 2020. The Company has agreed to offset this
loan with the other related party balance due to this same shareholder subsequent to yearend. (Refer to Note 18.2) below for balance due
to this related party.
During fiscal year 2021, the Company purchased
health products of $3,907 from Furuikang Biomedical Technology (Zhejiang) Co., Ltd. (“FuruiKang”). The shareholder of
Furuikang is a beneficial owner of the Company. The transactions are arm-length transactions. As of December 31, 2021, the amount due
from Mr. Zhiyong Tang, the Company’s Chief Executive Officer, was $5,941. This amount was advanced travel fees and non-interest
bearing. During the fiscal year 2021, the Company and Ms. Yuan Shen had agreed to offset the advanced loan of
$91,954 provided in fiscal year 2020 with the balance due to Ms. Yuan Shen. After the offsetting, the amount due to Ms. Yuan Shen was
$119,210 (Refer to Note 18.2). The amount was non-interest bearing and due on demand.
As of December 31, 2021, the balance of due
from related parties of $5,941 consisted of an advance of $5,941 to Mr. Zhiyong Tang.
As of December 31, 2021, the balance of due
to related parties of $123,117 consisted of an advanced fund of $119,210 provided by Ms. Yuan Shen, and a payable of $3,907 to Furuikang.
C. |
Interests
of Experts and Counsel |
Not applicable.
ITEM 8. FINANCIAL INFORMATION
A. |
Consolidated
Statements and Other Financial Information. |
Financial Statements
See Item 18 “Financial Statements”
included in this Annual Report.
Legal Proceedings
We are currently not a party to any material
legal or administrative proceedings and are not aware of any pending or threatened material legal or administrative proceedings against
us. We may from time to time become a party to various legal or administrative proceedings arising in the ordinary course of our business.
Dividend Policy
On March 21, 2017, the Company announced a dividend
of $0.036 per ordinary share which represents an amount equal to twenty-five percent (25%) of (i) the Company’s consolidated net
income for the period beginning October 1, 2016 through December 31, 2016, less (ii) the amount of dividends paid, payable or otherwise
accrued as preferred dividends with respect to the Company’s Class A preferred shares for such period. The dividend was paid on
April 24, 2017 to holders of record of the Company’s ordinary shares on March 31, 2017. The dividend was paid in ordinary shares.
No fractional shares were issued. All dividends were rounded up to the nearest whole number of ordinary shares. No cash payments were
made for any fractional shares.
On May 26, 2017, the Company announced a dividend
of $0.047 per ordinary share which represents an amount equal to twenty-five percent (25%) of (i) the Company’s consolidated net
income for the period beginning January 1, 2017 through March 31, 2017, less (ii) the amount of dividends paid, payable or otherwise
accrued as preferred dividends with respect to the Company’s Class A preferred shares for such period. The dividend was paid on
June 23, 2017 to holders of record of the Company’s ordinary shares on June 5, 2017. The dividend was payable in ordinary shares.
No fractional shares were issued. All dividends were rounded up to the nearest whole number of ordinary shares. No cash payments were
made for any fractional shares.
The Company may pay quarterly dividends dependent
on its revenues and earnings, if any, capital requirements and general financial conditions, at the discretion of the Board of Directors.
In addition, the Company intends to provide for an 8% dividend each year for the Class A Preferred shares. Under the Company’s articles
of association, the Company may pay such dividends in cash, in additional Class A Preferred shares, or in ordinary shares.
Except as disclosed elsewhere in this Annual
Report, there have been no other significant changes since December 31, 2021, until the date of the filing of this Annual Report.
ITEM 9. THE OFFER AND LISTING
A. |
Offer
and Listing Details |
Our ordinary shares and warrants have been listed
on the OTC Pink Open Market (“OTC Market”) since January 8, 2020 under the symbols “RAHGF” and “RONWF,”
respectively. Prior to January 8, 2020, our warrants were quoted under the symbol “CLDCF.” Our ordinary shares were listed
on the Nasdaq Capital Market (the “Nasdaq Stock Market”) under the symbol “CLDC” before being delisted on September
6, 2019, and had since been quoted on the OTC Market under the symbol “CLDOF” until the symbol was changed to “RAHGF.”
The transfer agent for our ordinary shares and
warrants is Continental Stock Transfer & Trust Company, 17 Battery Place, New York, New York 10004.
Not applicable.
Our ordinary shares and warrants are currently
quoted on the OTC Market under the symbols “RAHGF” and “RONWF,” respectively.
Not applicable.
Not applicable.
Not applicable.
ITEM 10. ADDITIONAL INFORMATION
Not applicable.
B. |
Memorandum
and Articles of Association |
General
We are a company incorporated in the British
Virgin Islands as a BVI business company (company number 1819503) and our affairs are governed by our memorandum and articles of
association, the BVI Business Companies Act, 2004, as amended, (the “Companies Act”) and the common law of the
British Virgin Islands. We are authorized to issue an unlimited number of both ordinary shares of no par value and preferred shares
of no par value.
Ordinary Shares
As of December 31, 2021, there were 25,287,851
ordinary shares outstanding. Under the Companies Act, the ordinary shares are deemed to be issued when the name of the shareholder is
entered in our register of members.
At any general meeting on a show of hands
every ordinary shareholder who is present in person (or, in the case of a shareholder being a corporation, by its duly authorized
representative) or by proxy will have one vote for each share held on all matters to be voted on by shareholders. Voting at any
meeting of the ordinary shareholders is by show of hands unless a poll is demanded. A poll may be demanded by shareholders present
in person or by proxy if the shareholder disputes the outcome of the vote on a proposed resolution and the chairman shall cause a
poll to be taken. Pursuant to the amended Memorandum and Articles of Association approved by the board of directors on December 22, 2021, our shareholders may pass resolutions in writing without a meeting.
Our Board of Directors consists of one class
of directors. There is no cumulative voting with respect to the election of directors, with the result that the holders of more than
50% of the shares voted for the election of directors can elect all of the directors (provided that, holders of at least 75% of the shares
can remove a director with or without cause).
Our shareholders are entitled to receive ratable
dividends when, as and if declared by the Board of Directors out of funds legally available therefor.
In the event of a liquidation or winding up
of the Company, our shareholders are entitled to share ratably in all assets remaining available for distribution to them after
payment of liabilities and after provision is made for each class of shares, if any, having preference over the ordinary shares. Our
shareholders have no preemptive or other subscription rights. There are no sinking fund provisions applicable to the ordinary
shares, except that we will provide our shareholders with the redemption rights set forth above. The shareholders of our ordinary
shares do not have liability to further capital calls by us and there are no provisions discriminating against any existing or
prospective holder of securities as a result of the shareholder owning a substantial number of shares.
Preferred Shares
Our charter authorizes the issuance without shareholder
approval of an unlimited number of preferred shares divided into five classes, Class A through Class E, each with such designation, rights
and preferences as are set out in the memorandum and articles of association or as may be determined by a resolution of our Board of
Directors to amend the charter to create such designations, rights and preferences. We have five classes of preferred shares to give
us flexibility as to the terms on which each class is issued. Accordingly, starting with five classes of preference shares will allow
us to issue shares at different times on different terms. Our Board of Directors is empowered, without shareholder approval, to issue
preferred shares with dividend, liquidation, redemption, voting or other rights, which could adversely affect the voting power or other
rights of the holders of ordinary shares. These preferred shares could be utilized as a method of discouraging, delaying or preventing
a change in control of us.
The rights of preferred shareholders may only
be amended by a resolution to amend our charter, provided such amendment is also approved by a separate resolution of a majority of the
votes of preferred shareholders who being so entitled attend and vote at the class meeting of the relevant preferred class. If our preferred
shareholders want us to hold a meeting of preferred shareholders (or of a class of preferred shareholders), they may requisition the
directors to hold one upon the written request of preferred shareholders entitled to exercise at least 30 percent of the voting rights
in respect of the matter (or class) for which the meeting is requested. Under BVI law, we may not increase the required percentage to
call a meeting above 30 percent.
As of December 31, 2021, there were 715,000 Class
A Convertible Preferred Shares and 291,795,150 Class B Convertible Preferred Shares issued and outstanding.
Class A Convertible Preferred Shares
On July 6, 2016, in connection with of the First
Business Combination, we issued 715,000 shares of Class A Convertible Preferred Shares in a PIPE offering. The total amount raised from
issuance of Class A Convertible Preferred Shares was $8,580,000. Pursuant to the terms of the Share Exchange Agreement, immediately prior
to the consummation of the Business Combination, the Company consummated a private placement of 715,000 shares of newly created Class
A Convertible Preferred Shares. The Class A Convertible Preferred Shares were sold at a purchase price of $12.00 per share and the Company
has treated its Class A Convertible Preferred Shares as being entitled to a dividend of 8% per annum. Each Class A Convertible Preferred
Shares are convertible at any time into one ordinary share at an initial conversion price of $12.00 per share, subject to adjustment;
provided, however that the Class A Convertible Preferred Shares shall automatically convert at such time that the average closing price
of the ordinary shares is at least $6.00. In the event of any liquidation, winding-up or dissolution of the Company, whether voluntary
or involuntary, each holder of a Class A Convertible Preferred Shares shall be entitled to receive a liquidation preference of $12.00
per share, plus an amount equal to accumulated and unpaid dividends on such shares to (but excluding) the date fixed for liquidation,
winding-up or dissolution to be paid out of the assets of the Company available for distribution to its members, after satisfaction of
liabilities owed to the Company’s creditors and holders of any senior shares and before any payment or distribution is made to holders
of any ordinary shares or other junior shares.
Each Class A Preferred Share confers upon the
Member (unless waived by such Member): (a) the right to one vote at a meeting of the Members of the Company or on any Resolution of Members;
(b) the right to be redeemed on the Redemption Date; (c) the right to the dividends on Class A Preferred Shares; (d) the right to the
liquidation preference; and (e) the right to convert to Ordinary Shares and the obligation to convert to Ordinary Shares, pursuant to
the provisions of the Company’s memorandum and articles of association.
On December 6, 2019, we amended our Memorandum
and Articles of Association to (a) create a new class of shares designated as the Class B Preferred Shares, and (b) amend the rights
of the existing Class A Preferred Shares, among other things, to allow for the new Class B Preferred Shares to rank senior to the Class
A Preferred Shares on a liquidation.
Pursuant to the Amended and Restated Memorandum
and Articles of Association (the “Amended M&A I”), the Class A Members shall have the right to convert their Class A
Preferred Shares, in whole or in part, into Ordinary Shares at a rate of one Ordinary Share for each Class A Preferred Share (the “Early
Conversion Rate”), subject to adjustment and satisfaction of the conversion procedures. The Directors shall have the right to convert
any or all of the Class A Preferred Shares, in whole or in part, into Ordinary Shares at the Early Conversion Rate, subject to adjustment
and satisfaction of the conversion procedures.
Upon the occurrence of any reorganization event,
the Directors shall have the right: (a) to convert any or all of the Class A Preferred Shares, in whole or in part, into Ordinary Shares
at the Early Conversion Rate subject to adjustment; or (b) to repurchase or redeem any or all of the Class A Preferred Shares, in whole
or in part, for a cash amount equal to the value of the Class A Preferred Shares being repurchased or redeemed on an as-converted basis.
In the event of any liquidation, winding-up or
dissolution of the Company, whether voluntary or involuntary, each Class A Member shall be entitled to receive the Liquidation Preference
per Class A Preferred Share, plus an amount (the Liquidation Dividend Amount) equal to accumulated and unpaid dividends on such
shares to (but excluding) the date fixed for liquidation, winding-up or dissolution to be paid out of the assets of the Company available
for distribution to its Members, after satisfaction of liabilities owed to the Company’s creditors and holders of any Senior Shares
and before any payment or distribution is made to holders of any Junior Shares, including, without limitation, Ordinary Shares. None
of the sale of all or substantially all of the assets or business of the Company and its subsidiaries taken as a whole (other than in
connection with the liquidation, winding-up or dissolution of the Company), the merger or consolidation of the Company into or with any
other person, the sale of a majority of the outstanding equity interests of the Company, nor other Reorganization Event or other similar
transaction that results in a change in control of the Company shall be deemed to be a liquidation, winding-up or dissolution, voluntary
or involuntary, of the Company.
The Memorandum and Articles of Association do
not include sinking fund provisions, liability to further capital calls by the Company and there are no provisions discriminating against
any existing or prospective holder of securities as a result of the shareholder owning a substantial number of shares with regards to
the Class A Preferred Shares.
As of December 31, 2021, dividend of $686,400
was accrued for Class A Preferred Shares. The balance for Class A Preferred Shares was $11,025,327.
Class B Convertible Preferred Share
On December 20, 2019, in connection with of the
Second Business Combination, we issued 291,795,150 Class B convertible preferred shares in the acquisition of Lixin Cayman and its subsidiaries.
Pursuant to the Share Purchase Agreement with Lixin Cayman and certain selling shareholders entered into on June 13, 2019, the Company
acquired a 65.0177% interest in Lixin Cayman from its selling shareholders in exchange for ordinary shares of the Company to be issued
to the selling shareholders for a total consideration of RMB 276.00 million (later adjusted to $31.09 million (RMB 217.88 million). On
August 23, 2019, the parties entered into a supplementary agreement to amend the payment term of the purchase price. Pursuant to the
supplementary agreement, Lixin shareholders will receive non-voting preferred shares that will have the right to convert into common
shares at the holders’ election after two years from the closing date of the acquisition. The transaction was closed on December
20, 2019 upon the Company’s issuance of 291,795,150 Class B convertible preferred shares as the consideration to the selling shareholders
for the 65.0177% equity interest in Lixin Cayman. The Class B convertible preferred shares are embedded with liquidation preference and
dividend preference but with no voting rights. Upon the second anniversary of the closing date, the preferred shares may be convertible
to ordinary shares at a conversion price calculated at the average closing price per share for ninety consecutive trading days before June 20, 2022.
Pursuant to the Amended M&A I, each
Class B Preferred Share confers upon the Member (unless waived by such Member): (a) no right to vote at a meeting of the Members of
the Company or on any Resolution of Members; (b) no right to receive any dividends declared on any Shares of the Company; (c) the
right to be converted on the Class B Conversion Date; and (d) the right to a liquidation preference specified in the Amended M&A I. The Class B Preferred Shares
shall automatically convert into Ordinary Shares of the Company on the Class B Conversion Date at a rate of one Ordinary Share per
Class B Preferred Share, provided that the Directors shall be entitled to amend the definition of ‘Class B Conversion
Date’ to alter the date on which each Class B Preferred Share is converted and thereby extending or reducing the term after
which each Class B Preferred Share is converted. Upon the occurrence of any reorganization event, the Directors shall have the
right: (a) to convert any or all of the Class B Preferred Shares, in whole or in part, into Ordinary Shares at a rate of 1 Ordinary
Share per Class B Preferred Share; or (b) to repurchase or redeem any or all of the Class B Preferred Shares, in whole or in part,
for a cash amount equal to the value of the Class B Preferred Shares being repurchased or redeemed on an as-converted basis.
In the event of any liquidation, winding-up or
dissolution of the Company, whether voluntary or involuntary, each Class B Member shall be entitled to receive, in priority to the holders
of any other class of Shares in the Company, an amount equal to their pro rata share of the Class B Liquidation Preference Amount (calculated
by reference to the number of Class B Preferred Shares held by the relevant Class B Member as a percentage of all issued Class B Preferred
Shares held by all Class B Members). In the event that the assets of the Company are insufficient to pay in full the Class B Liquidation
Preference Amount, the entitlement of each Class B Member shall be reduced ratably. For the liquidation purposes, the Class B Shares
shall be considered Senior Shares. After the payment to any Class B Member of their full entitlement to their pro rata share of the Class
B Liquidation Preference Amount for each of such Class B Member’s Class B Preferred Shares, such Class B Member as such shall have
no right or claim to any of the remaining assets of the Company.
The Memorandum and Articles of Association do
not include sinking fund provisions, redemption provisions, liability to further capital calls by the Company and there are no provisions
discriminating against any existing or prospective holder of securities as a result of the shareholder owning a substantial number of
shares with regards to the Class B Preferred Shares.
On December 22, 2021, the Board of Directors
of the Company unanimously passed a resolution to amend the Memorandum and Articles of Association (the “Amended M&A II”)
to amend the definition of “Class B Conversion Date” of Class B preferred shares, on which the Class B preferred shares of
the Company shall automatically convert into ordinary shares of the Company. Under the Amended M&A II, the “Class B Conversion
Date” has been extended from two years after the date on which the Class B Preferred Shares were issued to thirty months after
such issuance date.
As of December 31, 2021, there were 291,795,150
Class B preferred shares issued and outstanding.
Warrants
As of December 31, 2021, there were 623,078 warrants
of the Company outstanding, of which 576,924 warrant were issued to investors of private placement in July 2018 and 46,154 warrants issued
to placement agent of the private placement. These warrants will expire on July 9, 2022.
In connection with the private placement closed
on July 10, 2018, the Company issued Series A warrants to investors to purchase a total of 576,924 ordinary shares with a warrant term
of four (4) years. The Series A Warrants have an exercise price of $2.60 per share. On January 9, 2019, the Board of the Company approved
a downward adjustment of exercise price from $2.6 to $1.18. The Series A Warrants have customary anti-dilution protections including
a “full ratchet” anti-dilution adjustment provision which are triggered in the event the Company sells or grants any additional
shares of common stock, options, warrants or other securities that are convertible into common stock at a price lower than $2.60 per
share. The anti-dilution adjustment provision is not triggered by certain “exempt issuances” which among other issuances,
includes the issuance of shares of common stock, options or other securities to officers, employees, directors, consultants or service
providers.
In connection with the private placement closed
on July 10, 2018, the investors also received Series B warrants with an initial face amount of 200,000 ordinary shares, which are subject
to adjustment not in excess of an aggregate of 462,843 ordinary shares (the “Series B Warrants”) for nominal consideration.
If on the 30th day after the closing date of the transaction (the “Adjustment Date”), the closing bid price of the Company’s
ordinary shares is less than $2.60, the investors shall have the right to exercise the Series B Warrants and the number of ordinary shares
to be issued to the investors upon exercise of the Series B Warrants shall be adjusted (upward or downward, as necessary) based on the
closing bid price of the Company’s ordinary shares on such date. On August 9, 2018, the closing bid price of the Company’s
ordinary shares was $1.29, and thus the investors exercised the Series B Warrant for 390,579 ordinary shares at $391.
On April 6, 2018, the Company entered into a
letter agreement with FT Global Capital, Inc., as exclusive placement agent (the “Placement Agent”), pursuant to which the
Placement Agent has agreed to act as placement agent on a best efforts basis in connection with the above offering. In addition to the
cash payments, the Company has also agreed to issue to the Placement Agent a warrant to purchase a number of ordinary shares equal to
6.0% of the aggregate number of ordinary shares sold in this offering, which warrant will have the same term as Series A Warrants, including
exercise price, vesting period and anti-dilution terms.
The Company had issued 9,280,323 warrants, of
which 6,860,063 were designated “public warrants,” 33,134 are designated “private warrants”, 1,387,126 were designated
“Sponsor warrants”, and 1,000,000 warrants were transferred to employees of the Company from DeTiger. These warrants have
all expired on July 6, 2021 at 5:00 p.m., New York City time.
Purchase Option
EarlyBird (and/or its designees) was issued an
option to purchase up to 600,000 units at $11.75 per unit. The option represented the right to purchase up to 660,000 ordinary shares
and 600,000 warrants to purchase 300,000 full shares. The purchase option may be exercised for cash or on a cashless basis, at the holder’s
option, at any time prior to September 30, 2019, the five-year anniversary of the effective date of the IPO registration statement.
Notwithstanding anything to the contrary, neither the option nor the warrants underlying the option shall be exercisable after September 30,
2019. The option grants to holders demand and “piggy back” rights for periods of five and seven years, respectively, from
September 30, 2014 (the effective date of the IPO registration statement) with respect to the registration under the Securities
Act of the securities directly and indirectly issuable upon exercise of the option. We will bear all fees and expenses attendant to registering
the securities, other than underwriting commissions, which will be paid for by the holders themselves. The exercise price and number
of units issuable upon exercise of the option may be adjusted in certain circumstances including in the event of a stock dividend, or
our recapitalization, reorganization, merger or consolidation. However, the option will not be adjusted for issuances of ordinary shares
at a price below its exercise price. We will have no obligation to net cash settle the exercise of the purchase option or the rights
or warrants underlying the purchase option. The holder of the purchase option will not be entitled to exercise the purchase option or
the warrants underlying the purchase option unless a registration statement covering the securities underlying the purchase option is
effective or an exemption from registration is available. If the holder is unable to exercise the purchase option or underlying warrants,
the purchase option or warrants, as applicable, will expire worthless. The purchase option was not exercised by the option holder prior
to September 30, 2019 and, therefore, was expired in the year ended December 31, 2019.
Registration Rights
Concurrently with the consummation of our IPO,
in October 2014, the Company granted certain investors registration rights pursuant to a Registration Rights Agreement. The holders
of 25% of the securities subject to the Registration Rights Agreement are entitled to make up to three demands, excluding short form
registration demands, that we register such securities for sale under the Securities Act. In addition, the holders have certain “piggy-back”
registration rights with respect to registration statements filed subsequent to our Business Combination.
We
have agreed to use commercially reasonable efforts to have a registration statement registering the resale of the Company’s ordinary
shares issuable upon conversion of the Class A Convertible Preferred Shares under the Securities Act declared effective within one hundred
eighty (180) days after the closing of the Business Combination.
On
July 6, 2016 and in connection with the Business Combination, the Company entered into a Registration Rights Agreement with the
Sellers. Under the Registration Rights Agreement, the Sellers hold registration rights that will obligate the Company to register for
resale under the Securities Act, all or any portion of the shares held by them issued in connection with the share exchange so long as
such shares are not then restricted under the Lock-Up Agreement. Subject to certain exceptions, if any time after the closing of the
Business Combination, the Company proposes to file a registration statement under the Securities Act with respect to its securities,
under the Registration Rights Agreement, the Company shall give notice to the Sellers as to the proposed filing and offer the Sellers
an opportunity to register the sale of such number of shares as requested by the Sellers in writing. In addition, subject to certain
exceptions, Sellers will be entitled under the Registration Rights Agreement to request in writing that the Company register the resale
of their shares on Form F-3 and any similar short-form registration that may be available at such time.
Pursuant
to a registration statement on Form F-1 declared effective on December 21, 2017, we registered 2,229,572 Ordinary Shares, 2,420,260 Warrants
to purchase Ordinary Shares and 1,210,130 Ordinary Shares issuable upon exercise of our warrants.
Escrow
Agreements
On
July 6, 2016 and in connection with the Business Combination, the Company and the seller representative (on behalf of the Sellers)
entered into an Escrow Agreement with Continental Stock Transfer & Trust Company. Pursuant to the Escrow Agreement, the escrow agent
will hold the escrow shares in a segregated escrow account, to be held and disbursed as agreed to in the Share Exchange Agreement.
Differences
in Corporate Law
The
Companies Act and the laws of the British Virgin Islands affecting British Virgin Islands companies like us and our shareholders differ
from laws applicable to U.S. corporations and their shareholders. Set forth below is a summary of the material differences between the
provisions of the laws of the British Virgin Islands applicable to us and the laws applicable to companies incorporated in the United
States and their shareholders.
Mergers
and Similar Arrangements
Under
the laws of the British Virgin Islands, two or more companies may merge or consolidate in accordance with Section 170et seq. of
the Companies Act. A merger means the merging of two or more constituent companies into one of the constituent companies and a consolidation
means the uniting of two or more constituent companies into a new company. In order to merge or consolidate, the directors of each constituent
company must approve a written
Shareholders
not otherwise entitled to vote on the merger or consolidation may still acquire the right to vote if the plan of merger or consolidation
contains any provision which, if proposed as an amendment to the memorandum or articles of association, would entitle them to vote as
a class or series on the proposed amendment. In any event, all shareholders must be given a copy of the plan of merger or consolidation
irrespective of whether they are entitled to vote at the meeting to approve the plan of merger or consolidation.
The
shareholders of the constituent companies are not required to receive shares of the surviving or consolidated company but may receive
debt obligations or other securities of the surviving or consolidated company, other assets, or a combination thereof. Further, some
or all of the shares of a class or series may be converted into a kind of asset while the other shares of the same class or series may
receive a different kind of asset. As such, not all the shares of a class or series must receive the same kind of consideration.
After
the plan of merger or consolidation has been approved by the directors and authorized by a resolution of the shareholders, articles of
merger or consolidation (containing the plan of merger or consolidation) are executed by each company and filed with the Registrar of Corporate Affairs in the British Virgin Islands.
A
shareholder may dissent from a mandatory redemption of his shares, an arrangement (if permitted by the court), a merger (unless the shareholder
was a shareholder of the surviving company prior to the merger and continues to hold the same or similar shares after the merger) or
a consolidation. A shareholder properly exercising his dissent rights is entitled to a cash payment equal to the fair value of his shares.
A
shareholder dissenting from a merger or consolidation must object in writing to the merger or consolidation before the vote by the shareholders
on the merger or consolidation, unless notice of the meeting was not given to the shareholder, or it was approved by written resolution without a meeting. This objection must include a statement that the
shareholder proposes to demand payment for their shares in the action is taken. If the merger or consolidation is approved
by the shareholders, the company must give notice of this fact to each shareholder within 20 days who gave written objection. These shareholders
then have 20 days to give to the company their written election in the form specified by the Companies Act to dissent from
the merger or consolidation, provided that in the case of a merger, the 20 days starts when the plan of merger is delivered to the shareholder.
Upon
giving notice of his election to dissent, a shareholder ceases to have any shareholder rights except the right to be paid the fair value
of his shares. As such, the merger or consolidation may proceed in the ordinary course notwithstanding his dissent.
Within
seven days of the later of the expiration of the period within which shareholders may give their notice of election to dissent and the effective date of the merger or consolidation, the
company must make a written offer to each dissenting shareholder to purchase his shares at a specified price per share that the company
determines to be the fair value of the shares. The company and the shareholder then have 30 days to agree upon the price. If the company
and a shareholder fail to agree on the price within the 30 days, then the company and the shareholder shall, within 20 days immediately
following the expiration of the 30-day period, each designate an appraiser and these two appraisers shall designate a third appraiser.
These three appraisers shall fix the fair value of the shares as of the close of business on the day prior to the shareholders’
approval of the transaction without taking into account any change in value as a result of the transaction.
Anti-takeover
provisions in our memorandum and articles of association
Some
provisions of our memorandum and articles of association may discourage, delay or prevent a change in control of our company or management
that shareholders may consider favorable. Under British Virgin Islands law, our directors may only exercise the rights and powers granted
to them under our memorandum and articles of association, as amended and restated from time to time, as they believe in good faith to
be in the best interests of our company.
Directors’ Interests
While a director may, subject to the constitutional
documents of the relevant company, vote on the plan of merger or consolidation even if he has a financial interest in the plan, the interested
director must disclose the interest to all other directors of the company promptly upon becoming aware of the fact that he is interested
in the transaction entered into or to be entered into by the company.
(a) a director’s power to vote on a proposal,
arrangement or contract in which the director is materially interested;
Any director of the Company who has an interest
in any transaction entered into or to be entered into by the Company, must forthwith disclose that interest to all other directors of
the Company. A disclosure to all other directors to the effect that a director is a member, director or officer of another named entity
or has a fiduciary relationship with respect to the entity or a named individual and is to be regarded as interested in any transaction
which may, after the date of the entry or disclosure, be entered into with that entity or individual, is a sufficient disclosure of interest
in relation to that transaction.
A transaction entered into by our Company in
respect of which a director is interested is voidable by us unless the director’s
interest was (a) disclosed to the board prior to the transaction or (b) the transaction is (i) between the director and the Company and
(ii) the transaction is in the ordinary course of the Company’s
business and on usual terms and conditions.
Notwithstanding an interest in a transaction,
and subject to the discussion below, a director of the Company who is interested in a transaction entered into or to be entered into
by the Company may:
| (a) | vote on a matter relating to the transaction; |
| (b) | attend a meeting of directors at which a matter relating
to the transaction arises and be included among the directors present at the meeting for the purposes of a quorum; and |
| (c) | sign a document on behalf of the Company, or do any other
thing in his capacity as a director, that relates to the transaction, |
and, subject to compliance with the Companies
Act and the Company’s articles of association shall not, by reason of his office be accountable to the Company for any benefit which
he derives from such transaction and no such transaction shall be liable to be avoided on the grounds of any such interest or benefit.
In addition to the above, prior to the consummation
of any transaction with:
| (a) | any affiliate of the Company; |
| (b) | any shareholder owning an interest in the voting power of
the Company that gives such shareholder a significant influence over the Company; |
| (c) | any director or executive officer of the Company and any
relative of such director or executive officer; and |
| (d) | any person in which a substantial interest in the voting
power of the Company is owned, directly or indirectly, by a person referred to in (b) and (c) or over which such a person is able to
exercise significant influence, |
such transaction must be approved by a majority
of the members of the board of directors who do not have an interest in the transaction, such directors having been provided with access
(at the Company’s expense) to the Company’s attorney or independent legal counsel, unless the disinterested directors determine that
the terms of such transaction are no less favourable to the Company than those that would be available to the Company with respect to
such a transaction from unaffiliated third parties.
(b) the directors’
power, in the absence of an independent quorum, to vote compensation to themselves or any members of their body;
The emoluments of our directors are set by resolution
of directors, and are therefore subject to the limitations on the abilities of directors to act with respect to transactions in which
they have an interest. In the absence of an independent quorum, a director may not vote compensation to themselves, their relatives,
or any body in which they have an interest.
(c) borrowing powers exercisable by the directors
and how such borrowing powers can be varied; and
Our articles of association provide that the
directors of the Company may, by resolution of directors, exercise all the powers of the Company to incur indebtedness, liabilities or
obligations and to secure indebtedness, liabilities or obligations whether of the Company or of any third party. Any variation to this
power would require our articles of association to be amended to include such variation.
(d) retirement or non-retirement of directors
under an age limit requirement.
There is no age at which our directors must retire
from their positions with the Company.
Shareholder
action by written consent
Under
the Delaware General Corporation Law, a corporation may eliminate the right of shareholders to act by written consent by amendment
to its certificate of incorporation. British Virgin Islands law provides that, subject to the memorandum and articles of association of a company, that company’s shareholders may approve corporate matters by way of a
written resolution without a meeting signed by or on behalf of shareholders sufficient to constitute the requisite majority of shareholders
who would have been entitled to vote on such matter at a general meeting; provided that if the consent is less than unanimous, notice
must be given to all non-consenting shareholders. Our memorandum and articles of association permit shareholders to act by written consent.
Shareholder
proposals
Under
the Delaware General Corporation Law, a shareholder has the right to put any proposal before the annual meeting of shareholders, provided
it complies with the notice provisions in the governing documents. A special meeting may be called by the board of directors or any other
person authorized to do so in the governing documents, but shareholders may be precluded from calling special meetings. British Virgin
Islands law allows shareholders holding not less than 30% of the votes of the outstanding voting shares to requisition a shareholders’
meeting. We are not obliged by law to call shareholders’ annual general meetings, but our memorandum and articles of association
do permit the directors to call such a meeting.
Cumulative
voting
Under
the Delaware General Corporation Law, cumulative voting for elections of directors is not permitted unless the corporation’s certificate
of incorporation specifically provides for it. Cumulative voting potentially facilitates the representation of minority shareholders
on a board of directors since it permits the minority shareholder to cast all the votes to which the shareholder is entitled on a single
director, which increases the shareholder’s voting power with respect to electing such director. As permitted under British Virgin
Islands law, our memorandum and articles of association do not provide for cumulative voting. As a result, our shareholders are not afforded
any less protections or rights on this issue than shareholders of a Delaware corporation.
Removal
of directors
Under
the Delaware General Corporation Law, a director of a corporation with a classified board may be removed only for cause with the approval
of a majority of the outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. Under our memorandum
and articles of association, directors can be removed from office, with or without cause, by a resolution of shareholders passed
at a meeting of shareholders called for the purposes of removing the Director, by a written resolution passed by at least 75% of our
shareholders or by a resolution of directors passed at a meeting of directors.
Transactions
with interested shareholders
The
Delaware General Corporation Law contains a business combination statute applicable to Delaware public corporations whereby, unless the
corporation has specifically elected not to be governed by such statute by amendment to its certificate of incorporation, it is prohibited
from engaging in certain business combinations with an “interested shareholder” for three years following the date that such
person becomes an interested shareholder. An interested shareholder generally is a person or group who or which owns or owned 15% or
more of the target’s outstanding voting shares within the past three years. This has the effect of limiting the ability of a potential
acquirer to make a two-tiered bid for the target in which all shareholders would not be treated equally. The statute does not apply if,
among other things, prior to the date on which such shareholder becomes an interested shareholder, the board of directors approves either
the business combination or the transaction which resulted in the person becoming an interested shareholder. This encourages any potential
acquirer of a Delaware public corporation to negotiate the terms of any acquisition transaction with the target’s board of directors.
British Virgin Islands law has no comparable statute. Our Memorandum and Articles of Association allows interested party transactions
to be approved by a majority of the members of the Board of Directors who do not have an interest in the transaction, if such directors
having been provided with access to the Company’s attorney or independent legal counsel, unless the disinterested directors determine
that the terms of such transaction are no less favorable to the Company than those that would be available to the Company with respect
to such a transaction from unaffiliated third parties.
Dissolution;
Winding Up
Under
the Delaware General Corporation Law, unless the board of directors approves the proposal to dissolve, dissolution must be approved by
shareholders holding 100% of the total voting power of the corporation. Only if the dissolution is initiated by the board of directors
may it be approved by a simple majority of the corporation’s outstanding shares. Delaware law allows a Delaware corporation to
include in its certificate of incorporation a supermajority voting requirement in connection with dissolutions initiated by the board.
Under the Companies Act and our memorandum and articles of association, we may appoint a voluntary liquidator by a resolution of the
shareholders or a resolution of the directors.
Variation
of rights of shares
Under
the Delaware General Corporation Law, a corporation may vary the rights of a class of shares with the approval of a majority of the outstanding
shares of such class, unless the certificate of incorporation provides otherwise. Under our memorandum and articles of association, if
at any time our shares are divided into different classes of shares, the rights attached to any class may only be varied, whether or
not our company is in liquidation, with the consent in writing of or by a resolution passed at a meeting by the holders of not less than
50 percent of the issued shares in that class that are entitled to vote on the variation and actually vote thereon.
Amendment
of governing documents
Under
the Delaware General Corporation Law, a corporation’s governing documents may be amended with the approval of a majority of the
outstanding shares entitled to vote, unless the certificate of incorporation provides otherwise. As permitted by British Virgin Islands
law, our memorandum and articles of association may be amended by a resolution of shareholders and, subject to certain exceptions, by
a resolution of directors. Any amendment is effective from the date it is registered at the Registry of Corporate Affairs in the British
Virgin Islands.
We
have not entered into any material contracts other than in the ordinary course of business and other than those described in “Item
4. Information on the Company” or elsewhere in this Annual Report.
The
principal regulations governing foreign currency exchange in the PRC are the Foreign Exchange Administration Regulations promulgated
by the State Council, as amended on August 5, 2008, or the Foreign Exchange Regulations. Under the Foreign Exchange Regulations, the
RMB is freely convertible for current account items, as long as true and lawful transaction basis is provided, but not for capital account
items, such as capital transfer, direct investments, loans, repatriation of investments, investments in securities and derivatives outside
of the PRC, unless the prior approval of the State Administration of Foreign Exchange, or the SAFE, is obtained and prior registration
with the SAFE is made.
The
following description is not intended to constitute a complete analysis of all tax consequences relating to the ownership and disposition
of our securities. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any
tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction.
British
Virgin Islands Taxation
Under
the law of the British Virgin Islands as currently in effect, a holder of our shares who is not a resident of the British Virgin Islands
is not liable for British Virgin Islands income tax on dividends paid with respect to our shares, and all holders of our securities are
not liable to the British Virgin Islands for income tax on gains realized on the sale or disposal of such securities. The British Virgin
Islands does not impose a withholding tax on dividends paid by a company incorporated or re-registered under the Companies Act.
There
are no capital gains, gift or inheritance taxes levied by the British Virgin Islands on companies incorporated or re-registered under
the Companies Act, unless the relevant company has an interest in land located in the British Virgin Islands. In addition, and
subject to the same caveat, In addition, securities of companies incorporated or re-registered under the Companies Act are not subject to transfer taxes,
stamp duties or similar charges.
There
is no income tax treaty or convention currently in effect between the United States and the British Virgin Islands, although a Tax Information
Exchange Agreement is in force.
U.S.
Federal Income Taxation
General
The
following is a summary of the material U.S. federal income tax consequences of the acquisition, ownership and disposition of our ordinary
shares. The discussion below of the U.S. federal income tax consequences to “U.S. Holders” will apply to a beneficial owner
of our ordinary shares that is for U.S. federal income tax purposes:
|
● |
an individual citizen or
resident of the United States; |
|
|
|
|
● |
a corporation (or other
entity treated as a corporation) that is created or organized (or treated as created or organized) in or under the laws of the United
States, any state thereof or the District of Columbia; |
|
|
|
|
● |
an estate whose income
is includible in gross income for U.S. federal income tax purposes regardless of its source; or |
|
|
|
|
● |
a trust if (i) a U.S. court
can exercise primary supervision over the trust’s administration and one or more U.S. persons are authorized to control all
substantial decisions of the trust, or (ii) it has a valid election in effect under applicable U.S. Treasury regulations to be treated
as a U.S. person. |
A
beneficial owner of our ordinary shares that is described above is referred to herein as a “U.S. Holder.” If a beneficial
owner of our ordinary shares is not described as a U.S. Holder and is not an entity treated as a partnership or other pass-through entity
for U.S. federal income tax purposes, such owner will be considered a “Non-U.S. Holder.” The material U.S. federal income
tax consequences applicable specifically to Non-U.S. Holders are described below under the heading “Non-U.S. Holders.”
This
summary is based on the Internal Revenue Code of 1986, as amended (the “Code”), its legislative history, Treasury regulations
promulgated thereunder, published rulings and court decisions, all as currently in effect. These authorities are subject to change or
differing interpretations, possibly on a retroactive basis.
This
discussion does not address all aspects of U.S. federal income taxation that may be relevant to any particular holder based on such holder’s
individual circumstances. In particular, this discussion considers only holders that own and hold our ordinary shares as capital assets
within the meaning of Section 1221 of the Code, and does not discuss the potential application of the alternative minimum tax or the
U.S. federal income tax consequences to holders that are subject to special rules, including:
|
● |
financial institutions or financial services entities; |
|
|
|
|
● |
broker-dealers; |
|
|
|
|
● |
persons that are subject to the mark-to-market accounting
rules under Section 475 of the Code; |
|
|
|
|
● |
tax-exempt entities; |
|
|
|
|
● |
governments or agencies or instrumentalities thereof; |
|
|
|
|
● |
insurance companies; |
|
|
|
|
● |
regulated investment companies; |
|
|
|
|
● |
real estate investment trusts; |
|
|
|
|
● |
certain expatriates or former long-term residents of
the United States; |
|
|
|
|
● |
persons that actually or constructively own 5% or more
of our voting shares; |
|
● |
persons that acquired our
ordinary shares pursuant to an exercise of employee options, in connection with employee incentive plans or otherwise as compensation; |
|
|
|
|
● |
persons that hold our ordinary
shares as part of a straddle, constructive sale, hedging, conversion or other integrated transaction; |
|
|
|
|
● |
persons whose functional currency is not the U.S. dollar; |
|
|
|
|
● |
controlled foreign corporations; or |
|
|
|
|
● |
passive foreign investment companies. |
This
discussion does not address any aspect of U.S. federal non-income tax laws, such as gift or estate tax laws, or state, local or non-U.S.
tax laws or, except as discussed herein, any tax reporting obligations applicable to a holder of our ordinary shares. Additionally, this
discussion does not consider the tax treatment of partnerships or other pass-through entities or persons who hold our ordinary shares
through such entities. If a partnership (or other entity classified as a partnership for U.S. federal income tax purposes) is the beneficial
owner of our ordinary shares, the U.S. federal income tax treatment of a partner in the partnership generally will depend on the status
of the partner and the activities of the partnership. This discussion also assumes that any distribution made (or deemed made) in respect
of our ordinary shares and any consideration received (or deemed received) by a holder in connection with the sale or other disposition
of such ordinary shares will be in U.S. dollars. In addition, this discussion assumes that we will be treated as a foreign corporation
for U.S. federal income tax purposes.
We
have not sought, and will not seek, a ruling from the Internal Revenue Service (“IRS”) or an opinion of counsel as to any
U.S. federal income tax consequence described herein. The IRS may disagree with the description herein, and its determination may be
upheld by a court. Moreover, there can be no assurance that future legislation, regulations, administrative rulings or court decisions
will not adversely affect the accuracy of the statements in this discussion.
THIS
DISCUSSION IS ONLY A SUMMARY OF THE MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR
ORDINARY SHARES. IT IS NOT TAX ADVICE. EACH HOLDER OF OUR ORDINARY SHARES IS URGED TO CONSULT ITS OWN TAX ADVISOR IN RESPECT TO THE PARTICULAR
TAX CONSEQUENCES TO SUCH HOLDER OF THE ACQUISITION, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING THE APPLICABILITY AND
EFFECT OF ANY STATE, LOCAL, AND NON-U.S. TAX LAWS, AS WELL AS U.S. FEDERAL TAX LAWS AND ANY APPLICABLE TAX TREATIES.
U.S.
Holders
Taxation
of Cash Distributions Paid on Ordinary Shares
Subject
to the passive foreign investment company (“PFIC”) rules discussed below, a U.S. Holder generally will be required to include
in gross income as ordinary income the amount of any cash dividend paid on our ordinary shares. A cash distribution on such ordinary
shares generally will be treated as a dividend for U.S. federal income tax purposes to the extent the distribution is paid out of our
current or accumulated earnings and profits (as determined for U.S. federal income tax purposes). Such dividend generally will not be
eligible for the dividends-received deduction generally allowed to U.S. corporations in respect of dividends received from other U.S.
corporations. The portion of such cash distribution, if any, in excess of such earnings and profits will be applied against and reduce
(but not below zero) the U.S. Holder’s adjusted tax basis in our ordinary shares. Any remaining excess generally will be treated
as gain from the sale or other taxable disposition of such ordinary shares.
With
respect to non-corporate U.S. Holders, any such dividends may be subject to U.S. federal income tax at the lower applicable regular long
term capital gains tax rate (see “— Taxation on the Disposition of Ordinary Shares” below) provided that (1) our ordinary
shares are readily tradable on an established securities market in the United States, (2) we are not a PFIC, as discussed below, for
either the taxable year in which such dividend was paid or the preceding taxable year, and (3) certain holding period requirements are
met. Under published IRS authority, ordinary shares are considered for purposes of clause (1) above to be readily tradable on an established
securities market in the United States only if they are listed on certain exchanges, which presently include the Nasdaq Capital Market.
Although our ordinary shares are currently listed on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax
advisors regarding the availability of the lower rate for any dividends paid in respect to our ordinary shares.
Taxation
on the Disposition of Ordinary Shares
Upon
a sale or other taxable disposition of our ordinary shares, and subject to the PFIC rules discussed below, a U.S. Holder generally will
recognize capital gain or loss in an amount equal to the difference between the amount realized and the U.S. Holder’s adjusted
tax basis in the ordinary shares.
The
regular U.S. federal income tax rate on capital gains recognized by U.S. Holders generally is the same as the regular U.S. federal income
tax rate on ordinary income, except that long-term capital gains recognized by non-corporate U.S. Holders generally are subject to U.S.
federal income tax at a maximum regular rate of 20%. Capital gain or loss will constitute long-term capital gain or loss if the U.S.
Holder’s holding period for the ordinary shares exceeds one year. The deductibility of capital losses is subject to various limitations.
Passive
Foreign Investment Company Rules
A
foreign (i.e., non-U.S.) corporation will be a PFIC if either (a) at least 75% of its gross income in a taxable year of the foreign corporation,
including its pro rata share of the gross income of any corporation in which it is considered to own at least 25% of the shares by value,
is passive income, or (b) at least 50% of its assets in a taxable year of the foreign corporation, ordinarily determined based on fair
market value and averaged quarterly over the year, including its pro rata share of the assets of any corporation in which it is considered
to own at least 25% of the shares by value, are held for the production of, or produce, passive income. Passive income generally includes
dividends, interest, rents and royalties (other than certain rents or royalties derived from the active conduct of a trade or business),
and gains from the disposition of passive assets.
Based
on the composition (and estimated values) of the assets and the nature of our income and that of our subsidiaries during the taxable
year ended December 31, 2018, we believe that we may be treated as a PFIC for such year. However, because we have not performed a definitive
analysis as to our PFIC status for such taxable year, there can be no assurance in respect to our PFIC status for such taxable year.
There also can be no assurance in respect to our status as a PFIC for our current taxable year or any future taxable year.
If
we are determined to be a PFIC for any taxable year (or portion thereof) that is included in the holding period of a U.S. Holder of our
ordinary shares, and such U.S. Holder did not make either a timely qualified electing fund (“QEF”) election for our first
taxable year as a PFIC in which the U.S. Holder held (or was deemed to hold) our ordinary shares, a QEF election along with a purging
election or a mark-to-market election, each as described below, such holder generally will be subject to special rules for regular U.S.
federal income tax purposes in respect to:
|
● |
any gain recognized by
the U.S. Holder on the sale or other disposition of its ordinary shares; and |
|
|
|
|
● |
any “excess distribution”
made to the U.S. Holder (generally, any distributions to such U.S. Holder during a taxable year of the U.S. Holder that are greater
than 125% of the average annual distributions received by such U.S. Holder in respect of the ordinary shares during the three preceding
taxable years of such U.S. Holder or, if shorter, such U.S. Holder’s holding period for the ordinary shares). |
Under
these rules,
|
● |
the U.S. Holder’s
gain or excess distribution will be allocated ratably over the U.S. Holder’s holding period for the ordinary shares; |
|
|
|
|
● |
the amount allocated to
the U.S. Holder’s taxable year in which the U.S. Holder recognized the gain or received the excess distribution, or to the
period in the U.S. Holder’s holding period before the first day of our first taxable year in which we qualified as a PFIC,
will be taxed as ordinary income; |
|
|
|
|
● |
the amount allocated to
other taxable years (or portions thereof) of the U.S. Holder and included in its holding period will be taxed at the highest tax
rate in effect for that year and applicable to the U.S. Holder; and |
|
|
|
|
● |
the interest charge generally
applicable to underpayments of tax will be imposed in respect of the tax attributable to each such other taxable year of the U.S.
Holder. |
In
general, if we are determined to be a PFIC, a U.S. Holder may avoid the PFIC tax consequences described above in respect to our ordinary
shares by making a timely QEF election (or a QEF election along with a purging election). Pursuant to the QEF election, a U.S. Holder
will be required to include in income its pro rata share of our net capital gains (as long-term capital gain) and other earnings and
profits (as ordinary income), on a current basis, in each case whether or not distributed, in the taxable year of the U.S. Holder in
which or with which our taxable year ends. A U.S. Holder may make a separate election to defer the payment of taxes on undistributed
income inclusions under the QEF rules, but if deferred, any such taxes will be subject to an interest charge.
The
QEF election is made on a shareholder-by-shareholder basis and, once made, can be revoked only with the consent of the IRS. A U.S. Holder
generally makes a QEF election by attaching a completed IRS Form 8621 (Information Return by a Shareholder of a Passive Foreign Investment
Company or Qualified Electing Fund), including the information provided in a PFIC annual information statement, to a timely filed U.S.
federal income tax return for the taxable year to which the election relates. Retroactive QEF elections generally may be made only by
filing a protective statement with such return and if certain other conditions are met or with the consent of the IRS.
In
order to comply with the requirements of a QEF election, a U.S. Holder must receive certain information from us. Upon request from a
U.S. Holder, we will endeavor to provide to the U.S. Holder no later than 90 days after the request such information as the IRS may require,
including a PFIC annual information statement, in order to enable the U.S. Holder to make and maintain a QEF election. However, there
is no assurance that we will have timely knowledge of our status as a PFIC in the future or of the required information to be provided.
If
a U.S. Holder has made a QEF election in respect to our ordinary shares, and the special tax and interest charge rules do not apply to
such ordinary shares (because of a timely QEF election for our first taxable year as a PFIC in which the U.S. Holder holds (or is deemed
to hold) such shares or a QEF election along with a purge of the PFIC taint pursuant to a purging election, as described below), any
gain recognized on the sale or other taxable disposition of such ordinary shares generally will be taxable as capital gain and no interest
charge will be imposed. As discussed above, for regular U.S. federal income tax purposes, U.S. Holders of a QEF are currently taxed on
their pro rata shares of the QEF’s earnings and profits, whether or not distributed. In such case, a subsequent distribution of
such earnings and profits that were previously included in income generally should not be taxable as a dividend to such U.S. Holders.
The adjusted tax basis of a U.S. Holder’s ordinary shares in a QEF will be increased by amounts that are included in income, and
decreased by amounts distributed but not taxed as dividends, under the above rules. Similar basis adjustments apply to property if by
reason of holding such property the U.S. Holder is treated under the applicable attribution rules as owning ordinary shares in a QEF.
Although
a determination as to our PFIC status will be made annually, an initial determination that we are a PFIC generally will apply for subsequent
years to a U.S. Holder who held our ordinary shares while we were a PFIC, whether or not we meet the test for PFIC status in those subsequent
years. A U.S. Holder who makes the QEF election discussed above for our first taxable year as a PFIC in which the U.S. Holder holds (or
is deemed to hold) our ordinary shares, however, will not be subject to the PFIC tax and interest charge rules discussed above in respect
to such ordinary shares. In addition, such U.S. Holder will not be subject to the QEF inclusion regime in respect to such ordinary shares
for any of our taxable years that end within or with a taxable year of the U.S. Holder and in which we are not a PFIC. On the other hand,
if the QEF election is not effective for each of our taxable years in which we are a PFIC and during which the U.S. Holder holds (or
is deemed to hold) our ordinary shares, the PFIC rules discussed above will continue to apply to such shares unless the holder files
on a timely filed U.S. income tax return (including extensions) a QEF election and a purging election to recognize under the rules of
Section 1291 of the Code any gain that it would otherwise recognize if the U.S. Holder sold shares for their fair market value on the
“qualification date.” The qualification date is the first day of our tax year in which we qualify as a QEF with respect to
such U.S. Holder. The purging election can only be made if such U.S. Holder held shares on the qualification date. The gain recognized
by the purging election generally will be subject to the special tax and interest charge rules treating the gain as an excess distribution,
as described above. As a result of the purging election, the U.S. Holder generally will increase the adjusted tax basis in its shares
by the amount of gain recognized and will also have a new holding period in the shares for purposes of the PFIC rules.
Alternatively,
if a U.S. Holder, at the close of its taxable year, owns ordinary shares in a PFIC that are treated as marketable stock, the U.S. Holder
may make a mark-to-market election in respect to such ordinary shares for such taxable year. If the U.S. Holder makes a valid mark-to-market
election for the first taxable year of the U.S. Holder in which the U.S. Holder holds (or is deemed to hold) our ordinary shares and
for which we are determined to be a PFIC, such holder generally will not be subject to the PFIC rules described above in respect to its
ordinary shares as long as such shares continue to be treated as marketable stock. Instead, in general, the U.S. Holder will include
as ordinary income for each year that we are treated as a PFIC the excess, if any, of the fair market value of its ordinary shares at
the end of its taxable year over the adjusted tax basis in its ordinary shares. The U.S. Holder also will be allowed to take an ordinary
loss in respect of the excess, if any, of the adjusted tax basis of its ordinary shares over the fair market value of its ordinary shares
at the end of its taxable year (but only to the extent of the net amount of previously included income as a result of the mark-to-market
election). The U.S. Holder’s adjusted tax basis in its ordinary shares will be adjusted to reflect any such income or loss amounts,
and any further gain recognized on a sale or other taxable disposition of the ordinary shares in a taxable year in which we are treated
as a PFIC will be treated as ordinary income. Special tax rules may also apply if a U.S. holder makes a mark-to-market election for a
taxable year after the first taxable year in which the U.S. Holder holds (or is deemed to hold) its ordinary shares and for which we
are determined to be a PFIC.
The
mark-to-market election is available only for stock that is regularly traded on a national securities exchange that is registered with
the Securities and Exchange Commission, including the Nasdaq Capital Market, or on a foreign exchange or market that the IRS determines
has rules sufficient to ensure that the market price represents a legitimate and sound fair market value. Although our ordinary shares
are currently listed on the Nasdaq Capital Market, U.S. Holders nevertheless should consult their own tax advisors regarding the availability
and tax consequences of a mark-to-market election in respect to our ordinary shares.
If
we are a PFIC and, at any time, have a foreign subsidiary that is classified as a PFIC, a U.S. Holder of our ordinary shares generally
should be deemed to own a portion of the shares of such lower-tier PFIC, and generally could incur liability for the deferred tax and
interest charge described above if we receive a distribution from, or dispose of all or part of our interest in, or the U.S. Holder were
otherwise deemed to have disposed of an interest in, the lower-tier PFIC. Upon request, we will endeavor to cause any lower-tier PFIC
to provide to a U.S. Holder no later than 90 days after the request the information that may be required to make or maintain a QEF election
in respect to the lower-tier PFIC. However, there is no assurance that we will have timely knowledge of the status of any such lower-tier
PFIC or will be able to cause the lower-tier PFIC to provide the required information. A mark-to-market election generally would not
be available in respect to such a lower-tier PFIC. U.S. Holders are urged to consult their own tax advisors regarding the tax issues
raised by lower-tier PFICs.
A
U.S. Holder that owns (or is deemed to own) ordinary shares in a PFIC during any taxable year of the U.S. Holder may have to file an
IRS Form 8621 (whether or not a QEF election or mark-to-market election is or has been made) with such U.S. Holder’s U.S. federal
income tax return and provide such other information as may be required by the U.S. Treasury Department.
The
rules dealing with PFICs and with the QEF and mark-to-market elections are very complex and are affected by various factors in addition
to those described above. Accordingly, U.S. Holders of our ordinary shares should consult their own tax advisors concerning the application
of the PFIC rules to our ordinary shares under their particular circumstances.
Additional
Taxes
U.S.
Holders that are individuals, estates or trusts and whose income exceeds certain thresholds generally will be subject to a 3.8% Medicare
contribution tax on unearned income, including, without limitation, dividends on, and gains from, the sale or other taxable disposition
of, our ordinary shares, subject to certain limitations and exceptions. Under applicable regulations, in the absence of a special election,
such unearned income generally would not include income inclusions under the QEF rules discussed above under “— Passive Foreign
Investment Company Rules,” but would include distributions of earnings and profits from a QEF. U.S. Holders should consult their
own tax advisors regarding the effect, if any, of such tax on their ownership and disposition of our ordinary shares.
Non-U.S.
Holders
Cash
dividends paid to a Non-U.S. Holder in respect to our ordinary shares generally will not be subject to U.S. federal income tax unless
such dividends are effectively connected with the Non-U.S. Holder’s conduct of a trade or business within the United States (and,
if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains
or maintained in the United States).
In
addition, a Non-U.S. Holder generally will not be subject to U.S. federal income tax on any gain attributable to a sale or other taxable
disposition of our ordinary shares unless such gain is effectively connected with its conduct of a trade or business in the United States
(and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base that such holder maintains
or maintained in the United States) or the Non-U.S. Holder is an individual who is present in the United States for 183 days or more
in the taxable year of such sale or other disposition and certain other conditions are met (in which case, such gain from U.S. sources
generally is subject to U.S. federal income tax at a 30% rate or a lower applicable tax treaty rate).
Cash
dividends and gains that are effectively connected with the Non-U.S. Holder’s conduct of a trade or business in the United States
(and, if required by an applicable income tax treaty, are attributable to a permanent establishment or fixed base that such holder maintains
or maintained in the United States) generally will be subject to regular U.S. federal income tax at the same regular U.S. federal income
tax rates as applicable to a comparable U.S. Holder and, in the case of a Non-U.S. Holder that is a corporation for U.S. federal income
tax purposes, may also be subject to an additional branch profits tax at a 30% rate or a lower applicable tax treaty rate.
Backup
Withholding and Information Reporting
In
general, information reporting for U.S. federal income tax purposes will apply to cash distributions made on our ordinary shares within
the United States to a U.S. Holder (other than an exempt recipient) and to the proceeds from sales and other dispositions of our ordinary
shares by a U.S. Holder (other than an exempt recipient) to or through a U.S. office of a broker. Payments made (and sales and other
dispositions effected at an office) outside the United States will be subject to information reporting in limited circumstances. In addition,
certain information concerning a U.S. Holder’s adjusted tax basis in its ordinary shares and adjustments to that tax basis and
whether any gain or loss with respect to such ordinary shares is long-term or short-term also may be required to be reported to the IRS,
and certain holders may be required to file an IRS Form 8938 (Statement of Specified Foreign Financial Assets) to report their interest
in our ordinary shares.
Moreover,
backup withholding of U.S. federal income tax at a rate of 28%, generally will apply to cash dividends paid on our ordinary shares to
a U.S. Holder (other than an exempt recipient) and the proceeds from sales and other dispositions of our ordinary shares by a U.S. Holder
(other than an exempt recipient), in each case who:
|
● |
fails to provide an accurate taxpayer identification
number; |
|
|
|
|
● |
is notified by the IRS that backup withholding is required;
or |
|
|
|
|
● |
in certain circumstances, fails to comply with applicable
certification requirements. |
A
Non-U.S. Holder generally may eliminate the requirement for information reporting and backup withholding by providing certification of
its foreign status, under penalties of perjury, on a duly executed applicable IRS Form W-8 or by otherwise establishing an exemption.
Backup
withholding is not an additional tax. Rather, the amount of any backup withholding will be allowed as a credit against a U.S. Holder’s
or a Non-U.S. Holder’s U.S. federal income tax liability and may entitle such holder to a refund, provided that certain required
information is timely furnished to the IRS. Holders are urged to consult their own tax advisors regarding the application of backup withholding
and the availability of and procedures for obtaining an exemption from backup withholding in their particular circumstances.
F. |
Dividends and paying
agents |
Not
applicable.
Not
applicable.
You
may inspect our securities filings, including this Annual Report and the exhibits and schedules thereto, without charge at the offices
of the SEC at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of the Annual Report from the Public
Reference Section of the SEC, 100 F Street, NE, Washington, D.C. 20549 upon the payment of the prescribed fees. You may obtain information
on the operation of the Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website at www.sec.gov that contains
reports, proxy and information statements and other information regarding registrants like us that file electronically with the SEC.
You can also inspect the Annual Report on this website.
A
copy of each document (or a translation thereof to the extent not in English) concerning our company that is referred to in this Annual
Report is available for public view (subject to confidential treatment of certain agreements pursuant to applicable law) at our principal
executive offices.
I. |
Subsidiary Information |
See
“Item 4. Information on the Company – C. Organizational Structure.”
ITEM
11. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
Credit
Risk
Credit
risk is one of the most significant risks for the Company’s business. Credit risk exposures arise principally in financial guarantee
activities which is an off-balance sheet financial instrument.
Credit
risk is controlled by the application of credit approvals, limits and monitoring procedures including due-diligence visits and post-lending
visits to the clients. The Company manages credit risk through in-house research and analysis of the Chinese economy and the underlying
obligors and transaction structures. To minimize credit risk, the Company requires collateral in the form of rights to cash, securities
or property and equipment. The Company identifies credit risk collectively based on industry, geography and customer type. This information
is monitored regularly by management.
- |
Financial guarantee
activities |
In
measuring the credit risk of financial guarantee services with customers, the Company mainly reflects the “probability of default”
by the customer on its contractual obligations and considers the current financial position of the customer and the exposures to the
customer and its likely future development.
The
Company manages their credit risk guarantee exposure by performing preliminary credit checks of each guarantee customer and ongoing monitoring
of payments each month. Management periodically reviews the probability of default of guarantee customer and will accrue a guarantee
liability when necessary.
In
addition, the Company calculates the provision amount as below:
|
1. |
General Reserve - is based
on total balance of off-balance-sheet guarantee and to be used to cover unidentified probable loan loss. According to management
assessment, the General Reserve is required to be no less than 1% of total loan guarantee balance. |
|
|
|
|
2. |
Specific Reserve –
is based on a guarantee by guarantee basis covering losses due to risks related to the ability and intention of repayment of guarantee
commissions by each customer. The reserve rate was individually assessed based on management estimate of guarantee fee commission
collectability. According to management assessment, the Specific Reserve is no less than 50% of guarantee fee commission earned during
the year. |
The
Company has been providing the financial guarantees of loans for limited history. The customer deposits or other assets are held as collateral
for the repayment of each loan. As of December 31, 2021, the amount of outstanding loans and related interests that the Company
has guaranteed is approximately $47,020,055. The Company estimates the fair market value of the collateral to be approximately $43,269,000 as of December 31, 2021.
- |
Other operating activities |
Assets
that potentially subject the Company to significant concentration of credit risk primarily consist of cash and cash equivalents. The
maximum exposure of such assets to credit risk is their carrying amount as at the balance sheet dates. As of December 31, 2021,
the Company had no deposits with a bank in the United States. As of December 31, 2021, cash of $1,947,142 and restricted cash of
$29,693,689, respectively, were primarily deposited in banks located in Mainland China, which were uninsured by the government authority.
To limit exposure to credit risk relating to deposits, the Company primarily place cash deposits with large financial institutions in
China which management believes are of high credit quality.
The
Company’s operations are carried out in Mainland China. Accordingly, the Company’s business, financial condition and results
of operations may be influenced by the political, economic and legal environments in the PRC as well as by the general state of the PRC’s
economy. In addition, the Company’s business may be influenced by changes in governmental policies with respect to laws and regulations,
anti-inflationary measures, currency conversion and remittance abroad, rates and methods of taxation, and the extraction of mining resources,
among other factors.
Liquidity
Risk
The
Company is also exposed to liquidity risk which is risk that it is unable to provide sufficient capital resources and liquidity to meet
its commitments and business needs. Liquidity risk is controlled by the application of financial position analysis and monitoring procedures.
When necessary, the Company will turn to other financial institutions and the shareholders to obtain short-term funding to meet the liquidity
shortage.
Foreign
Currency Risk
Substantially
all of the Company’s operating activities and the Company’s assets and liabilities are denominated in RMB, which is not freely
convertible into foreign currencies. All foreign exchange transactions take place either through the Peoples’ Bank of China (“PBOC”)
or other authorized financial institutions at exchange rates quoted by PBOC. Approval of foreign currency payments by the PBOC or other
regulatory institutions requires submitting a payment application form together with suppliers’ invoices and signed contracts.
The value of RMB is subject to changes in central government policies and to international economic and political developments affecting
supply and demand in the China Foreign Exchange Trading System market.
Other
risk
The
Company’s business, financial condition and results of operations may also be negatively impacted by risks related to natural disasters,
extreme weather conditions, health epidemics and other catastrophic incidents, such as the COVID-19 outbreak and spread, which could
significantly disrupt the Company’s operations.
In
December 2019, a novel strain of coronavirus (COVID-19) was first identified in China and has since spread rapidly globally. The outbreak
of COVID-19 has resulted in quarantines, travel restrictions, and the temporary closure of offices and business facilities globally.
In March 2020, the World Health Organization declared the COVID-19 a pandemic. In 2020 and 2021, COVID-19 had a material impact on our
business, financial condition, and results of operations. After the second quarter of 2020, the COVID outbreak in China has gradually
been controlled. Our business has also returned to normal operations, although management assessed that our results of operations had
been negatively impacted for the year. In 2021, Omicron variants emerged, resulting in continued disruption to our business and the global
economy and supply chain. COVID-19 could continue to adversely affect our business and results of operations in 2022 if any COVID resurgence
causes significant disruptions to our operations or the business of our customers, logistics and service providers. COVID-19 could adversely
affect our business and results of operations in 2021 if any COVID resurgence causes significant disruptions to our operations or the
business of our customers, logistics and service providers. If any new outbreak of COVID-19 is not effectively and timely controlled,
or if government responses to outbreaks or potential outbreaks are severe or long-lasting, our business operations and financial condition
may be materially and adversely affected as a result of the deteriorating market outlook, the slowdown in regional and national economic
growth, weakened liquidity and financial condition of our customers or other factors that we cannot foresee. Any of these factors and
other factors beyond our control could have an adverse effect on the overall business environment, cause uncertainties in the regions
where we conduct business, and could materially and adversely impact our business, financial condition and results of operations.
ITEM
12. DESCRIPTION OF SECURITIES OTHER THAN EQUITY SECURITIES
Not
applicable.